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Children are vulnerable to inappropriate prescribing yet rational prescribing criteria, 
although widely used in adult medicine, are not well-established in paediatric research. 
Rational prescribing tools, criteria lists of potentially irrational prescribing, are used to 
study the use of medicines and can be used to detect and quantify inappropriate 
prescribing. This allows researchers to compare quality of prescribing across different 
populations, identify factors associated with irrational prescribing, and evaluate the 
effectiveness of interventions to improve prescribing. 
Aims 
The aims of this thesis were to identify and appraise all existing tools for studying 
irrational prescribing for children; to develop a rational prescribing tool that could be 
used across paediatric practice in the United Kingdom (UK); and to validate the novel 
tool for application in research and clinical practice in the UK. 
Methods 
A systematic review of paediatric rational prescribing tools was undertaken and identified 
two such tools. One of these, the POPI (Pediatrics: omissions of prescriptions and 
inappropriate prescriptions) tool, was designed for application to any paediatric practice 
setting but founded in French clinical practice. The second, PIPc (Indicators of 
potentially inappropriate prescribing in children) is a tool designed for use in primary care 
only, in Ireland and the UK. 
 
In order to develop criteria applicable to any UK paediatric setting, the POPI tool was 
modified for use in the UK, resulting in the novel POPI UK tool. Each criterion was 
compared to relevant UK national guidelines, with three possible outcomes: no change; 
modification; or omission. Criteria concordant with UK guidelines were integrated into 
the new tool unchanged, criteria differing from guidelines were modified, and criteria with 
contradicting guidelines or no relevant UK guidelines were omitted. 
 
Two validation studies were designed and carried out to evaluate POPI UK. Firstly, a 
prospective clinical validation study was designed to review the prescriptions of 600 
children in a UK children s hospi al, in inpa ien  and emergenc  depar men  se ings. This 
 
 xiii 
study evaluated the relevance of the POPI UK criteria to the study population, assessed 
its ability to detect potentially inappropriate prescribing, and examined factors associated 
with any potentially inappropriate prescribing detected. 
 
Secondly, the precision of the POPI UK tool was tested through an inter- and intra-rater 
reliability study. Cohen s Kappa was calculated for agreement between two raters applying 
the criteria to twenty anonymised cases. 
Results 
The systematic review identified five articles meeting inclusion criteria. These related to 
three paediatric rational prescribing tools, POPI, PIPc, and POPI UK. 
 
The POPI tool comprises 105 criteria and was designed for use in any paediatric practice 
setting, based on French standards of practice. The PIPc comprises twelve criteria, 
designed for use in primary care in Ireland and the UK. Due to the PIPc being 
specifically designed for use in primary care, the POPI tool was the focus of further 
study. 
 
Modification of the POPI criteria was undertaken to develop the POPI UK tool. No 
change was made to 49 criteria., 29 were modified, four were reduced into two through 
combination with closely related criteria and 23 were omitted, including the omission of a 
category. The resulting POPI UK tool comprises 80 criteria divided into 21 clinical 
categories.  
 
In the clinical validation study, the POPI UK criteria were relevant to the majority (96%) 
of the study population and the tool identified potentially irrational prescribing. In 
addition, several limitations were identified, including the detailed level of clinical 
information required to apply the criteria. 
 
The inter- and intra-rater repeatability of POPI UK were rated as good, with Kappa 
values of 0.44 and 0.57 respectively. This was lower than the reliability of the original 
POPI tool. On examination of the studies, it appeared that methodological differences 
rather than the modification of the tool explained the observed difference in reliability of 




Two existing paediatric rational prescribing tools were identified and appraised, POPI 
and PIPc. In order to develop a tool applicable to children across UK paediatric settings a 
novel tool, POPI UK, was developed by modifying the POPI criteria. Validation studies 
demonstrated that POPI UK was relevant to a majority of the studied population and 
was able to identify potentially irrational prescribing with good reliability. This tool could 
be used in UK paediatric practice settings to evaluate rational prescribing. However, a 
number of significant limitations to all three paediatric rational prescribing tools have 
been identified and further research avenues are suggested including refinement of the 





Dissemination of research related to thesis 
 
Corrick F, Conroy S, Sammons H, Choonara I. Paediatric Rational Prescribing: A 
Systematic Review of Assessment Tools. International journal of environmental research 
and public health. 2020;17(5):1473. (Appendix 1) 
 
Corrick F, Choonara I, Conroy S, Sammons H, editors. Modifying a paediatric rational 
prescribing tool (POPI) for use in the UK. Healthcare; 2019;7(1) (Appendix 2) 
 
Corrick F, Smith C, Choonara I, Sammons HM. Developing paediatric rational 
prescribing criteria: a pilot study. Midlands Academy of Medical Sciences Research 
Festival; 2017 (Poster) (Appendix 3) 
 
Corrick FJ, Conroy S, Choonara I, Sammons H. Developing paediatric rational 
prescribing criteria. Archives of Disease in Childhood. 2017;102 (Supplement 1):A84. 
(Oral presentation) (Appendix 4) 
 
Corrick F, Smith C, Choonara I, Sammons HM. Rational Prescribing for Children: 
Evaluating the modified POPI criteria. RCPCH Annual QI Conference; 2016 (Poster and 
oral presentation)  awarded best trainee project (Appendix 5) 
 
Corrick, F, Sammons HM. Assessment Tools of Rational Prescribing in Children. Trent 
Paediatric Society Meeting; 2016 (Poster) (Appendix 6) 
 
 
Chapter 1: Background and rationale for the thesis 
 1 
1 Background and rationale for the thesis 
1.1 Introduction 
 
Rational prescribing describes practices aimed at minimising inappropriate prescribing at 
a systems level or, in other words, considering all elements at all stages of the process 
involved in prescribing, from the legal framework governing therapeutics to individual 
prescriber decisions. This includes, for example, the development of essential drug lists or 
the use of guidelines. This approach to improving the use of medicines is supported by 
the World Health Organisation (WHO) and was identified as an objective of the WHO 
Twelfth General Programme of Work 2014-2019 (1).  
 
Lack of rational prescribing has both human and economic costs (2). Inappropriate 
prescriptions may harm individual patients by causing adverse events or in opportunity 
cost when more effective treatments exist for a disease. They may also incur a health cost 
to a wider community, for instance where injudicious antibiotic prescribing practice 
increases the rate of resistant infections or where appropriate vaccination programmes are 
not implemented at the cost of subsequently higher rates of infection. There are also 
economic costs in terms of inefficiency of health spending and the financial implications 
of any detriment to health incurred by poor prescribing practices (3). 
 
Children pose some additional challenges to rational prescribing compared with adults 
(4). Dosing regimens commonly require the prescriber to make calculations based on age 
or weight (5), therefore increasing the risk of inappropriate prescribing; for less 
experienced prescribers, this may compound uncertainty about what to prescribe and 
contribute to omissions. 
 
Another impediment to rational use of medicines in children is the relative paucity of 
high-quality research exploring the use of medicines for children compared to adults. This 
hinders efforts to implement high-quality evidence-based practice as inadequacy of 
evidence forces clinical decisions to be made based on consensus or personal clinical 
experience alone, as is evident in a number of National Institute for Health and Care 
Excellence (NICE) guidelines for children and young people (6-8). There are a number of 
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contributing factors to this bias, including complex ethical issues, high cost and difficulty 
in recruiting participants for paediatric trials (9-11). This is discussed further in section 1.5 
 
 
Studying prescribing for children (on page 16). 
 
 
1.2 What is rational prescribing? 
1.2.1 Defining rational prescribing 
 
Rational prescribing was named an objective of the WHO Twelfth General Programme 
of Work 2014-2019 (1).  The WHO defined rational prescribing in 1985 as he  a ie  
receive the appropriate medicines, in doses that meet their own individual requirements, for an adequate 
period of time, and at the lowest cost both to them and the community (12) and continues to use this 
definition in their on-going work. Other terms sometimes used as synonymous include 
rational use of medicines, appropriate prescribing and optimal prescribing (3). 
 
I  is impor an  o no e ha  some a hors limi  he erm ra ional  prescribing o 
prescribing that is based on reasoned motives but that may still be inappropriate, 
dis ing ishing his from appropria e  prescribing as heir preferred erm o exclude both 
irrational and suboptimal prescribing (13) In his hesis, ra ional prescribing  is sed o 
describe optimal prescribing in line with the above WHO definition. 
 
As indicated in the WHO definition, rational prescribing is prescribing that results in the 
patient receiving medicines that are appropriate to treat them, not only in terms of drug 
selection but also dosage, duration and use of a lower cost drug in preference to a higher 
cost equivalent. This means that research into rational prescribing is a broad field that 
incorporates studies with varied approaches, including research into inappropriate 
prescribing, administration errors, prescribing trends, adherence to clinical 
recommendations for treatments, patient concordance, accessibility of essential drugs, 
and use of generic versus branded drugs(14). These studies are relevant both at the level 
of individual prescribers or organisations, and at national or international levels. 
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Irrational prescribing can take a number of different forms. In the field of rational 
prescribing for older adults, inappropriate prescribing has been categorised into three 
broad groups: misprescribing, overprescribing, and underprescribing (15). Misprescribing 
includes choice of incorrect medication for a disease, incorrect dosage or duration of 
therapy, selection of a drug that is otherwise contraindicated in a patient due to a 
comorbid illness or concurrent drug(s) with which it may interact. Overprescribing is 
prescription of an unnecessary or insufficiently beneficial medication, and 
underprescribing is the omission of a medication that would be beneficial. 
 
1.2.2 Barriers to rational prescribing 
 
There are many factors that contribute to the prevalence of irrational prescribing. These 
include issues around education and supervision of prescribers, the prevailing culture of 
the medical community in terms of reference and adherence to guidelines, and patient 
beliefs and preferences (16-18). Infrastructure and economic pressures may prevent 
prescribers and patients from having access to appropriate medicines, or cultural beliefs 
may act as a barrier to patient use of appropriate medicines even when they are available 
(19). Prescriber, infrastructure, economic and patient factors have all been described as 
potential barriers to rational prescribing, with some examples of each shown in  
Figure 1-1 adapted from Holloway, 2011 (20). 
Prescriber 
factors
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Figure 1-1: Barriers to rational prescribing 
 
 
Any of the categories of prescriber, infrastructure, economic or patient factors can have 
an impact on children and in several aspects children may be particularly vulnerable to 
inappropriate prescribing. The vulnerability of children to inappropriate prescribing is in 
part due to the diversity of the paediatric population, ranging from neonates to 
adolescents, with concomitant changes in body weight and maturity of metabolic 
pathways. These challenges affecting rational prescribing for children are examined in 
Section 1.5.3. 
 
Considering examples of patient factors in a paediatric population, adherence to 
treatment may be hindered by children rejecting medications due to oppositional 
behaviour, embarrassment in taking medications around peers, difficulty in swallowing 
tablets, rejection of taste of medications, and other feeding issues (21). In addition, lack of 
ed ca ion or c l ral beliefs of paren s ma  ha e an impac  on a child s adherence o 
prescribed medications (22). 
 
Prescriber factors affecting paediatric prescribing include the limited space for training on 
paediatric prescribing in undergraduate curricula (23) and the fact that, while decision-
making is more likely to be led by senior clinicians, junior doctors are the most likely to 
actually complete prescriptions, whether handwritten or electronic (24). 
 
In addition, infrastructure and economic factors have led to underrepresentation of 
children in pharmacological research (25), meaning that drug selection and dosage may 
rely upon lower quality evidence for children than for adult populations. Electronic 
prescribing systems designed to reduce prescribing error in adult medicine are not 
immediately applicable to paediatric practice due to the more varied dosing regimens 
appropriate to paediatric patients (24). 
 
1.2.3 Harms of irrational prescribing 
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The risks of irrational prescribing are not only to the individual patient in receipt of 
inappropriate medicines (or lack of access to appropriate medicines), but also to their 
community in terms of both health costs and economic costs. 
 
Overuse and misuse of medicines may cause significant morbidity and mortality. 
Irrational prescribing may lead directly to adverse drug reactions (ADRs) where 
contraindicated medications are used; in a meta-analysis of hospital admissions due to 
ADRs, it was found that one in ten hospital admissions in older patients were due to 
ADRS and the majority of ADRs were considered to be preventable (26). Polypharmacy 
has consistently been identified as a factor associated with higher risk of ADRs (27-29). 
 
ADRs present a significant burden in terms of of morbidity and healthcare costs. 
Avoidable ADRs have been estimated to contribute to additional need for hospital stays 
amounting to 181,626 bed-days in the UK National Health Service (NHS); the cost of the 
additional hospital stays alone came to £98.5 million per year (30). Other studies have 
estimated what proportion of admissions were related to prescribing, with a systematic 
review of such studies finding that 3.7% of preventable hospital admissions were drug-
related, one-third of which were due to prescribing problems, one-third due to patient 
adherence problems, and one-fifth due to monitoring problems (31). Another review 
similarly found 3.5% of hospital admissions were due to ADRs, and further reported that 
approximately 10% of inpatients will experience an ADR during their admission(32). All 
of these health costs translate to high economic costs. For instance, in one study 
considering all ADR-related admissions to UK hospitals, the total economic impact was 
estimated to come to £466m annually in healthcare costs(33). 
 
Children are also vulnerable to ADRs. One s d  in a er iar  children s hospi al in he 
UK estimated that 2.9% of paediatric emergency admissions were caused by ADRs. A 
large proportion of these related to treatment of cancer (48%), with adverse effects that 
are known risks such as thrombocytopaenia and neutropaenia. However, 22% of ADRs 
were considered avoidable (34). Examples of avoidable ADRs included; diarrhoea and 
vomiting secondary to antibiotics given for viral illness, and constipation secondary to 
opioid analgesia occurring without any prescribed prophylaxis. This study suggested that 
rational prescribing could prevent a number of ADRs that are serious enough to warrant 
emergency admission. For illustration of the healthcare associated costs of such cases, 
Chapter 1: Background and rationale for the thesis 
 6 
hospital admission for a child with gastrointestinal illness was estimated to cost £989 per 
patient in 2015 (35).  
 
Any admission due to an ADR clearly represents harm to the patient in terms of 
morbidity and economic harm in healthcare-associated costs, but also has wider 
ramifications. There is also an additional burden of indirect costs, such as lost 
productivity of affected individuals, travel, expenses, and the wider impact on others in 
the household (36). Additional costs like this are equally germane to paediatric medicine, 
where parents may experience loss of earnings and additional childcare costs for other 
children in the family (37) . The overall figures are therefore likely to be much higher. 
 
Antibiotic misuse provides a clear example of community costs of inappropriate 
prescribing. Antimicrobial resistance carries with it significant risks of morbidity and 
mortality and continues to increase worldwide (38, 39). Inappropriate use of antibiotics is 
considered a key contributor to the rise in antimicrobial resistance, demonstrated by the 
correlation between outpatient antibiotic use and penicillin-resistant pneumococci found 
in Europe (40). In 2018, antimicrobial resistance was estimated to cost $179,000 per 
100,000 population in the UK(41). This equates to £140,000 at the conversion rate at the 
time of publication of those figures, or a total of £92.8 million for the whole of the UK.  
 
1.2.4 Interventions to promote rational prescribing 
 
The WHO identified twelve core interventions to promote rational use of medicines, 
shown in Figure 1-2, reproduced from Promoting rational use of medicines: core 
components, WHO (page 3, (42)).  




Twelve core interventions to promote more rational use of medicines  
1. A mandated multi-disciplinary national body to coordinate medicine use policies 
2. Clinical guidelines 
3. Essential medicines list based on treatments of choice 
4. Drugs and therapeutics committees in districts and hospitals 
5. Problem-based pharmacotherapy training in undergraduate curricula 
6. Continuing in-service medical education as a licensure requirement 
7. Supervision, audit and feedback 
8. Independent information on medicines 
9. Public education about medicines 
10. Avoidance of perverse financial incentives 
11. Appropriate and enforced regulation 
12. Sufficient government expenditure to ensure availability of medicines and staff 
Figure 1-2: WHO core interventions for rational use of medicines 
 
Many of these interventions, such as interventions eight to twelve, require state-level 
changes to regulations and practice. Others, like two and four, may be at the level of 
international or national guidelines, or more localised institution-based guidelines.  
 
The focus of this thesis will be around intervention seven, establishing systems of 
supervision, audit and feedback, and in particular, the focus will be on methods of 
measuring quality of prescribing that can be used to facilitate such systems. In order to 
improve practice through these systems, it is essential to have an objective measurement 
that can be used as a standard against which actual practice is compared. This gives 
reliability and consistency to feedback and allows prescribers, managers, and researchers 
to make comparisons between different prescribers, different areas, or at different times. 
It also, therefore, enables a quantitative assessment of the effect of interventions on the 
quality of prescribing. 
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1.3 Assessing rational prescribing 
 
As discussed in section 1.5, in order to pursue systemic improvements towards more 
rational prescribing, it is necessary to develop methods of measuring the quality of 
prescribing to identify targets for interventions and to review the results of such 
interventions. There are broadly two possible extremes of approach: 1) assessment of 
prescribing on an individual case-by-case basis taking into account the comprehensive 
patient and clinical context, with no predetermined definitions for appropriate or 
inappropriate prescriptions, or 2) using predefined standards to define appropriate and 
inappropriate prescribing, which can be applied by any rater. Each of these approaches 
has its advantages and limitations. 
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1.3.1 Case-by-case expert analysis 
 
In a case-by-case assessment of rational prescribing, there are no predetermined criteria 
defining specific medicines that will be considered appropriate or inappropriate for a 
given condition. Instead, an expert or a panel of experts reviews each prescription and 
determines its appropriateness in the context of that specific case. For instance, this 
approach has been used to assess not only prescribed medicines but also the decision not 
to prescribe, through evaluation of recorded consultations and patient records (43).  The 
assessment may be structured by a number of questions about the prescriptions, for 
instance a classification system developed by Kunin et al, shown in Figure 1-3, provides a 
framework for an expert rater to assess antibiotic prescriptions (44). While the 
classification provides a structure for the assessment, the determination of whether or not 
a prescription is appropriate is determined by the rater s o n j dgemen . 
 
 
Figure 1-3: Kunin framework to evaluate antibiotic prescriptions  
 
An advantage of this approach is that the approach can be used in any setting, 
accommodating differing local guidelines or formularies (45). The assessment of 
prescriptions by this method can also take into account the context of the individual 
patient, including co-morbidities, other concurrent treatments, or laboratory test results 






Class I Appropriate indication, dose and choice of antibiotic therapy
Potentially appropriate but benefits of treatment 
are controversial
Appropriate use of antibiotics but a different 
antibiotic would be better
Appropriate use of antibiotics but a different 
dose would be better
Inappropriate use of antibiotics
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However, there are also a number of drawbacks to a case-by-case approach. It may be 
more time-consuming than other methods and is likely to require more data about each 
patient (47), which may necessitate prospective data collection directly from attending 
clinicians or patient records. This means they cannot be applied to retrospective 
dispensing databases which are often used in studies into the use of medicines, as data 
about comorbidities or laboratory test results are unlikely to be available (48).  In 
addition, the individuality of each assessment may increase accuracy at the cost of 
precision leading to inconsistent results due to subjectivity. This may reduce repeatability 
and therefore limit the usefulness of comparing results obtained using different experts or 
combining data in meta-analyses. 
 
Methods of assessing the reliability of rational prescribing tools is discussed further in 
Section 4.1 Evaluating rational prescribing tools. 
 
1.3.2 Rational prescribing assessment tools 
 
There are a number of well-established criteria used to study rational prescribing in adult 
medicine. Their development and use are closely linked to the principles of quality 
indicators, which are explicit, measurable statements about aspects of healthcare that can 
be used to assess care (49, 50). Prescribing indicators have been differentiated from 
rational prescribing criteria by being defined as an assessment of quality of care, where 
rational prescribing criteria and other review criteria assess the appropriateness of specific 
decisions (51). It is common for indicators to contain statements that rely on 
measurements at a population-level, for instance the five World Health Organisation 
(WHO) prescribing indicators, discussed further below. As in the WHO prescribing 
indicators, it is common that indicators are in the form of an expected percentage or 
measured prevalence within the studied population (52, 53). 
 
1.3.3 WHO prescribing indicators 
 
The WHO has made rational prescribing and improving medicines policies one of their 
priorities, and began developing indicators for measuring and monitoring use of 
medicines at a national level in 1985 (16). The WHO core prescribing indicators were 
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developed through iterative studies in prescribing across a number of countries and are 
not intended to be comprehensive. Rather, they comprise a simple tool that is 
standardised, does not need adaptation for use in different nations, and can be used to 
reliabl  assess a fe  cri ical aspec s of pharmace ical se  (54). 
 
The five core prescribing indicators are:  
1. Average number of drugs per encounter 
2. Percentage of drugs prescribed by generic name 
3. Percentage of encounters with an antibiotic prescribed 
4. Percentage of encounters with an injection prescribed 
5. Percentage of drugs prescribed from essential medicines list or formulary 
 
The WHO core prescribing indicators have been used internationally for over twenty 
years, studying prescribing in a wide range of settings, including public and private 
institutions, in both primary and secondary healthcare (55-57). Although their use is not 
explicitly restricted to any particular setting, they were designed and field-tested primarily 
in developing countries (58) 
 
1.3.4 Rational prescribing criteria 
 
In contrast to indicators, rational prescribing criteria, or rational prescribing tool, would 
be expected to capable of assessing a specific prescription without data about the rest of a 
study population (51). In other words, unlike an indicator statement based upon 
prevalence within a population, which can never be applied to an individual prescription, 
criteria would be expected to enable a rater to determine whether a specific prescription 
was appropriate according to a predetermined standard.  
  
Criteria lists are well-established tools in research in rational prescribing in adult medicine. 
A number of assessment tools have been developed to permit audit and research of 
rational prescribing using implicit or explicit criteria to measure prescribing practice in 
adults. Implicit criteria are patient-specific and take into account all medicines in the 
pa ien s c rren  regimen (59). They rely upon the assessor s j dgemen  of 
appropriateness and may accommodate patient preference, making them vulnerable to 
subjectivity and bias, and they are time-consuming to apply (15). Explicit criteria are 
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usually founded upon published reviews or consensus opinions, and often provide rigid 
drug-specific or disease-specific r les  of prac ice (59). They are therefore unable to 
account for individual patient differences and require regular updating, as well as 
modification for different regions (15). 
 
In a systematic review of published rational prescribing criteria, Kaufmann et al identified 
46 different assessment tools (60). Of these, 61% were explicit tools, 17% were implicit, 
and 22% used a mixed approach. 78% of the tools targeted older people, with the 
remaining tools having no specified targeted group. The study did not identify any tools 
designed for assessment of prescribing for children. There have been no systematic 
reviews of published rational prescribing criteria in children. 
 
It should be noted that rational prescribing criteria are not clinical guidelines or rulebooks 
for prescribers, but tools that are used to attempt to identify patterns of potentially 
irrational prescribing (in the very broad sense of ra ional prescribing  as defined b  he 
WHO, see Section 1.2.1) and in some cases to provide a quantifiable measurement of 
rational prescribing that facilitates comparative and interventional research. An individual 
prescription may be highlighted as potentially irrational by a criterion, but in fact be 
wholly appropriate and rational in the specific patient and environmental context it 
occurred. 
 
1.4 Examples of rational prescribing criteria from adult medicine 
 
1.4.1 Rational prescribing criteria for older adults 
 
The use of rational prescribing criteria as tools to study appropriate use of medicines is 
particularly well-established in older adult medicine, for which at least seven sets of 
explicit criteria listing potentially irrational prescribing have been published, as detailed in 
a 2010 systematic review (61).  
 
All seven of these criteria lists were developed through a modified Delphi consensus 
process. This development process is a method whereby consensus is reached by a panel 
of experts via an iterative activity in which members of the panel rate agreement with 
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statements, and the statements with levels of agreement above pre-defined cut-offs are 
redistributed to panellists for further consideration. Those that achieve a high level of 
agreement are ultimately included in the final product, in this case the list of criteria in the 
rational prescribing tool.  
 
The seven rational prescribing tools for older adults identified in the 2010 systematic 
review are shown in Table 1-A from Chang and Chan, 2010 (61). 
 
Table 1-A: Rational prescribing tools for older adult medicine 
Rational prescribing tool Country of development Number of criteria 
Beers US 68 
Laroche France 34 
McLeod Canada 38 
NORGEP* Norway 36 
Rancourt Canada 111 
STOPP/START** Ireland 65 
Winit-Watjana Thailand 77 
*NORGEP=Norwegian General Practice Criteria **STOPP/START=Screening Tool of Older Person s 
Potentially Inappropriate Prescriptions/Screening Tool to Alert doctors to Right Treatment 
 
In order to illustrate the development, scope and application of such tools, one was 
selected for further discussion. The Beers Criteria are a well-known and extensively 
studied example of these tools, having been repeatedly modified for use in different 
countries and to update to current practice(62-66), and are further described below.  
 
1.4.1.1 Beers Criteria 
 
The Beers Criteria were originally developed by Delphi consensus in 1991 specifically for 
application to nursing home residents (63) and have since been modified several times, to 
extend application to older adults in the community (62) and to update criteria over time 
(64, 65). They have been utilised both in prevalence studies assessing rates of irrational 
prescribing and also in outcome studies examining relationships between potentially 
inappropriate prescribing and health outcomes. They were most recently updated into the 
American Geriatrics Society (AGS) 2012 Beers Criteria (64). The criteria list potentially 
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inappropriate medications for adults aged 65 years and older, categorised into three 
groups: medications to avoid in all older adults, medications considered potentially 
inappropriate in older adults with certain diseases or syndromes, and medications that 
should be used with caution.  
 
The AGS 2012 Beers Criteria comprise fifty-three medications or medication classes. For 
example, fourteen fall within the category of medications considered potentially 
inappropriate in older adults with certain diseases or syndromes. 
 
The Beers Criteria have been used in a diverse range of studies. One systematic review 
found 18 studies evaluating patient outcomes related to Beers Criteria, undertaken in 
community and healthcare settings (67). This review supported the clinical accuracy of 
the criteria in terms of a relationship between potentially inappropriate medicines and 
poorer patient outcomes. It showed that inappropriate prescribing (as detected by the 
Beers Criteria) was associated with hospitalisation of older adults who were studied in 
community settings, and with adverse drug reactions and increased healthcare costs in 
healthcare settings. The Beers Criteria have also been used to study rational prescribing in 
primary care settings (68) and due to their design, are applicable to retrospective datasets 
such as those accessible via prescribing and administrative databases (69). 
 
The success of the Beers Criteria in achieving wide use and demonstrated usefulness has 
been credited to their explicit nature, simplicity for application by non-pharmacist 
researchers or auditors, and broad dissemination (66). 
 
1.4.2 Validation of rational prescribing criteria  
 
There are a number of approaches to validating rational prescribing tools. Any 
measurement can be considered in terms of accuracy and reliability, where accuracy 
represents how closely a measurement fits with a true value and reliability represents how 
close repeated measurements will be to one another. This is discussed further in Chapter 
5. 
 
When trying to assess the accuracy of a rational prescribing tool, the literal accuracy 
would be the correlation between a derived score with the true rate of irrational 
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prescribing. In the absence of a means to estimate the true rate, this might be calculated 
through comparison between different tools. Alternatively, rather than calculate the 
accuracy of the tool as a measure of prescribing, tools could be evaluated by assessing 
correlation between clinical outcomes with scores (15). Although this less closely 
represents the accuracy of the tool, high levels of correlation demonstrate the clinical 
usefulness of the tool. This validation approach is very useful for showing clinical impact 
of the inappropriate prescribing that has been identified but is time-consuming and 
technical to conduct. Only seven of the 46 adult tools discussed by Kaufmann et al had 
documented clinical validation studies assessing correlation between scores and clinical 
outcomes (60).  
 
A common and less complex approach to validating tools is evaluating their ability to 
identify irrational prescriptions in practice, without then attempting to test correlation 
with clinical outcomes. This methodology tests whether tools are able to identify any 
potentially irrational prescribing, although it does not measure the sensitivity or specificity 
of he ool as here is no comparison o r e  al es. This approach has been used 
widely, for instance to evaluate the START criteria (70). This can be taken further by 
applying two tools to the same data, such that rates of identified irrational prescribing 
detected can be compared between the two different tools. 
 
In order to assess the reliability of a tool, repeatability studies should be conducted. For 
instance, there are two published repeatability studies assessing the STOPP/START 
criteria, one evaluating inter-rater reliability when scored by pharmacists (71) and one 
evaluating inter-rater reliability when scored by physicians (72). These studies calculated 
the degree of agreement between different raters when looking at the same patient data 
(in each case, raters scored twenty anonymised patient records according to the 
STOPP/START criteria) and found good levels of agreement, suggesting that studies 
using the STOPP/START criteria that are conducted in different institutions or regions 
can be validly compared. 
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1.5 Studying prescribing for children 
1.5.1 Children are under-represented in clinical research 
 
Children are frequently excluded from clinical trials altogether, leaving adult data to be 
generalised to a paediatric population(9, 73). There is a recognised bias in health research 
priorities towards adult research. Studies of pharmacokinetics and pharmacodynamics in 
children are essential and have been historically neglected; more recent work has 
increased understanding of pharmacokinetics in the paediatric population, but paediatric 
pharmacodynamics remain less well understood (76). There are a number of challenges in 
studying pharmacodynamics in children; for example, the development of validated 
outcome measures is complicated by the need to accommodate a range of developmental 
stages (25). An illustration of this difficulty is the well-established use of exercise 
tolerance in the form of a timed walking distance, which is clearly not applicable to 
neonates and has a normal range that changes with age. Extrapolating data from adult 
studies, or so-called piggy-backing of a paediatric group onto a trial designed to evaluate 
drug safety and efficacy in adults can result in inadequate evaluation of the dose-response 
relationship across the range of the paediatric population (10).  
 
Using randomised controlled trials (RCTs) as an example, there are almost five times as 
many RCTs with exclusively adult participants compared with RCTs with exclusively 
child participants in data up to 2004 (74) and ongoing challenges despite ongoing efforts 
to increase the inclusion of paediatric populations (25). In studies that include both adult 
and child participants, data is often presented without separation by age groups and 
without subgroup analysis for children. This often limits conclusions for both safety and 
efficacy in this age group(75).  
 
Even when children are included in research, it is often not the whole childhood 
population of neonates through to adolescence (10). Trials are needed in all ages due to 
the changing physiology during growth and development. For example, the 
pharmacokinetics of some therapies, such as paracetamol, vary significantly between 
neonates, children, and adults (76) and dose calculation needs to take into account 
maturation of enzymes involved in metabolism and clearance. Likewise, biological 
markers that may be used to measure therapeutic response vary with age, for instance 
urea and creatinine are high in newborns and decline with maturation, later rising again in 
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older age(77). Such age-related differences mean studies that incorporate only a partial 
range of ages or fail to report data by age may obscure clinically significant results for 
particular age groups. 
 
The relative paucity of high-quality research involving children is especially acute in the 
field of pharmacology, as even where drugs are likely to be of significant relevance to 
paediatrics- such as those for treating Human Immunodeficiency Virus (HIV) and 
diabetes mellitus- they are often not licensed for use in children (78). Studies have shown 
that at least a quarter, and up to 90%, of all children treated in hospitals across Europe 
receive unlicensed and off-label drugs (79). Efforts to address this include the European 
Union (EU) regulations passed in 2006, which made it mandatory to evaluate all new 
medicines, or new indications for existing medicines, for potential paediatric use and 
sought to incentivise paediatric drug development research (80).  
 
The 10 year report to the European Commission showed that while there had been 
improvement, including authorisation of over 260 new medicines between 2007-2016 and 
over 131 completed paediatric investigation plans by the end of 2016, there remained 
substantial issues with important areas, such as paediatric oncology, remaining vulnerable 
to continued neglect compared to adult oncology research (81, 82). This is in spite of 
valuable progress that has been made in paediatric oncology, which has benefitted greatly 
from increased research activity in recent years and is a subject of paediatric study that 
has high rates of success in recruitment (10). There are other areas where the relative 
absence of paediatric evidence has resulted in potentially significant harm and certainly 
controversy, for example the treatment of adolescent depression and reported increased 
risk of suicidality (74). In addition to child and adolescent mental health, paediatric 
neurology and neonatology have been highlighted as disadvantaged by neglect compared 
to adult medicine (73). 
 
1.5.2 Perceived barriers to research involving children 
 
A number of possible explanations have been proposed for the under-representation of 
children in research, including economic, practical, and ethical issues (9, 83). 
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The phenomenon may in part be attributable to funding biases driven by governments 
and independent funding organisations towards greater funding opportunities in adult 
research (9). 
 
The disparity in funding is influenced by marketing considerations including the higher 
potential profitability of products and burden of disease in the adult population. Serious 
illness is rarer in children than adults, meaning that there are often smaller pools of 
potential participants available to trials targeting specific diseases in children compared 
with adults. Likewise, if an effective treatment is developed, there is ultimately a smaller 
market for the use of that treatment, which has led to children being described as 
herape ic orphans  since he phrase as coined in he 1960s (84).  
 
There are movements to counter this bias, with some governments and international 
agreements providing specific financial incentives for pharmaceutical companies to 
include children in their research (80, 83, 85). Support is also distributed through research 
networks (86) and child-focussed independent groups, including charities, providing 
alternative funding my own research having been supported by the Derbyshire 
Children s Research F nd. 
 
In practical terms, research that involves children may be more challenging to design and 
undertake because of the need to accommodate the range of cognitive and emotional 
development of child participants, and design outcome measures that are meaningful and 
measureable across different ages (87).  
 
There is also a perception that ethical issues surrounding paediatric research are more 
challenging than in adult research(88). Most guidelines internationally require researchers 
o gain bo h paren al consen  and, here children are capable of gi ing i , he child s 
assent(73). This supports the principle asserted in Article 12 of the United Nations 
Convention on the Rights of the Child that every child has a right for his or her views to 
be heard (89).  
 
The Nuffield Council on Bioethics 2015 report on children and clinical research 
proposed hree paradigms, or e ample cases, of children s capaci  i h respec  o 
decision-making in research (90): 
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1. Some children and young people are not able (at a given time) to give their view 
on their participation in clinical research. This example includes all babies and 
very young children, and some older children at certain times, for example if very 
unwell or unconscious. 
2. Some children and young people are not able (at a given time) to make 
independent decisions about their participation in clinical research but are able to 
form and express views, to varying degrees of sophistication. 
3. Some children and young people potentially have the ability, in terms of both 
intellectual understanding and emotional maturity, to make their own decisions 
about participation in clinical research while still being considered minors in some 
legal capacity. 
 
The report highlighted that many children will progress from the first through the second 
to the third of these paradigms with time and development, while some children may 
never progress past the first or second case, for instance due to developmental delay. 
Indeed, the progression is not necessarily always towards more capacity, as illness or 
injury may mean that a child moves from being more able to less able to make or express 
decisions. The authors emphasised that assessment of a child s abili ies in rela ion o hese 
paradigms should not be made on the basis of a diagnostic or age label but according to 
he indi id al child s de elopmen  and ma ri  in he con e  and a  he specific ime of 
decision-making. 
 
In order to gain informed assent, it is therefore necessary to develop information 
resources that are accessible to children of varying ages, literacy levels, and cognitive 
abili . There are a n mber of s ra egies ha  can be sed o increase par icipan s  
engagement with written material, and it is important to consider parental literacy as well 
as he child s de elopmen al s age and li erac . S ra egies include improving the 
readability of educational materials by ensuring that they use simple language, are short, 
clearly organised, and illustrated. Other strategies are the provision of concurrent verbal 
information with the written information. These methods have been shown to improve 
understanding, although they do not entirely mitigate the effects of low literacy(91). 
Wider involvement of parents, young people and children in study design is strongly 
encouraged as part of a general move to increasing public engagement in research; this 
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has the dual aim of ensuring ethical and responsible research by empowering lay 
participants and improving the quality of research by optimising study design (92). 
 
For younger children or those with developmental delay such that they do not progress 
past the first or second paradigms highlighted in the Nuffield Council on Bioethics 
report, it is not possible to gain meaningful assent, yet research in neonates and other 
children is still crucial to ensuring high-quality and evidence-based treatments are 
available for them. Neonates present unique challenges, for instance their low blood 
volumes mean that they are vulnerable to anaemia due to blood sampling, limiting the 
volume of permissible research-related blood sampling (83). 
 
A bes  in eres s  approach allo s e perimen al rea men s i h reasonable probabili  of 
benefit to participants to proceed in the same way as any clinical therapy for the child, but 
in the case of neutral or non-beneficial research (for instance, where a child is included as 
a healthy control), there are some schools of philosophy that would deem all such 
research completely impermissible. This is reflected in European law, where research is 
only permitted when direct benefit is expected for the child (81, 82). This necessitates a 
close consideration of the balance between risk and benefit, as well as considering the 
balance be een risk and benefi  in he con e  of a child s a ailable al erna i es (83). In 
these areas, others argue that collective benefit, altruism, and compensation to the parents 
or child are morally relevant and influence the acceptability of non-beneficial (but non-
harmful) research (93).  
 
However, it should perhaps be argued that similar challenges exist in adult medicine, 
where a common level of education and literacy cannot be assumed across a broad field 
of potential participants, and clinical outcomes may need to be set in the context of 
pa ien s  baseline activities of daily living. This would seem particular pertinent in older 
adult medicine, and it is relevant to note that adults aged over 65 are also relatively under-
represented in clinical research(94-96). 
 
In the case of literacy, the design and accessibility of information involved in consent is 
extremely important in adult medicine as well as paediatrics, given that more than a 
quarter of adults in the UK have low literacy or numeracy skills, meaning that they 
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s r ggle i h basic q an i a i e reasoning or ha e diffic l  i h simple ri en 
informa ion  (97). 
 
Equally, when considering the developmental stage of a child in terms of the paradigms 
presented by the Nuffield Council on Bioethics report, it must be recognised that such 
challenges are faced in many areas of adult research including research involving patients 
with cognitive impairment or dementia(98, 99), who may lack capacity to consent, and 
research into emergency and trauma medicine where patients may have altered levels of 
consciousness affecting their ability to consent(100). As in paediatric research, in these 
areas it is usual that consent by proxy is sought. In the case of paediatric participants this 
is usually from parents or guardians, but it remains important to consider the par icipan s 
views and interests throughout. 
 
In summary, the ethical challenges present in paediatric medicine exist across the 
spectrum of adult research too, but are possibly more visible, in part due to the 
appropriate high level of attention that is paid to issues around capacity and consent. 
There certainly is a challenge, however, in carrying out research with meaningful 
application across the wide range of paediatric medicine, from neonates to adolescents. 
 
1.5.3 Rational Prescribing for Children 
 
Rational prescribing for children faces the challenge of a frequently limited evidence base 
to guide clinical decision-making and has been described as an e idence based deser  
(page 1465 (101)).  
 
Due to the under-representation of children in research, discussed in Section 1.5.1 (page 
16), it could be argued that rational prescribing for children is more challenging due to 
there being less available evidence to guide decision-making and the necessary use of 
medicines for unlicensed off-label indications in children (78). In addition, children 
present additional challenges to high-quality prescribing, for example the need to account 
for growth and maturation, affect not only bodyweight and weight to surface area ratios 
but also drug absorption, maturation of metabolic pathways, and drug distribution (5). 
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There is no published review of rational prescribing tools for children. However, there 
are a number of areas of prescribing for children that have been widely studied and are 
known to be vulnerable to inappropriate prescribing. Examples of misprescribing, 
overprescribing and underprescribing have been demonstrated. 
 
Misprescribing is a broad area of irrational prescribing that includes inappropriate dosing, 
drug interactions, and clinical indication (15). This is an area where children may be 
particularly vulnerable due to the need for age- and weight-based dosing calculations, 
which are an added opportunity for inappropriate prescribing as compared to adult 
medicines with a standard dose (4). A study of antiretroviral therapy for children with 
HIV found that up to 62% of the time, children were prescribed inadequate doses (less 
than 90% of the recommended dose) (102). The study identified three key factors leading 
to misprescribing. The first was incorrect dose guidance at initial licensing, inconsistent 
dosing due to guidelines given dose by both weight and surface area, and inadequate or 
delayed adjustment of doses for ongoing growth. This highlights the particular challenges 
of chronic disease management in children, where ongoing metabolic maturation and 
growth necessitate regular dose adjustments (5). 
 
A 2019 statement from the European Academy of Paediatrics identified a number of 
concerning areas where overtreatment is thought to be common practice across Europe, 
including the use of proton-pump inhibitors for gastro-oesophageal reflux (GORD) in 
infants (103). While these drugs are sometimes indicated to manage GORD that causes 
distress and may have an impact on feeding and growth, they are often prescribed with 
little evidence of true GORD on the basis of common feeding problems like vomiting or 
crying (104). This is an area where overtreatment has clear potential for harm as long-
term use of acid-suppressing medications for GORD in infants is associated with a 
number of adverse effects, including nosocomial infections, vitamin B12 deficiency, 
hypomagnesaemia, and bone fragility (105).  
 
Pain management has been an area of historical undertreatment of children, to the extent 
that it was previously believed neonates did not feel pain and were routinely operated on 
and managed in intensive care with little or no sedation (106).  There continues to be 
evidence of undertreatment of pain in children due to a number of factors, including 
clinician fear of adverse effects, difficulty in assessing pain in younger age groups,  
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underdosing, and time constraints in emergency care exacerbated by the difficulty in 
securing patient compliance (107-109). 
 
Despite the evidence of significant irrational prescribing in paediatrics, the use of rational 
prescribing tools to study the phenomenon is not yet widespread as it is in adult 
medicine. A systematic review of adult rational prescribing assessment tools was 
conducted in 2014 (60), this is discussed further in Chapter 2. Prior to my work there had 





Rational prescribing is an area of research with the potential to have significant economic, 
social, and health impact. Irrational prescribing costs institutions and systems in 
unnecessary or needlessly expensive drugs, and in the cost of care for any subsequent 
morbidity that results from suboptimal treatment of patients or direct adverse reactions 
to superfluous medications. Patients and communities benefit from high-quality 
prescribing and it is essential to be able to identify good prescribing in order to recognise 
targets for improvement, to study interventions, and to compare systems, institutions, or 
regions.  
 
The use of medicines in children has historically been under-researched and consequently 
paediatric pharmacology suffers from a paucity of strong evidence to support practices, 
with many and sometimes (such as in neonates) the majority of medications being used in 
an unlicensed or off-label manner. This illustrates the importance of further work 
examining the use of medicines in children to facilitate improvement.  
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1.7 Rationale for the thesis 
 
This thesis is presented in six chapters, including this introductory chapter. 
 
1.7.1 Aims of the thesis 
 
The aim of the thesis was to identify any existing rational prescribing tools for studying 
irrational prescribing for children; to appraise existing tools; in the absence of an existing 
tool, to develop rational prescribing criteria that could be used across paediatric practice 
in the UK; and to validate the novel tool in the study of rational prescribing for children. 
 
1.7.2 Objectives and outline 
 
The objectives of the thesis are to: 
 
Chapter 2 
1. Conduct a systematic review of databases of medical, allied healthcare and 
pharmaceutical research to identify existing paediatric rational prescribing tools. 
2. Analyse the characteristics of existing paediatric rational prescribing tools 
including the methodology of development, breadth of clinical application, and 
validity.  
Chapter 3 
1. Modify an identified paediatric rational prescribing tool designed for use outside 
the UK to enable its application to UK paediatric practice. 
Chapter 4 
1. Validate the new tool in UK paediatric practice in order to assess its usefulness to 
identify irrational prescribing. 
2. Evaluate the patterns of irrational prescribing identified by the new tool. 
Chapter 5 
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Figure 1-4 below presents an overview of how each chapter achieved the objectives of 
the thesis. 
 
Chapter 2 The systematic review of rational prescribing tools for children 
identifies two extant tools for assessing rational prescribing for children. 
Two tools, POPI and PIPc, are discussed in detail in terms of their 
development, characteristics, and any existing research using the tools. 
Chapter 3 The chapter on modifying the POPI criteria discusses the original 
POPI tool and describes the methods and results of identifying and 
applying modifications that were necessary to utilise the tool in a UK 
setting. The resulting POPI UK tool is presented. 
Chapter 4 A study was conducted to clinically evaluate the POPI UK criteria, 
in order to assess its usefulness in a clinical setting. The methodology 
and results of this evaluation of the POPI UK tool are presented. 
Chapter 5 A further study to test the precision of the POPI UK criteria was 
conducted. The methodology and results of inter- and intra-rater testing 
of the POPI UK criteria are presented and are put in context with 
comparison to other rational prescribing tools. 
Chapter 6 The conclusions of the above research are summarised and discussed. 
The three paediatric rational prescribing tools described in the work are 
compared. The impact of the work is considered and future directions 
for further research are identified. 
Figure 1-4: Overview of thesis 
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The use of criteria lists as tools to quantify rational prescribing in adult medicine has been 
discussed in chapter one. As described in chapter one, there are a number of potential 
benefits to rational prescribing tools. By enabling quantification of the quality of 
prescribing, assessment tools facilitate research into interventions aiming to improve 
prescribing by allowing before and after measurements of quality. Furthermore, explicit 
criteria enable objective measurement of prescribing, which allows research to reliably 
compare prescribing in different settings, between different institutions, nationally and 
internationally. This facilitates deeper research into root causes of problematic 
prescribing, or excellent prescribing, and fosters collaboration between different groups 
(64). 
 
As discussed in Chapter 1, Ka fmann e  al s 2014 s s ema ic re ie  of rational 
prescribing tools for adults identified 46 published tools (60). Of these, 22% did not have 
a stated targeted population, while 78% were specifically targeted to prescribing for older 
adults.  
 
One possible reason for the high number of tools targeted to older adults is that some 
authors have identified them as being particularly vulnerable to irrational prescribing due 
to a variety of factors, including frequent existence of co-morbidities, polypharmacy, care 
taking place in a number of different settings, and the effect of ageing on the selection of 
appropriate medications (15, 110). Many similar challenges exist in paediatric medicine, 
with well-recognised developmental changes in physiology and metabolism having 
significant impact on pharmacokinetics in children of different ages (5) In addition, 
children may be prescribed medications in a number of different settings, including 
general practice, undifferentiated emergency departments, walk-in centres, paediatric 
wards in district general hospitals, and specialist paediatric hospital settings. This means 
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that prescribers with varied levels of paediatric experience and expertise may be 
responsible for prescribing. 
 
Kaufmann et al explicitly excluded tools targeted to children in their 2014 review (60). 
The objective of this systematic review of paediatric rational prescribing tools was to 
produce a comprehensive overview of current tools available to measure rational 
prescribing in children. It also sought to characterise the tools in terms of methodology 
of development, content and scope (in terms of included drug or disease groups), and 
aspects of rational prescribing measured. 
 
The systematic review reported in this chapter has been peer-reviewed and published 





The primary outcome of the systematic review was to identify all published paediatric 
rational prescribing tools. The secondary outcome was to identify the types of rational 
prescribing and drugs or drug groups included in these tools. The population of children 




The systematic review was designed in accordance with the PRISMA checklist (112), only 
excluding irrelevant items. Excluded items were those specific to reviews of 
interventional research (risk of bias assessment in items 12, 15, 19 and 22) and to 
statistical analysis in meta-analyses (13, 16 and 21). The completed PRISMA checklist 
with page numbers given for this thesis is shown in   
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Table 2-A: PRISMA checklist from Moher et al, 2009 (112).  
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  26 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
xii 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  27 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
27 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including 
registration number.  
26 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 




7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and date 
last searched.  
28 
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
29 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 




10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators.  
29-30 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
30 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 




13 State the principal summary measures (e.g., risk ratio, difference in means).  X 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis.  
30 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence 




16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
X 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
30-32 




18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.  
33 
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
X 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 




21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
X 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  X 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 





24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
42 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of identified research, reporting bias).  
52-53 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research.  
54 
FUNDING  
Funding 27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
i 
 
2.3.1 Eligibility criteria 
 
The search was designed to identify articles describing tools to evaluate rational 
prescribing for children, including updated or modified versions of established tools, 
adaptations of previously published tools, or the new development of tools. Eligible tools 
were those targeted at prescribing for children aged less than or equal to 18 years. Tools 
targeted at prescribing for adults or without a specified target patient group were not 
eligible. Indicators that did not identify individual prescriptions as rational or irrational 
but relied upon population datasets to suggest appropriate levels of prescribing (e.g. as 
percentages) were also not eligible. 
 
An age range of 0-18 was selected as the most inclusive definition; 0-16 or 0-17 years are 
alternative definitions which have been used in some texts but not others, and these 
therefore risks inappropriately excluding some relevant tools. 
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Inclusion criteria were: articles describing tools targeted at evaluating the rationality or 
appropriateness of prescriptions for children aged less than or equal to 18 years, updated 
and revised versions of previously published tools, and including tools limited to specific 
drugs, drug groups, diseases or disease groups.  
 
Exclusion criteria were: tools targeting adults, tools without specified target patient 
groups, indicators that assess rates or percentages of prescription types in a population, 
articles describing a validation study of a previously published tool, educational 
interventions aimed at improving prescribing, and guidelines describing recommended 
prescribing. 
 
2.3.2 Search strategy 
 
The search was conducted in four databases in order to attempt to capture relevant 
medical, allied healthcare and pharmaceutical research. These were: Medical Literature 
Analysis and Retrieval System Online (MEDLINE), Embase, International 
Pharmaceutical Abstracts (IPA) and the Cumulative Index of Nursing and Allied Health 
Literature (CINAHL). Databases were searched on 23rd February 2016 from their earliest 
records possible, i.e. until 2016 week 8. The same search strategy was subsequently used 
to update the review on 29th July 2019 until 2019 week 31. 
 
2.3.2.1 Search terms 
 
Search terms to capture studies including children were derived from the recommended 
search strategy described by Kastner et al 2006 (113), as these have demonstrated high 
sensitivity. The MeSH erm inappropria e prescribing  as in rod ced in 2011 and as 
pre io sl  incorpora ed in he broad erm Dr g herap . Search erms for ra ional 
prescribing were derived from the systematic review of adult rational prescribing tools by 
Kaufmann et al 2014 (60), as this review had very similar aims to my own search (for 
adult rather than paediatric tools). Therefore the combined terms were: 
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(inappropriate prescribing or suboptimal prescribing or inappropriate medication or 
inappropriate practices or drug prescriptions or Medication Appropriateness Index) and 
(child* or children* or p*ediatric* or infant* or adolescent*). 
 
The terms were applied to each database, results collated and duplicates removed prior to 
screening. 
 
2.3.3 Study selection 
 
All potentially relevant publications were screened by the author by title and abstract and 
articles that met the exclusion criteria were excluded. The remaining articles were 
retrieved in full. Full-texts were examined by the author and a research nurse (JA) who 
performed independent full-text screening, independently assessing articles according to 
the inclusion and exclusion criteria. In the updated search in 2019, the full-text sceening 
was completed by the author and a doctor (TM). After this process, any articles without 
consensus were resolved by discussion and mutual agreement. 
 
2.3.4 Data collection 
 
The following proforma was designed to record data from included articles. Aspects of 
inappropriate prescribing were divided, as has previously been described, into 
misprescribing, underprescribing, and overprescribing, with further categories of 
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Figure 2-1: Data collection proforma, adapted from Kaufmann et al (60) 
 
2.4 Results 
2.4.1 Original search results 
 
The search performed in 2016 produced 1,462 potentially relevant publications in 2016. 
One hundred and seventy-two duplicated articles were removed, 1,290 articles were 
screened by title and abstract and 1,143 were excluded. Four full-texts were unavailable 
online, from University library resources, and from the British Library. Both reviewers 
then reviewed 143 full-texts and 140 were excluded.  
 
In terms of reasons for exclusion of the 140 excluded full-texts, 110 did not describe 
rational prescribing tools, 21 did not relate to children, 8 were not related to rational 
prescribing, and one reported a validation study of a previously published tool. 
 
In the case of the four full-texts that were unavailable the abstracts suggested that these 
articles would not meet inclusion criteria, although this could not be determined with 
certainty. Three articles met the inclusion criteria. Bibliography mining of the included 
articles did not produce any further relevant articles. This is depicted in the flowchart in 
Figure 2-2. 
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Figure 2-2: Flowchart of screening process for original search in 2016.  
 
Figure 2-2 is adapted from:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA 
Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
  





1,143 articles excluded 
according to titles 
and/or abstracts
• 135 were not related 
to rational 
prescribing
• 77 were not related 
to children
• 931 did not describe 
tools
147 articles assessed 
for eligibility
0 additional records 
identified by manual 
search of references of 
included articles
140 articles excluded

























• 4 full-texts not
available
143 full-texts  assessed 
for eligibility
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2.4.2 Updated search results 
 
The literature search was updated in June 2019 to ensure currency of the findings. The 
updated search identified 680 potentially relevant new publications since the search in 
2016. Sixty-two duplicated articles were removed. Of the 618 articles screened by title and 
abstract, 593 were excluded, 25 full-texts were reviewed by both reviewers and 23 were 
excluded. Two articles met the inclusion criteria. Bibliography mining of the included 
articles did not produce any further relevant articles. This is depicted in the flowchart in  
Figure 2-3. 
 
Figure 2-3: Flowchart of screening process for updated search in 2019.  
 





593 articles excluded 
according to titles 
and/or abstracts
• 109 were not related 
to rational 
prescribing
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• 416 did not describe 
tools
25 full-texts assessed 
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search of references of 
included articles
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children
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Figure 2-3 is adapted from:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA 
Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
2.4.3 Rational prescribing tools identified 
In total, five relevant articles were identified, relating to three paediatric rational 
prescribing tools: POPI, PIPc and POPI UK. These are shown below in Table 2-B. 
 
Table 2-B: Included articles describing paediatric rational prescribing tools. 
Included article Rational 
prescribing tool 
Year Language Country 
POPI; pédiatrie: omissions et 
prescriptions inappropriées 
[POPI: A tool to identify 
potentially inappropriate 
prescribing practices for children.] 
(114) 
POPI 2011 French France 
POPI (Pediatrics: Omission of 
Prescriptions and Inappropriate 
prescriptions): development of a 
tool to identify inappropriate 
prescribing (115) 
POPI 2014 English France 
Valida ion pa  con en  d n 
o il d iden ifica ion de 
prescriptions inappropriées en 
pédiatrie (POPI) [Consensus 
validation of a tool to identify 
inappropriate prescribing in 
paediatrics (POPI)] (116) 
POPI 2016 French France 
PIPc study: development of 
indicators of potentially 
inappropriate prescribing in 
children (PIPc) in primary care 
using a modified Delphi 
technique. (117) 
PIPc 2016 English Ireland and 
UK  
Developing paediatric rational 
prescribing criteria. (118) 
POPI UK 2017 English UK 




The initial systematic search identified three relevant articles, all relating to a single tool: 
POPI (English: Pediatrics: Omissions of Prescriptions and Inappropriate Prescriptions; 
French: pédiatrie: omissions et prescriptions inappropriées) tool (114-116).  All three included 
articles are very similar, two in French and one in English, and describe the process of 
developing the POPI tool. All three articles have the same first author, S. Prot-Labarthe, 
with various other authors contributing to each. The earliest, from 2011, is a letter 
describing the tool. This does not detail all the criteria, only giving nine examples. The 
2014 and 2016 articles are English and French language respectively and both report the 
consensus validation of the tool and give full details of the criteria.  
 
For the purposes of clarity, from this point onwards reference to the POPI criteria is 
specifically to the wording and numbering in the English 2014 publication unless 
otherwise stated. The differences between the versions are described in Section 2.5.4 
(page 55).  
 
Two additional relevant articles were identified in the 2019 updated search, each relating 
to separate tools. One of these was a publication related to the novel tool developed 
within this thesis, describing the POPI UK tool as discussed in Chapter 3 (118). As this 
publication was a product of this thesis, it is not further analysed within this chapter but 
can be viewed in full in Appendix 2. 
 
The other article related to the development of a rational prescribing tool for evaluation 
of paediatric prescribing in primary care, indicators of potentially inappropriate 
prescribing in children (PIPc) (117). This was developed in Ireland and the UK and was 
published in September 2016. 
 
2.4.4 Characteristics of POPI  
 
The POPI tool comprises 105 criteria (80 PIMs and 25 PIOs) categorised by the authors 
according to broadly grouped clinical conditions: diverse illnesses, digestive problems, 
ENT-pulmonary problems; dermatological problems; and neuropsychiatric disorders. 
The groups are further subdivided into particular symptoms or conditions. The criteria 
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cover a range of aspects of inappropriate prescribing, including overprescribing, 
underprescribing, and almost all areas of misprescribing except drug-food interactions. 
No specific arge  se ing for he ool s applica ion is iden ified, al ho gh he majori  of 
guidelines and all experts in the panel were French. 
 
The POPI tool is not specifically limited to use in any particular clinical setting. The 
propositions were selected from paediatric health problems in the general population and 
as causes for hospitalisation, suggesting the tool would be relevant to both primary and 
secondary care. However, no primary care specialists or general practitioners were 
involved in the development of the tool. The paediatric population targeted by the tool as 
a whole is not defined by the authors but some propositions are age-specific, for instance 
pharmacological treatment for attention deficit disorder is described as inappropriate 
before age 6 (before school)  (page 7, (115)) and topical 0.1% tacrolimus is considered 
inappropria e for a opic ec ema before 16 ears of age  (page 6, (115)). 
 
The criteria of the POPI tool cover a wide range of types of irrational prescribing, 
including all three categories of underprescribing, overprescribing, and misprescribing. 
Underprescribing is specifically identified in the tool as omissions. The inappropriate 
prescription propositions include some examples of overprescribing and misprescribing. 
Further examples of types of irrational prescribing are listed in Figure 2-4. 
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Aspect of rational prescribing Example of related inappropriate 
prescription or inappropriate omission 
of prescription proposition from POPI 
(theme) 
Drug Nitrofurantoin used as a curative agent in 
children under six years (Urinary 
infections) 
Dosage Oral solutions of ibuprofen administered 
in more than three doses per day using a 
graduated pipette of 10mg/kg (Pain and 
fever) 
Duplication The combined use of two NSAIDs (Pain 
and fever) 
Duration The application of ben l ben oa e  for 
periods longer han eigh  ho rs  
(Scabies) 
Drug-drug interaction Isotretinoin in combination with a 
member of the tetracycline family of 
antibiotics (Acne Vulgaris) 
Drug-disease interaction Loperamide in the case of invasive 
diarrhoea (Diarrhoea) 
Overprescribing Antibiotic treatment for a sore throat, 
i ho  a posi i e rapid diagnos ic es  
(ENT infections) 
Underprescribing Omission: Oral rehydration solution 
(Diarrhoea) 
Figure 2-4: Aspects of rational prescribing included in the POPI tool 
 
2.4.5 Characteristics of PIPc  
 
PIPc comprises twelve criteria of PIMs and PIOs, categorised according to four 
physiological systems: respiratory, gastrointestinal, dermatological, and neurological. 
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Seven statements describe PIMs with potential overprescribing or misprescribing 
practices, five statements relate to PIOs. PIPc is designed specifically for use in primary 
care in Ireland and the UK. 
 
By contrast to POPI, the PIPc is by design a tool that is simpler to apply and that requires 
minimal clinical information about a patient. The only clinical diagnosis specified in the 
tool is a presumed diagnosis of asthma in two criteria. In the absence of clinical 
information, this diagnosis is presumed on the basis of the prescriptions described, e.g., 
An inhaled shor -acting ß2 agonist should be prescribed to children under 5 years who 
are also aking a le ko riene recep or an agonis  for pres med as hma  (page 8 (117)). 
 
I  sho ld be no ed ha  he a hors of PIPc se he erm indica ors  o describe and 
name the tool, however the statements all meet the definition of rational prescribing 
criteria as discussed in Section 1.4.1 (page 12). The authors use the terms interchangeably: 
prescribing cri eria (indica ors)  (page 1, (117)). In this thesis the terms are used 
distinctly to facilitate greater nuance in some areas of discussion. 
 
The PIPc is a tool that has been designed specifically for application in a primary care 
setting. Unlike the POPI tool, it was developed with the intention of being applicable 
without access to clinical information, meaning that it can be used to evaluate data from 
large previously collected prescribing databases where clinical information is often either 
omitted or concealed. 
 
The authors of the PIPc defined their paediatric population as children less than 16 years 
of age. The age at which young people transition from paediatric to adult healthcare 
services can vary depending on health needs, social circumstances such as attendance in 
full-time education, and availability of specialist services (119). In addition, to the 
specified population for the tool, some criteria further specify particular age ranges, for 
example, Loperamide sho ld no  be prescribed o children nder 4 ears  (page 8, 
(117)); this particular criterion fits with the licensing restriction of loperamide as recorded 
in the BNFc (120). 
 
As shown in Figure 2-5, the PIPc criteria describe almost as broad a range of types of 
potentially irrational prescribing as POPI despite having far fewer criteria. An example 
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criterion for each aspect of irrational prescribing described in the PIPc criteria is shown 
below in Table 2-C. 
 
Table 2-C: Aspects of irrational prescribing included in PIPc 
Aspect of rational prescribing Related inappropriate prescription or inappropriate omission 
of prescription proposition from PIPc (theme) 
Drug choice Tetracyclines should not be prescribed to children under 12 years 
(Dermatological) 
Drug-disease interactions An inhaled short-acting ß2 agonist should be prescribed to all 
children who are prescribed two or more inhaled corticosteroids for 
presumed asthma (Respiratory) 
Drug-drug interactions Domperidone should not be prescribed concomitantly with 
erythromycin (Gastrointestinal) 
Overprescribing Sedating antihistamines should not be prescribed to children under 2 
years (Neurological) 
Underprescribing Children under 12 years who are prescribed a pressurised metered-
dose inhaler should also be prescribed a spacer device at least every 
12 months (Respiratory) 
 
 
2.4.6 Development of POPI  
 
The methodology used to develop the POPI tool was designed to closely match the 
development of STOPP/START criteria, according to the authors (page 7, (115). As 
discussed in Section 1.4.1 (page 12), the STOPP/START criteria were developed in 
Ireland as a rational prescribing tool for use in older adult medicine (121) comprising two 
lis s; he STOPP  lis  of medica ions ha  are inappropria e and sho ld be s opped, and 
the START  lis  of po en iall  inappropria e omissions. The  ere designed o pda e 
the widely used Beers Criteria (62), as it listed a number of medications not in use in 
Europe and at the time had a number of out-dated criteria. In the STOPP/START tool, 
the authors chose to structure their criteria according to physiological systems in order to 
mirror the usual organisation of drug formularies.  The propositions of STOPP/START 
were finalised via an eighteen-member panel two-round Delphi consensus where 
agreement was determined according to the Kappa (𝜅) statistic for agreement and 
participants were able to suggest additional criteria if desired (122). The propositions of 
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The authors aimed to structure POPI around approximately 100 propositions classified 
according to biological system and divided into PIOs and PIMs. The number of 
proposi ions as chosen as a good compromise be een he n mber of major biological 
systems to explore, the number of items in the geriatric lists and the maximum number of 
i ems compa ible i h a ool eas  se  (page 2, (115)). The authors then compiled a list of 
health problems that are frequently encountered in paediatric practice, according to 
frequency in the general population (source not specified), prevalence (derived from data 
from the French National Insurance Fund for Employers for long term conditions), and 
frequency as cause for hospitalisation (per French hospital medico-administrative 
records). The authors identified health problems from this list, referred to as themes, that 
would either require drug intervention or where pharmacological intervention would be 
considered inappropriate. 
 
For each selected theme, the authors then conducted a literature search (unpublished) to 
identify recommendations on management. There was a requirement for 
recommendations to be evidence-based, but the authors did not specify the level of 
evidence. Only recommendations published after 2000 were accepted, and these were 
then weighted by date of publication. Accepted sources of recommendations were the 
French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Produits de 
Santé), the French National Authority for Health (Haute Autorité de Santé Française), the 
French Society for Paediatricians (Sociétè Française de Pédiatrie), the American Academy of 
Pediatrics (National Guideline Clearing House), and the National Institute for Health and 
Clinical Evidence Cochrane Library. They also used the MEDLINE database to search 
for examples of medication error and inappropriate prescription (search strategy 
unpublished). The selection of French versus international guidelines was not explored 
f r her in he repor  describing POPI s de elopmen . 
 
Subsequently, the propositions were then validated by a two-round Delphi consensus. 
Sixteen experts, including pharmacists and paediatricians, were included, of which ten 
responded to both rounds of the Delphi consensus. The process of recruitment of 
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experts is not explicitly stated, only that most pharmacists were members of the French 
Society of Clinical Pharmacy and most paediatricians were members of the French 
Society of Pediatricians. Propositions were rated by panellists on a nine-point Likert scale 
for agreement; additionally the panellist experts were invited to make free text comments 
and to suggest dosage, frequency or duration of therapies if they could provide evidence-
based sources to support the suggestions. Propositions with a median score in the upper 
tertile (i.e. 7-9 points) with agreement above 65% were retained, modified according to 
comments, then sent out in the second round. Propositions with a median score in the 
upper tertile with agreement above 75% were then retained. 
 
2.4.7 Development of PIPc 
 
PIPc was also developed by a two round Delphi consensus method. Initial propositions 
were selected via a systematic literature search for previously developed indicators for 
paediatric prescribing with the criteria as shown in Table 2-D, adapted from Barry et al, 
2016 (117). 
 
Table 2-D: Inclusion and exclusion criteria of indicators selected for PIPc 
Inclusion criteria describe hazardous or ineffective prescribing  
describe prescribing outwith best practice or current guidelines 
apply to children < 16 years 
Exclusion criteria medications unavailable in the study setting 
criteria that require clinical information 
criteria containing rarely used medications  
 
A steering group from Ireland and Northern Ireland, comprising academic and clinical 
general practitioners (GPs), academic and clinical pharmacists, a 
pharmacoepidemiologist/statistician, and a postdoctoral researcher, assessed each 
indicator. Indicators that were not felt to meet the above criteria were excluded. In some 
cases, indicators were modified to meet the need for criteria that could be applied without 
access to clinical information, for example when evaluating data from a dispensing 
database.  
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The panel for the Delphi consensus was recruited by email invitation, which was sent to 
30 specialists identified by the project steering group as experts in their field. Of those 
invited, eighteen accepted the invitation, nine from the Republic of Ireland (three GPs, 
three paediatricians, and three pharmacists) and nine from the UK (three GPs, three 
paediatricians, and three pharmacists). Web-based questionnaires were sent to panel 
members containing proposed indicators, rationale for their inclusion, and relevant 
evidence such as national or international guidelines. Panellists indicated level of 
agreement with the inclusion of indicators on a five-point Likert scale and items with 
consensus among the panel were accepted. Items without consensus were reviewed and 
either rejected or revised and presented in the second questionnaire. After the second 
round, any criteria without consensus were rejected. 
 
The literature search identified 47 potential criteria, of which 31 were removed by the 
steering group after assessment against the inclusion and exclusion criteria listed in Table 
2-D. Sixteen indicators were presented in the first round of the Delphi process and nine 
items had consensus for inclusion, with seven being reviewed. Two of the seven were 
rejected on the basis of comments from the Delphi panel and five were amended and 
presented in the second round. Three of these reached consensus while two were again 
rejected. This resulted in twelve criteria being ultimately accepted into the final PIPc. 
 
Reasons for rejected criteria included the need for clinical information, for example in 
determining the appropriateness of use of very potent corticosteroids. Other criteria were 
rejected due to panellists commenting that on rare occasions, the described prescribing 
would be appropriate, for example systemic corticosteroids in children aged 5-15 years 
as rejec ed i h commen s s ch as, Agree unless there is a clinical indication such as flare of 
j e ile he ma id a h i i . 
 
The twelve accepted criteria came within four clinical categories: respiratory system (six 
criteria), gastrointestinal system (two criteria), dermatological system (two criteria), and 









This systematic literature review identified two paediatric rational prescribing tools, the 
PIPc and the POPI tool.  
 
2.5.1 Comparison of rational prescribing tools 
 
The PIPc is designed for use in primary care settings, while the POPI tool is developed 
for application in a range of settings and has already been tested in emergency department 
and community pharmacy paediatric practice (123). This breadth of settings where POPI 
can be applied is similar to the range of settings in which rational prescribing tools for 
older adults are used, which include residential or nursing homes (Sloane (124)), hospitals 
(Oborne s (125)), and primary care (NORGEP (126)). 
 
Both paediatric tools identified cover a range of types of rational prescribing, the POPI 
tool covering a particularly broad range. By comparison, the majority of adult rational 
prescribing tools identified by Kaufmann et al (60) had a narrower focus. Kaufmann et al 
described twelve categories of irrational prescribing, listed below. 
 
x Drug choice 
x Dosage 
x Duration of therapy 
x Duplication 
x Drug-drug interaction 
x Drug-disease interactions 
x Drug-food interactions 
x Overprescribing 
x Underprescribing 
x Cost effectiveness 
x Non-adherence 
x Alternative therapies 
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Of the 46 adult tools identified by Kaufmann et al, the median number of categories of 
rational prescribing covered by each tool was 4.5, similar to the PIPc, which covers five 
aspects. However, four tools did cover eight or nine categories of prescribing, 
comparable to POPI, which covers eight. 
 
Of the adult tools evaluated by Kaufmann et al, the majority of tools (28) were explicit, a 
minority (eight) were implicit, and the remaining 10 used a mixed approach. As described, 
PIPc was developed as an explicit tool while POPI has both implicit and explicit criteria. 
There are advantages to each as discussed in Chapter 1. Implicit criteria may be more 
accurate, as they can take into account individual patient requirements, but this may come 
at the cost of reliabili  as he  are more dependen  on he ra er s kno ledge and 
judgement (15). The reverse is true of explicit tools, which are less reliant on rater 
judgement and therefore might be expected to have greater repeatability and reliability 
and be less time-consuming to apply, with concomitant lower accuracy. Mixed tools 
therefore may stand to inherit both the advantages and disadvantages of each approach. 
 
Defining implici  cri eria as hose hich req ire informa ion abo  a pa ien s o her 
medications or medical history, and explicit criteria as those which only require basic 
demographic information and the indication for a given prescription, both POPI and 
PIPc are shown to be mixed implicit and explicit criteria lists.  
 
These definitions can be illustrated from PIPc; an example of an implicit criterion is: An 
inhaled short-acting B2 agonist should be prescribed to all children who are prescribed 
o or more cor icos eroids for pres med as hma . An example of an explicit criterion is: 
Loperamide sho ld no  be prescribed o children nder 4 ears . POPI comprises 65% 
implicit and 35% explicit criteria, while PIPc comprises 50% of each type, as shown in 
Table 2-E. 
 
Table 2-E: Number of implicit and explicit criteria in POPI and PIPc 
Tool Implicit criteria Explicit criteria 
POPI 68 (65%) 37 (35%) 
PIPc 6 (50%) 6 (50%) 
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In terms of structure and complexity the POPI tool comprises a relatively high number of 
criteria compared with many tools, although there is one published tool targeted at older 
adults with 392 quality indicators (not all of which relate to rational prescribing), 
Assessing Care of Vulnerable Adults 3  (ACOVE-3) (127). The PIPc has closer to the 
lowest number of criteria of the adult tools. Some of the tools detailed in the Kaufmann 
systematic review have as few as ten criteria, for instance the Medication Appropriateness 
Index (MAI) (128), also targeted at older adults. A simple count of criteria is not 
necessarily a useful measure of complexity, however. For example, in the case of the 
MAI, it is intended that all ten criteria are applied to each drug in turn, where some 
systems simply list medications that are contraindicated or essential. 
 
As a result of the higher number of criteria, POPI covers a wider range of clinical 
conditions that are not contained within PIPc. PIPc covers four systems: respiratory, 
gastrointestinal, dermatological, and neurological. POPI has four category groups, each 
with subsidiary categories for a total of 22 categories: diverse illness (pain and fever; ; 
urinary infections; vitamin supplements and antibiotic prophylaxis; mosquitos); digestive 
problems (nausea, vomiting, or gastroesophageal reflux; diarrhoea); ear, nose and throat 
(ENT)-pulmonary problems (cough; bronchiolitis in infants; ENT infections; asthma); 
dermatological problems (acne vulgaris; scabies; lice; ringworm; impetigo; herpes simplex;  
atopic eczema); neuropsychiatric disorders (epilepsy; depression; nocturnal enuresis; 
anorexia; attention deficit hyperactivity disorder (ADHD). 
 
The PIPc is likely to be quicker to apply and does not require the high level of clinical 
information required by POPI. However, it is also narrower in scope and therefore will 
not identify some aspects of irrational prescribing such as duplication, inappropriate drug 
duration, or incorrect drug dosage. As there are fewer clinical conditions included within 
the PIPc as compared with POPI, this may not reduce its efficacy as a screening tool in 
general settings but might reduce its usefulness in more specialist settings. 
 
There are several areas of clinical practice not covered by either paediatric rational 
prescribing tool, for instance renal medicine, cardiology, hepatology, and endocrinology. 
 
The characteristics of the identified tools (excluding the POPI UK tool, see Chapter 3) 
are summarised in Figure 2-5. 





















































































































































Figure 2-5: Characteristics of the two identified paediatric rational prescribing tools 
 
2.5.2 Comparison of validation of POPI and PIPc 
 
2.5.2.1 Validation studies of POPI  
 
One clinical validation study of POPI has been disseminated at a conference (129) and 
more recently published (123). This took the approach described in Section 1.4.2 (page 
14) of testing whether POPI identifies any potentially inappropriate prescribing practice 
in clinical settings. The authors evaluated the ability of POPI to retrospectively detect 
PIMs and PIOs in an emergency department and community pharmacy. The reported 
rates of inappropriate prescriptions differ slightly between the reports. Unless stated 
otherwise, figures discussed will be from the more comprehensive latter publication. 
 
A total of 23,342 prescriptions for 18,198 patients were assessed using the POPI criteria. 
The number of prescriptions differed significantly between settings, with 18,562 
prescriptions for 15,973 patients in the emergency department group and 4,780 
prescriptions for 2,225 patients in the community setting. In this report, the authors state 
POPI comprises 101 criteria and that only 82 applicable to patients in hospital were 
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applied to the emergency department setting, while only 28 that did not require an 
assessment of diagnosis were applied in the community pharmacy. They furthermore 
state that among five criteria related to analgesia and antipyrexics, only three were 
e al a ed d e o an o er helming n mber of prescrip ions and heir associa ion i h 
man  diseases  (page 6, (123)). The discrepancy in the number of criteria and selective 
approach to using the criteria is discussed further in Section 2.5.3 (page 50). 
 
Rates of PIMs and PIOs per prescription in the emergency department setting were 2.9% 
and 2.3% respectively, but 12.3% and 6.1% in the community pharmacy setting. When 
assessed as the proportion of patients affected, rates of PIMs and PIOs in the emergency 
department were 3.3% and 2.7% respectively, and 26.4% and 11.2% in the community 
pharmacy. The very high rate of PIMs in the community pharmacy is ascribed by the 
authors to the availability of medications that they report were not available in the 
hospital setting, such as cough suppressants.  
 
Logistic regression was used to analyse risk factors associated with irrational prescribing 
as detected by POPI and in the earlier brief report the authors described that 
prescriptions in the community pharmacy setting and age between 2 and 6 years were 
both significantly associated with higher risk (129). The age range at increased risk was 
broadened to 0-12 years in the later report (123). The uncertain significance of the age-
based risk finding is discussed in Section 2.5.4 (page 55).  
 
As discussed in 2.3.7 Characteristics of the POPI tool, clinical information is required to 
rate a number of the criteria. Such criteria were excluded from the analysis of the 
community data. Since both datasets were evaluated used different criteria, the 
comparability of the identified rates of PIMs and PIOs is compromised. 
 
The POPI tool was developed using French, American and UK guidelines but has only 
been validated to a limited degree, with the above study showing that it is able to detect 
some potentially irrational prescribing in French settings. It is not known whether it 
detects irrational prescribing that correlates to adverse events or patient outcomes, or 
whether it could be used to evaluate prescribing outside French practice. 
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There is also a published reliability study of the POPI tool (130). Twenty cases were 
selected from the dataset used for the clinical validation study and assessed by two raters 
familiar with the tool. Their assessment was used as a gold standard against which eleven 
o her ra ers  findings ere compared. The POPI tool was reported to have inter-rater 
reliability of 0.8 (for PIMs) and 0.71 (for PIOs). As the publication is only available  
abstract from conference proceedings, full details are not available. In particular, it is not 
made clear whether only the limited selection of POPI criteria applied in the clinical 
validation study were again used in the inter-rater study, which would mean the entire 
tool had not been tested. Accepting these limitations, the study demonstrated good 
repeatability despite the high complexity and mixed implicit and explicit approach of the 
tool. This is discussed further in Chapter 5. 
 
2.5.2.2 Validation studies of PIPc 
 
Although not published as a clinical validation study, the group who developed PIPc have 
published one study using the criteria to detect potentially irrational prescribing (131). In 
this study, the criteria were applied using a cross-sectional methodology to a national 
pharmacy claims database in Ireland, the Primary Care Reimbursement Service (PCRS). 
The database records pharmacy claims for medicines for eligible patients prescribed by 
general practitioners or transcribed from hospital prescriptions by general practitioners, 
with limited patient demographic data (age, gender and region). No clinical details of the 
patient are recorded. The study included 414,856 children aged <16 years. 
 
The prevalence of PIMs and PIOs was reported as 3.5% and 2.5% respectively. These 
rates are quite comparable to those observed in the POPI study, excluding the outlying 
high rate of PIMs in the POPI community setting. However, the rate of PIO using all 
PIPc criteria was in fact 11.5% when including all criteria, as the above rates excluded one 
of the reported PIPc indicators. 
 
The excluded criterion was a PIO related to a spacer device (omission of a spacer device 
being prescribed at least annually to children prescribed a pMDI aged <12 years). This 
PIO had a prevalence of 70% among eligible children. The second most prevalent PIO 
(failure to prescribe emollient to children who were prescribed greater than two topical 
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corticosteroids) will also have heavily influenced the overall rates of reported PIOs, with a 
prevalence of 54% among eligible children. 
 
In their discussion of the high prevalence of PIO relating to a spacer device, the authors 
acknowledged that as spacer devices can be bought over-the-counter, this omission is 
difficult to interpret, although they did note that the devices would be much cheaper to 
parents if prescribed than if bought without prescription (page 5, (131)). The rate of 
emollient omission was not further discussed, but this criterion is equally affected by the 
availability of a wide variety of emollients without prescription.  
 
Similarly, a single criterion had a large impact on PIMs and when this criterion, relating to 
carbocisteine, was discounted the PIM rate fell to 0.29%. The authors discussed the 
impact of the criterion relating to carbocisteine further. The full criterion, not listed in the 
clinical study but from the original publication about the development of PIPc, is 
Carbocis eine sho ld no  be prescribed o children  (page 8, (117)). This was the most 
prevalent PIM identified in the study. The authors noted that two Cochrane reviews how 
found little evidence for the efficacy of mucolytics for respiratory tract infections 
although carbocisteine is licensed in children aged more than 2 years. 
 
In this study, there was a significantly higher risk of PIOs in males compared to females, 
with no gender difference observed for PIMs (page 4, (117)). This remained the case even 
when the above dominating criteria (carbocisteine and spacer devices) were discounted. 
The specific PIOs and potential reasons for this difference are not further discussed in 
the study. 
 
There is no published repeatability study of PIPc. 
 
2.5.3 Limitations of POPI 
 
In the reported development process of POPI, initially 108 propositions were presented 
to the experts. There is inconsistency between the published reports as to how many 
propositions were ultimately accepted into the final list. The 2014 English language report 
states 104 criteria were validated, whereas the 2016 French language paper states 101 
criteria were validated (115, 116). Furthermore, while it is stated in the 2014 paper that 
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104 propositions were validated, two removed, and 102 ultimately included, in fact 105 
propositions are included in the published list.  In the clinical application study published 
in 2019, the criteria list used comprised the 101 criteria from the 2016 publication (123). 
 
The differences between the two papers includes three cases of combining two 
statements into a single criterion in the 2016 (French) publication. Specifically, two 
propositions about desmopressin for nocturnal enuresis are combined into one and six 
propositions about atopic eczema are combined into four. One proposition about benzyl 
benzoate for scabies is omitted from the 2016 list entirely. The combined propositions 
are listed in Figure 2-6. Other than this, the described process and criteria are the same.  
 
Two propositions, which related to codeine and permethrin, were removed following the 
consensus study due to new contraindications having been published for the use of these 
drugs in children, therefore it is stated that 102 propositions were ultimately validated. 
However, as described above, the final list of POPI criteria contained 105 propositions. 
In the 2016 French language publication also describing the consensus validation of the 
POPI tool(116), the authors state that 101 of 108 criteria were validated. For the 
purposes of evaluation and discussion below, the English language published list of 105 
validated propositions in the 2014 report is used.  
 
Propositions combined into a single criterion in the 2016 publication of POPI 
Desmopressin administered by a nasal 
spray.  
Desmopressin in the case of daytime 
symptoms. 
A strong dermocorticoid (clobetasol 
propionate 0.05% Dermoval, 
betamethasone diproprionate Diprosone) 
applied to the face, the armpits or groin, 
and the backside of babies or young 
children. 
More than one application per day of a 
dermocorticoid except in cases of severe 
lichenification. 
Topically applied 0.03% tacrolimus before 
2 years of age. 
Topically applied 0.1% tacrolimus before 
16 years of age 
Figure 2-6: Propositions combined into one criterion in 2016 publication compared to 2014 
publication 
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Rating the POPI cri eria req ires access o all of a pa ien s prescrip ions; beca se he ool 
rates omissions as well as inappropriate prescriptions, it cannot be used in whole to 
evaluate a single prescription for a child. Equally, it could not be used in application to 
anonymised retrospective prescribing data such as pharmacy reimbursement records, as 
such datasets do not generally show all prescriptions an individual has received, meaning 
that omissions could not be scored.  
 
The authors of POPI stated that the tool comprises explicit (evidence/opinion based) 
criteria; however, a number of criteria contain judgement-based and patient-specific 
considera ions. O her proposi ions req ire aking in o acco n  he pa ien s co-
morbidities and entire medication regimen, characteristics which are usually considered 
components of implicit (patient-specific) criteria. For example, within the clinical category 
of cough a s a ed omission is: Fail re o propose hooping co gh boos er accine for 
adults who are likely to become parents in he coming mon hs or ears  (page 5, 
(114)). Several propositions require the rater to make subjective judgements, including the 
criterion Pharmacological rea men  before age 6  e cep  in se ere cases  (page 7, 
(114))  in the category of attention deficit disorder and The se of pe H2 
antihistamines for long periods of rea men  (page 4, (114)) in the category of nausea, 
vomiting, or gastroesophageal reflux. In each case, se ere  and long periods  are no  
specifically defined. 
 
Furthermore, prescribing information alone is insufficient to rate prescribing using the 
POPI tool as detailed clinical information is required, beyond even the coding of an 
indication for a prescription. For instance, in the category ENT infections, one of the 
inappropria e prescrip ion cri eria is An ibio ics o rea  o i is media i h eff sion 
(OME), e cep  in he case of hearing loss or if OME las s for more han hree mon hs . 
Clearly, in order to evaluate a prescription against this criterion, clinical information about 
the patient would be required. 
 
Some of he cri eria req ire an e en higher le el of informa ion abo  he pa ien s 
medical care. T o e amples are, Fail re o gi e s gar sol ion o ne -born babies and 
infants under four months old t o min es prior o enep nc re , in hich case i  
would be necessary to have access to clinical notes expected to record every 
enep nc re he infan  had recei ed, and Fail re o propose a hooping co gh boos er 
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vaccine for adults who are likely to become parents in the coming months or years (only 
applicable if he pre io s accina ion as more han 10 ears ago)  in hich case, 
records o ld need o indica e e er  ad l  presen  and e en each ad l s accina ion 
history during the consultation or clinical contact whose quality of prescribing is being 
assessed.  
 
In addition, the criterion on whooping cough vaccination relates to perinatal healthcare 
for a mother rather than directly to paediatric prescribing; the decision to include this 
criterion in POPI, which is expressly designed as a paediatric rational prescribing too is 
not discussed by the author.  
 
Several of the POPI criteria also require a high degree of clinical knowledge and a 
subjective judgement to be taken by the rater. For example, in the category bronchiolitis 
in infants, an inappropriate prescription criterion is the prescription of antibio ics in he 
absence of signs indica ed a bac erial infec ion (ac e o i is media, fe er, e c.) . B  no  
providing a prescriptive list of signs of bacterial infection, the tool requires a rater to have 
the clinical knowledge to determine whether any unlisted signs of bacterial infection were 
present in the patient. 
 
The high number of propositions and the mixed implicit and explicit approach of the 
POPI tool makes it quite high in complexity. There are criteria requiring a high level of 
clinical information to apply, for example one criterion in the atopic eczema category 
s a es ha  More han one applica ion per da  of a dermocor icoid, e cep  in cases of 
se ere lichenifica ion  as an inappropria e prescrip ion. This criterion requires the rater 
therefore to assess the severity of lichenification of eczema, which would require detailed 
clinical information to determine.  
 
On the other hand, in one criterion, the absence of subjectivity or detail reduces the 
accuracy of the criterion, which states that prescribing anything other than paracetamol 
first-line for pain (except migraine) is potentially inappropriate. This criterion would 
therefore rate opiates for severe pain as inappropriate if they are given before 
paracetamol. Although explicit criteria by definition lack the nuance to apply to all 
circumstances at all times, this criterion would flag a common (appropriate) practice, i.e. 
appropriate early analgesia for severe pain, as irrational. 
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Some patients may fall within multiple themes, for instance pain and fever might be 
expected alongside a number of other themes with infectious focuses, such as urinary 
infections and ENT infections, and other themes describe long-term conditions that any 
child might have as a co-morbidity. The theme of vitamin supplements and antibiotic 
prophylaxis includes a proposition describing minimum vitamin D intake, which would 
need to be assessed for every child. This would therefore require a high level of familiarity 
with the tool for accurate use and necessitates access to a high level of information about 
each patient. 
 
The clinical application study of POPI highlighted a number of these issues. Only 82 of 
the criteria were applied to the hospital population studied, and just 28 to the community 
pharmacy population. While this is a pragmatic solution to the applying the criteria to 
limited datasets (such as the absence of clinical data about one group), this significantly 
impairs the ability to make meaningful comparisons between studied groups. The list of 
criteria used in each case were not included, therefore comparison between even the 
included criteria is not possible. 
 
In addition, only three out of five criteria applying to analgesics and antipyrexics were 
applied, due to the o er helming  (page 6, (123)) frequency of this indication. Similarly, 
he a hors s a ed ha  ra ing a cri erion rela ing o amo icillin prescribing as no  
possible d e o he fac  ha  his dr g is prescribed in grea  q an i  (page 7, (123)). For 
this criterion, a randomly selected 100 prescriptions were assessed from the hospital. It is 
not stated whether all or a selection of prescriptions for amoxicillin were analysed in the 
community group, but the rate of inappropriate prescribing for this criterion is reported 
as 97% out of 13.2% of patients. 
 
In the clinical application study of POPI, the authors identified a higher rate of irrational 
prescribing in children aged between 2 and 6 years (129) or 0 to 12 years in the later 
report (123). However, given a number of age-specific propositions for children under 6 
years of age, this may rather represent the population for whom the POPI criteria are 
most sensitive rather than the population most at risk of any types of irrational 
prescribing. By having a varying number of criteria that are applicable to age groups, this 
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may reduce the usefulness of POPI for accurately identifying variance in irrational 




2.5.4 Limitations of PIPc  
 
The authors of PIPc stated that the tool comprises explicit (evidence/opinion based) 
criteria; however, a number of criteria contain patient-specific considerations. Although 
the criteria of PIPc were designed for application without access to clinical information, 
two require assumption of the clinical indication, specifically for presumed asthma. The 
a hors s a e in he de elopmen  of he ool ha  prescrip ion of two or more inhaled 
cor icos eroids  is sed as a pro  for he diagnosis of as hma. The phrase for pres med 
as hma  (page 8 (117) used in the report of the development of the PIPc tool is absent 
from the listed criteria in the clinical application study (131). 
 
Using such a proxy for a diagnostic category enables the criteria to be used on 
anonymised prescribing data alone so long as all prescriptions are linked to patients, for 
instance through allocated participant numbers to facilitate reviewing prescriptions in the 
context of the prescribing history. However, there are other possible diagnoses such as 
viral-induced wheeze in children under 2 years, where there is evidence supporting the 
episodic use of inhaled corticosteroids (132) but not for ß2-agonists (133). Therefore, 
using prescription data without information about the indication for the prescription may 
red ce he sef lness of he cri erion An inhaled short-acting ß2 agonist should be 
prescribed to all children who are prescribed two or more inhaled corticosteroids for 
presumed asthma  (page 8 (117). 
 
In addi ion, one of he cri eria s a es ha  Te rac clines sho ld no  be prescribed o 
children nder 12 ears . However, doxycycline is the recommended first-line treatment 
for Lyme disease in children aged 9 to 12 years according to NICE guidance (134). This 
guidance recognises that use of tetracyclines in children under twelve years is 
contraindicated and does not have market authorisation, but that this use is accepted 
specialist practice. The authors of PIPc reported that indications considered appropriate 
under specialist use were removed from the proposed list of criteria (page 7, (117)). Lyme 
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disease is endemic in the UK,but with much higher prevalence in Scotland than England, 
Wales or Northern Ireland, as demonstrated in a 2019 cohort study (135). The study 
showed incidence was low in Northern Ireland with an incidence per 100,000 population 
of 6.3 and highest in Scotland at 37.3 per 100,000 (37). The study did not report on 
Ireland, but the Irish Health Protection Surveillance Centre reported in 2019 an estimated 
200 cases of Lyme disease per year in Ireland (136), giving an approximate incidence of 3 
per 100,000. 
 
As all members of the PIPc steering group were affiliated with institutions in Ireland and 
Northern Ireland, it is possible that low incidence of Lyme disease in their clinical 
practice due to the low prevalence in Northern Ireland and Ireland may have led to the 
decision to include the tetracycline criterion. The regions of practice of the Delphi 
consensus experts were not listed beyond Ireland and the UK. This issue may be a 
limitation in the applicability of PIPc to practice across the whole of the UK, particularly 
in Scotland. Issues such as this are a limitation of the Delphi consensus process 
acknowledged by the authors of PIPc in their published repor  of i s de elopmen ; he 
information gathered using a Delphi method represents the views of chosen experts 
about a specific practice at a given time and this may vary depending on the experts 
in ol ed  (page 7, (117)). 
 
Like POPI, PIPc has several criteria that identify a specific target age group. As already 
discussed, this may make it more challenging to use PIPc to evaluate whether there are 
differences in rational prescribing due to different age groups in studied populations.  
 
Another significant limitation of PIPc identified in its clinical application study was that it 
highlighted the difficulty in applying even the intentionally simple and explicit criteria of 
PIPc to retrospective anonymised data (131). The age of patients in the PCRS database 
was recorded in age bands of 0-4 years, 5-11 years, and 12-15 years. In several cases, these 
bands overlapped age limits described in PIPc criteria. In order to analyse the data, the 
authors made calculations to estimate the number of children of a certain age. For 
example, to calculate the number of children under 2 years in the 0-4 years band, the total 
number of children in the band was divided by five and multiplied by two. This assumes a 
normal distribution of ages, which may not be the case. 
 





There are two published rational prescribing tools for use in paediatrics, the PIPc and the 
POPI tool. Both rational prescribing tools comprise a number of explicit criteria defining 
potentially inappropriate medicines (PIMs) and potentially inappropriate omissions 
(PIOs). POPI also contains some criteria with implicit features. 
 
The POPI tool was the only paediatric rational prescribing tool in publication at the date 
of my initial work undertaken in this thesis. As the PIPc is focused on primary care 
settings, the development of this tool in the UK did not fill the gap in availability of 
rational prescribing tools that can be applied across the broad range of paediatric practice 
settings. For both of these reasons, the POPI tool is the focus of the work of this thesis. 
 
Prior to utilisation in the UK, comparison of the propositions to UK formularies and 
clinical guidelines was needed to establish the appropriateness of the criteria for assessing 
UK practice. Repeatability studies were also considered useful in order to evaluate 
whether subjective implicit criteria were similarly scored by independent raters. Greater 
repeatability would increase the usefulness of a tool for comparison between different 
institutions or regions, where different raters may use the tool. Therefore, modification of 
the POPI tool for applicability to UK practice followed by both clinical validation of the 
POPI tool in UK practice settings and reliability studies of the modified tool were 
identified as valuable avenues of further research. 
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3 Developing the POPI UK criteria 
 
3.1 Introduction 
3.1.1 The POPI tool in context 
 
As described in Chapter 2, the POPI tool is one of two published paediatric rational 
prescribing tools. Unlike the PIPc, which is developed for application to primary care, the 
POPI tool is designed for use in any paediatric clinical setting. The tool comprises explicit 
criteria based on French, American, and UK guidelines, although the report is not explicit 
as to the selection process of guidelines or how incongruity between national guidelines 
was dealt with to reach consensus for the purposes of the tool. A specific grade of 
evidence was not stated, only that selec ed recommenda ions had o be backed p b  
e idence and  p blished af er 2000  (page 2, (115)). Given that all experts involved in 
the Delphi consensus were based in France, it may be that French practices and 
guidelines were given preference; in the references supporting the selected criteria, 27 are 
French, eight are American, and five are British. In addition, the selection of clinical 
indications was based upon French prevalence data. Given variation in prevalence of 
disease, availability of different formularies, and diversity in paediatric practice 
internationally, it is therefore probable that there will be some elements of a tool designed 
in the specific context of one country that may not be universally applicable 
internationally.  
 
There are a number of rational prescribing tools for adults or undifferentiated 
populations that are designed for use in a specific context, for example the Laroche 
Criteria (137) evaluate potentially inappropriate prescribing for older adults and are 
designed for use in France. Some tools have also been adapted for use in other settings, 
with various adaptation of the (US-based) Beers Criteria including the Maio Criteria (138) 
for use in Italy and the Lechevallier Criteria (139) for use in France. On the other hand, 
some rational prescribing tools are intentionally broad enough to be applicable in a wide 
range of settings, with perhaps the best example being the WHO prescribing indicators 
(140), which were described in Section 1.3.3 (page 10). 
 
Chapter 3: Developing the POPI UK criteria 
 60 
The validity of rational prescribing criteria in clinical practice can be in a number of ways, 
as discussed in Section 1.4.2 (page 14). One approach is to test whether a higher level of 
irrational prescribing as identified by the tool correlates with adverse patient outcomes; a 
simpler approach is simply to evaluate the ability of the tool to identify types of irrational 
prescribing that occur in the target population. In a comparison of screening tools for 
inappropriate prescriptions in older people, Chang and Chen (61) found that all four of 
the tools that had been tested in their ability to reduce the prevalence of inappropriate 
prescribing were successful in doing so. None of the criteria they evaluated had been 
assessed in its ability to reduce negative clinical outcomes, an assessment that would 
require complex longitudinal studies. 
 
Another limitation of rational prescribing tools is that the Delphi method by which they 
are most commonly developed are eminence-based, which runs counter to the principles 
of evidence-based medicine (EBM) (141). However, while the POPI UK criteria are 
derived from propositions reached using the Delphi consensus method, these criteria 
have been subjected to two rounds of scrutiny from the perspective of EBM: firstly, the 
propositions were produced with reference to American, French and British guidelines; in 
the modification process, they were then each individually tested against the explicitly 
evidence-based guidelines produced by NICE, Scottish Intercollegiate Guidelines 
Network (SIGN) and the BNFc. This method of producing the tool therefore draws 
upon an enormous body of evidence condensed into a relatively simple tool that is 
practical for clinical application.  
 
The study described in this chapter was designed to develop paediatric rational 
prescribing criteria that could be applied in any paediatric setting in the UK.  
 
The modification of an established tool to increase its applicability to another setting, 
commonly another country, has been used for a number of adult rational prescribing 
tools. For example, Beers criteria, developed in the USA, have been adapted for 
application in Germany, France, Italy and Austria (60). In other cases, entirely new 
rational prescribing tools have been developed anew through the Delphi consensus 
method, such as the development of the STOPP/START criteria in the UK (61). 
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The approach used in this study was to evaluate the appropriateness of the original POPI 
criteria to application in the UK through comparison to the British National Formulary 
for Children (BNFc) and national clinical guidelines. The aim was to modify the tool 
where necessary for application to UK paediatric practice and therefore to facilitate 
further evaluation of the tool using UK prescribing data. The intention was to minimise 
changes to the tool as far as possible, so that it remained as far as possible the product of 
the original Delphi consensus, while making any amendments necessary to produce 
criteria relevant to evaluate prescribing against accepted standards in the UK. 
 
The development of the POPI UK criteria, reported in this chapter, has been 
disseminated in oral and poster presentations (118), and has also been peer-reviewed and 




The 105 propositions of the POPI criteria were compared to evidence-based UK clinical 
guidelines and clinical knowledge summaries from NICE, SIGN, the BNFc, and the 
European Medicines Agency (EMA).  The national guidance from NICE, SIGN and the 
BNFc were preferred; EMA recommendations were referred to when no national 
guidelines were available.   This process was based on the most recent guidelines available 
at the time the study was undertaken in October 2015. Where amendments were made, 
the specific related guideline is cited.  
 
Following comparison with the guidelines, there were three possible outcomes: 
1. Guidelines concurred with the POPI criteria. No change was made.  
2. There was partial discordance.  POPI criteria were amended to match UK 
guidance.  
3. There was no guidance available or the criterion was in complete discordance 
with UK guidance and the criterion was omitted.  
The final wording of the POPI UK criteria was reached as consensus in consultation with 
two paediatric clinical pharmacology consultants. 
 




The resulting POPI UK comprises 80 criteria. Having started with 105 propositions in 
the original POPI criteria, no change was made to 49 propositions. Twenty-nine were 
amended to concord more closely with UK guidelines. Four were reduced into two 
criteria where they could be combined with closely related propositions due to the 
relevant guidelines referring to them together, simplifying the tool. Twenty-three were 
omitted altogether, which included the omission of an entire category. One category title 
was amended  from a en ion defici  disorder i h or i ho  h perac i i  o 
a en ion defici  h perac i i  disorder  (ADHD)  as the diagnosis of attention deficit 
disorder without hyperactivity is not in use in the UK; variants are described in the 
International Classification of Diseases 11th Revision (ICD-11) system describes subtypes 
without hyperactivity under the umbrella diagnosis of ADHD (143) . Appendix 7 shows 
the original POPI criteria and Appendix 8 the modified criteria comprising POPI UK. 
 
The most substantial single change was the omission of the category of Mosquitos[sic] . 
As there are not currently any areas of the UK where insect-borne diseases are endemic, 
this was not considered applicable to UK practice and therefore the category, comprising 
seven criteria, was removed.  
 
Twelve criteria were omitted due to a lack of relevant clinical guidelines. These are all 
listed in   
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Table 3-A. In other cases, four criteria were omitted where UK clinical guidelines 
contradicted the proposition. These are listed in   





Chapter 3: Developing the POPI UK criteria 
 65 
Table 3-A: Criteria omitted due to absence of relevant UK clinical guidelines 
Symptom or illness category Omitted POPI criterion 
Pain and fever (inappropriate 
prescriptions) 
Rectal administration of paracetamol as a first-line treatment 
Pain and fever (omission) Failure to give sugar solution to new-born babies and infants under four 
months old two minutes prior to venepuncture  
Urinary infection 
(inappropriate prescription) 
Nitrofurantoin used as a prophylactic  
Diarrhoea 
(inappropriate prescription) 
The use of Diosmectite (Smecta) in combination with another medication  
The use of Saccharomyces boulardii (Ultralevure) in powder form, or in a 
capsule that has to be opened prior to ingestion, to treat patients with a 
central venous catheter or an immunodeficiency 
Intestinal antiseptics  
Cough 
(inappropriate prescription) 
Mucolytic drugs, mucokinetic drugs, or helicidine before 2 years of age  
Alimemazine (Theralene), oxomemazine (Toplexil), promethazine 
(Phenergan, and other types)  
Terpene-based suppositories  
Bronchiolitis (inappropriate 
prescription) 
0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is 
already being treated with 3% NaCl delivered by a nebulizer)  
ENT infections (inappropriate 
prescription) 
Ethanolamine tenoate (Rhinotrophyl) and other nasal antiseptics  
Acne vulgaris (inappropriate 
prescription) 
Androgenic progestins (levonorgestrel, norgestrel, norethisterone, 
lynestrenol, dienogest, contraceptive implants or vaginal rings) 
 
In several of the criteria listed in   
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Table 3-A, the lack of related UK guidelines was due to named medicines in the 
proposition not being in use in the UK. For example, diosmectite is not approved for use, 
helicidine is not available, and ethanolamine tenoate is not listed in the BNFc. In other 
instances, there was a lack of guidelines related to the topic, for instance in the case of 
first-line rectal administration of paracetamol; the possible reasons for absence of 
guidelines are further considered in the discussion in Section 3.4 (page 78). 
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Table 3-B: Criteria omitted due to conflicting UK clinical guidelines 
Symptom or illness category Omitted POPI criterion 
Conflicting UK guideline 
Urinary infection 
(inappropriate prescription) 
Nitrofurantoin used as a curative agent in children under 6 years of age, or 
indeed any other antibiotic if avoidable  
 
NICE guidance CG54 
http://www.nice.org.uk/guidance/CG54/chapter/1-Guidance 
(Recommends nitrofurantoin for children aged three months and over.) 
Vitamin supplements and 
antibiotic prophylaxis 
(inappropriate prescription) 
Fluoride supplements prior to 6 months of age  
 
SIGN guidance 138 
http://www.sign.ac.uk/pdf/SIGN138.pdf 
(Describes risks and benefits as balanced.) 
NICE Delivering Better Oral Health Toolkit 
http://www.nice.org.uk/guidance/ph55/chapter/context#delivering-better-oral-health-
toolkit 
(Recommends fluoride toothpaste as soon as teeth erupt) 
Nausea, vomiting, or 
gastroesophageal reflux 
(inappropriate prescription) 





(Chemotherapy-associated nausea and vomiting listed as an indication for ondansetron.) 
Acne vulgaris (inappropriate 
prescription) 
Isotretinoin in combination with a member of the tetracycline family of 
antibiotics 
 
NICE Acne Vulgaris Clinical Knowledge Summary 
http://cks.nice.org.uk/acne-vulgaris#!topicsummary 
(Recommended second-line for moderate acne.) 
 
The criteria listed in   
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Table 3-B were omitted due to national guidelines in the UK conflicting with the 
statements, suggesting that it would not be reasonable to consider such prescribing 
behaviour irrational in the UK. The case of setrons for chemotherapy-associated nausea 
and vomiting is considered in more depth in the discussion, as their inclusion in the 
original POPI criteria seems unusual given that setrons are widely used internationally for 
this very indication (144). 
 
Two criteria were combined with closely related propositions where the 
recommendations were linked in a single UK guideline. The combined criteria are shown 





























































o not use any of the following to treat bronchiolitis in children: antibiotics, hypertonic saline, 
adrenaline (nebulised), salbutamol, montelukast, ipratropium brom
ide, systemic or inhaled 
corticosteroids, a combination of systemic corticosteroids and nebulised adrenaline. 
 
A
ntibiotics, ß2 agonists or 
corticosteroids to treat bronchiolitis 
A
ntibiotics in the absence of signs 
indicating a bacterial infection (acute otitis 
m




n antibiotic other than am
oxicillin as a 
first-line treatm
ent for acute otitis m
edia, 
strep throat, or sinusitis (provided that the 
patient is not allergic to am
oxicillin). A
n 
effective dose of am
oxicillin for a 
pneum
ococcal infection is 80
90 
m
g/kg/day and an effective dose for a 














 no antibiotic prescribing strategy or a delayed antibiotic prescribing strategy should be 
agreed for patients with the following conditions: acute otitis media, acute sore throat/acute 
pharyngitis/acute tonsillitis, common cold, acute rhinosinusitis, acute cough/acute bronchitis 
 D
epending on clinical assessment of severity, patients in the following subgroups can also be 
considered for an immediate antibiotic prescribing strategy (in addition to a no antibiotic or a 
delayed antibiotic prescribing strategy): bilateral acute otitis media in children younger than 2 
years, acute otitis media in children with otorrhoea, acute sore throat/acute pharyngitis/acute 
tonsillitis when three or more Centor criteria are present. 
 SIG
N
 guideline 117 
 In severe cases, where the practitioner is concerned about the clinical condition of the patient, 
antibiotics should not be withheld. (Penicillin V
 500 mg four times daily for 10 days is the 
dosage used in the majority of studies. A
 macrolide can be considered as an alternative first 
line treatment, in line with local guidance.) 
A
n antibiotic for <
 4 days sym
ptom
s 
of acute upper respiratory tract 
infection except: 
x bilateral acute otitis media in children 
younger than 2 years 
x acute otitis media in children with 
otorrhoea 
x acute sore throat/acute 
pharyngitis/acute tonsillitis when three 
or more Centor criteria are present. 
 
A
ntibiotics for nasopharyngitis, congestive 
otitis, sore throat before 3 years of age, or 
laryngitis; antibiotics as a first-line 
treatm






s, before 2 years of age 
(PIM
) 
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The combined propositions described in Table 3-C involved amendments of the wording 
of the original POPI criteria in order to closely match UK guidelines, while also avoiding 
unnecessary duplication within the POPI UK criteria. 
 
Twenty-nine criteria were amended to more closely concord with UK guidelines. These 
are listed with their related guidelines in Table 3-D. In addition, the category title of 
A en ion defici  disorder i h or i ho  h perac i i  as amended o A en ion 
defici  h perac i i  disorder . 
 
Table 3-D: PIM criteria modified to concord with UK guidelines   
Original POPI 
criteria 
Relevant UK guidance (NICE, SIGN or BNFc) 




Prescription of a 
medication other 
than paracetamol 
as a first line 
treatment [for pain] 
(except in the case 
of migraine) 
NICE Clinical Knowledge Summary: Management of 
mild-to-moderate pain  
http://cks.nice.org.uk/analgesia-mild-to-moderate-
pain#!scenario 
Prescribe either paracetamol or ibuprofen alone. Both are suitable 
first-line choices for treating mild-to-moderate pain in children. 
 
Prescription of a 
medication other 
than paracetamol 
or ibuprofen as a 
first-line treatment 
for pain (except in 
the case of 
migraine) 
Oral solutions of 
ibuprofen 
administered in 
more than three 
doses per day using 
a graduated pipette 
of 10mg/kg (other 




Child 1 3 months 5 mg/kg 3 4 times daily 
Child 3 6 months 50 mg 3 times daily; max. 30 mg/kg daily in 
3 4 divided doses 
Child 6 months 1 year 50 mg 3 4 times daily; max. 30 mg/kg 
daily in 3 4 divided doses 
Child 1 4 years 100 mg 3 times daily; max. 30 mg/kg daily in 
3 4 divided doses 
Child 4 7 years 150 mg 3 times daily; max. 30 mg/kg daily in 
3 4 divided doses 
Child 7 10 years 200 mg 3 times daily; max. 30 mg/kg (max. 
2.4 g) daily in 3 4 divided doses 
Child 10 12 years 300 mg 3 times daily; max. 30 mg/kg (max. 
2.4 g) daily in 3 4 divided doses 
Child 12 18 years initially 300 400 mg 3 4 times daily; 
increased if necessary to max. 600 mg 4 times daily; maintenance 




more than three 
doses per day or 
exceeding 
maximum dose of 
30mg/kg given 












drugs to treat 
overt regurgitation 
in the absence of 
feeding 
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the crying of new-
born babies (in the 
absence of any 
other signs or 
symptoms), as well 
as faintness in 
infants  
 
Do not offer acid-suppressing drugs, such as proton pump inhibitors 
(PPIs) or H2 receptor antagonists (H2RAs), to treat overt 
regurgitation in infants and children occurring as an isolated 
symptom. 
 
Recommendation 1.3.2  
Consider a 4-week trial of a PPI or H2RA for those who are 
unable to tell you about their symptoms (for example, infants and 
young children, and those with a neurodisability associated with 
expressive communication difficulties) who have overt regurgitation 
with 1 or more of the following: 
x unexplained feeding difficulties (for example, refusing 
feeds, gagging or choking) 
x distressed behaviour 




The use of type H2 
antihistamines for 
long periods of 
treatment  
 




4 week trial then stop, assess response, refer if symptoms recur 
Amend: The use 
of H2 receptor 
antagonists for 
more than 4 weeks 
Erythromycin as a 
prokinetic agent  
 
NICE guidance NG1 
http://www.nice.org.uk/guidance/NG1/chapter/1-
Recommendations 
Do not offer metoclopramide, domperidone or erythromycin without 









Licensed from 4 years 
Amend: 
Loperamide 
before 4 years of 
age 
Antibiotic 
treatment for a sore 
throat, without a 
positive rapid 
diagnostic test 
result, in children 
less than three 
years old  
 
SIGN guideline 117 
http://www.sign.ac.uk/guidelines/fulltext/117/  
Minimises usefulness of rapid diagnostic test results in 
guiding therapy 
 
In severe cases, where the practitioner is concerned about the clinical 
condition of the patient, antibiotics should not be withheld. 
(Penicillin V 500 mg four times daily for 10 days is the dosage used 
in the majority of studies. A macrolide can be considered as an 
alternative first line treatment, in line with local guidance.) 
Amend: Antibiotic 
treatment for a 
sore throat except 
in severe cases 
(where the 




Antibiotics to treat 
otitis media with 
effusion (OME), 
except in the case 
of hearing loss or if 
OME lasts for more 
than three months  




Period of active observation for 6-12 weeks 
During this period, do not prescribe antibiotics, steroids, 
antihistamines, decongestants, or mucolytics specifically for the 
treatment of otitis media with effusion (OME). 
Amend: 
Antibiotics to treat 
otitis media with 
effusion in the 


















before 2 years 






(or any terpene 
derivatives) before 
30 months of age  
 
Sedating antihistamines not for use in neonates, 
phenothiazine sedating antihistamines not for use < 2 




Menthol inhalations permissible, no sprays or 
suppositories in BNFc nor terpene-containing medicines 
(except for 
anaphylaxis) 









Antihistamines and ketotifen are ineffective. 




The application of 
benzyl benzoate 
(Ascabiol) for 
periods longer than 
eight hours for 
infants and 12 
hours for children 







and NICE Clinical Knowledge Summary  
http://cks.nice.org.uk/scabies#!scenario  
 
Benzyl benzoate should be avoided in children (permethrin or 
malathion are less irritant and more effective and should be used 
instead) 
Amend:  










Recommends topical treatment first-line. Gruseofulvin the 





Any antibiotic other 
than mupirocin as a 
first-line treatment 
(except in cases of 
hypersensitivity to 
mupirocin) 
NICE Clinical Knowledge Summary Impetigo 
http://cks.nice.org.uk/impetigo#!scenario 
 
x For localized [sic] infection, treat with topical fusidic 
acid  T ical m i ci , e a am li , a d a i e ic  
are not recommended initially. 
Amend: 
Any antibiotic 
other than fusidic 
acid as a first-line 
treatment (except 












Consider oral antivirals for immunocompetent individuals 
with severe gingivostomatitis.  
Amend: Orally 
administered 














x use mild potency for the face and neck, except for short-
term (3 5 days) use of moderate potency for severe flares 
Amend: 
A potent topical 
corticosteroid 
applied to the 
face, or for > 14 
days applied to the 
axilla or groin 
Chapter 3: Developing the POPI UK criteria 
 73 
Diprosone) applied 
to the face, the 
armpits or groin, 
and the backside of 
babies or young 
children  
 
x use moderate or potent preparations for short periods only 
(7 14 days) for flares in vulnerable sites such as axillae 
and groin 
x do not use very potent preparations in children without 
specialist dermatological advice. 
 














Healthcare professionals should offer a 1-month trial of a non-
sedating antihistamine to children with severe atopic eczema or 
children with mild or moderate atopic eczema where there is severe 
itching or urticaria. 
Healthcare professionals should offer a 7 14 day trial of an age-
appropriate sedating antihistamine to children aged 6 months or over 
during an acute flare of atopic eczema if sleep disturbance has a 




except as a trial 
for severe itching 
or where sleep 
disturbance has a 
significant impact 















medications as a 














Antipsychotics are not recommended for the treatment of ADHD in 
children and young people. 
Amend: 
Antipsychotic 






two doses per day, 
rather than only 
one dose 
 











as two doses per 
day rather than 
only one dose 
 
 
Of the PIM criteria amended, shown in Table 3-D, several of the amendments resulted in 
simplifica ion of he cri erion, for ins ance from The applica ion of ben l ben oa e  
for periods longer than eight hours for infants and 12 hours for children or for pregnant 
girls  o Ben l ben oa e , hich is considered less appropriate than permethrin or 
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malathion according to the cited clinical guidance. In other cases, the only amendment 
was the age range, which usually arose from licensing of the medication, for instance 
loperamide and chlorphenamine.  
 
In some cases, the amendments introduced subjectivity to the criterion, such as changing 
an ibio ic rea men  for sore hroa , i ho  a posi i e rapid diagnos ic es  res l , in 
children less han hree ears  o an ibio ic rea men  for a sore hroa  e cep  in se ere 
cases . While his ma  increase he comple i  of he cri erion, his change reflec ed UK 
national guidelines which advised against reliance upon rapid diagnostic testing, therefore 
the original proposition would not appropriately assess the rationale behind clinicians  
decision-making in the UK context. 
 
It should be noted that, as Table 3-D shows, ibuprofen dosing is recommended as three 
to four times daily in the BNFc, however the modified criterion more closely mirrored 
the original POPI criterion by stating it should be dosed only three times daily. This was 
an error as the modified criterion does not therefore accurately represent UK national 
guidance. The error was detected after completion of validation studies, therefore 
modified POPI criteria referred to in subsequent chapters include this criterion. 
 
PIOs that were modified are shown in Table 3-E. 
 
Table 3-E: PIO criteria modified to concord with UK guidelines   
Original POPI criterion Relevant UK guidance (NICE, SIGN or BNFc) 




Insufficient intake of vitamin 
D. Minimum vitamin D intake: 
Breastfed baby = 1,000 to 
1,200 IU/day; Infant,18 
months of age (milk enriched in 
vitamin D) = 600 to 800 
IU/day; Child aged between 18 
months and 5 years, and 
adolescents aged between 10 
and 18 years: two quarterly 
loading doses of 80,000 to 
100,000 IU/day in winter 
(adolescents can take this dose 
in one go)  
NICE guidance PH56 
http://www.nice.org.uk/guidance/ph56/chapter/1-
Recommendations 
Vitamin D supplements should be available for at-risk groups, 
including infants and children < 5years, Healthy Start 
vitamins 
Healthy Start vitamins 
for infants and children 
6 months- 5 years or 
having less than 500ml 
infant formula per day 
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Antibiotic prophylaxis with 
phenoxymethylpenicillin 
(Oracilline) starting from 2 
months of age and lasting until 
5 years of age for children with 
sickle-cell anemia: 100,000 
IU/kg /day (in two doses) for 
children weighing 10kg or less 
and 50,000 IU/kg/day for 
children weighing over 10kg 
(also in two doses) 
 
NICE Clinical Knowledge Summary 
http://cks.nice.org.uk/sickle-cell-disease#!scenario:3 
 
x Explain that lifelong prophylaxis is recommended, 
but it is particularly important that there is full 
adherence up to 5 years of age. 
x Prescribe phenoxymethylpenicillin (penicillin V) 
prophylaxis from the age of 1 month, at a dose of: 
o 125 mg twice a day for infants and 
children up to 5 years of age. 
o 250 mg twice a day for children from 6 
to 12 years of age. 
o 500 mg twice a day for adults and 
children older than 12 years of age. 
x Erythromycin is recommended for people who are 
allergic to penicillin, at a dose of: 
o 125 mg twice a day for infants and 
children up to 2 years of age. 
o 250 mg twice a day for adults and 





(penicillin V) from age 1 
month until 5 years for 
children with sickle-cell 
anaemia at a dose of: 
x 125 mg twice a 
day for infants 
and children 
up to 5 years 
of age. 
x 250 mg twice a 
day for 
children from 
6 to 12 years 
of age. 
x 500 mg twice a 
day for adults 
and children 
older than 
12 years of age. 
OR Erythromycin for 
children who are allergic 
to penicillin, at a dose 
of: 
x 125 mg twice a 
day for infants 
and children 
up to 2 years 
of age. 
250 mg twice a day for 
children older than 
2 years of age. 
Oral rehydration solution 
 
NICE guidance CG84 
http://www.nice.org.uk/guidance/cg84/chapter/1-
Guidance#fluid-management 
Offer ORS solution as supplemental fluid to children at risk of 
dehydration or use in dehydrated children unless IV fluid is 
indicated 
Amend: Oral 
rehydration solution for 
dehydrated children 
unless IV fluid therapy 
is indicated (shock, red 
flag symptoms despite 
ORS, persist vomiting 
of ORS) 
Oral rehydration solution 
 
NICE guidance CG84 
http://www.nice.org.uk/guidance/cg84/chapter/1-
Guidance#fluid-management 
Offer ORS solution as supplemental fluid to children at risk of 
dehydration or use in dehydrated children unless IV fluid is 
indicated 
Amend: Oral 
rehydration solution for 
dehydrated children 
unless IV fluid therapy 
is indicated (shock, red 
flag symptoms despite 
ORS, persist vomiting 
of ORS) 
Failure to propose a whooping 
cough booster vaccine for 
adults who are likely to become 
NICE Clinical Knowledge Summary: Antenatal care 
of uncomplicated pregnancy 
Amend: Failure to 
propose a whooping 
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parents in the coming months 
or years (only applicable if the 
previous vaccination was more 
than 10 years ago). This booster 
vaccination should also be 
proposed to the family and 






28 weeks gestation: Offer vaccination against pertussis 
cough vaccine for 
pregnant women. 
Palivizumab in the following 
cases: (1) babies born both at 
less than 35 weeks of gestation 
and less than six months prior 
to the onset of a seasonal RSV 
epidemic;  
(2) children less than two years 
old who have received 
treatment for 
bronchopulmonary dysplasia in 
the past six months;  
(3) children less than two years 
old suffering from congenital 
heart disease with 
hemodynamic abnormalities 
 
SIGN guidance 91 (Bronchiolitis in children) 
http://www.sign.ac.uk/guidelines/fulltext/91/index.
html  
 ec mme d  e f ali i mab i  high i k g , a  
defined by the committee (children under 2 years of age with 
chronic lung disease, on home oxygen or who have had 
prolonged use of oxygen; infants less than 6 months of age who 
have left to right shunt haemodynamically significant congenital 
heart disease and/or pulmonary hypertension; children under 2 
years of age with severe congenital immuno-deficiency) 
 
Amend: 
Palivizumab in high-risk 
cases, defined as: 





or who have 
prolonged use 
of oxygen 











children < 2 years with 
severe congenital 
immunodeficiency 
Asthma inhaler appropriate for 
he child s age 
 
NICE guidance TA10 
https://www.nice.org.uk/guidance/ta10 
 
NICE has recommended that for children under the age of 5 
years who have chronic stable asthma: 
x both corticosteroids and bronchodilator therapy 
should routinely delivered by Pressurised Metered 
Dose Inhaler (pMDI) and spacer system, with a 
facemask where necessary. 
x where this combination is not clinically effective for 
the child, and depending on the child's condition, 
nebulised therapy may be considered and in the case 
of children aged 3 to 5 years, a dry powder inhaler 
(DPI) may also be considered. 
the choice of which pMDI device and spacer to use should be 
determined by the specific needs of the child and how well it 
works for them. Once these factors have been taken into 
account the choice should be made on the basis of reducing costs. 
Amend: 
Asthma inhaler 
appropriate for the 
child s age (aged < 5 
years, either Metered 
Dose Inhaler with 
spacer system or 
nebuliser; age 3-5 years 
Dry Powder Inhaler 
may be appropriate) 
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Contraception (provided with a 
logbook/diary) for 









Effective contraception must be used. 
Amend: Contraception 
for menstruating girls 
taking isotretinoin 
A second dose of ivermectin 










Apply once weekly for 2 doses 
Amend: 
A second application of 
permethrin or malathion 
one week after the first 
Decontamination of household 
linen and clothes and treatment 
for other family members 
 
NICE Clinical Knowledge Summary 
http://cks.nice.org.uk/scabies#!scenario 
 
Decontamination of household linen and clothes and same day 
treatment of all members of the household 
Amend: 
Decontamination of 
household linen and 
clothes and same day 
treatment of all 




As shown in Table 3-E, several of the modified omissions related to the provision of 
prophylactic treatments, such as vitamin supplementation, antibiotic prophylaxis, and 
vaccination, to identified at-risk groups. In these cases, the amendments reflected 
differences in national guidelines identifying who should be considered to fall within the 
at-risk group category. One s bjec i e cri erion, As hma inhaler appropria e for he 
child s age , as amended in o e plicit recommendations as per national UK guidelines.  
 
The amendment relating to contraception for isotretinoin omits the inclusion of a 
mandatory logbook or diary. However, this does not reflect a lower degree of vigilance in 
adherence to careful measures against accidental pregnancy while using isotretinoin. In 
the UK, the Pregnancy Prevention Programme for women and girls of childbearing 
potential who are taking isotretinoin is supported by a number of additional measures, 
including new prescriber checklists, patient reminder cards, and pharmacy checklists 
(120). 
 
Following the process of updating the original criteria to fit within UK clinical practice, 
the resulting POPI UK criteria comprise 80 propositions assessing rational prescribing 
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for children in accordance with up-to-date UK guidelines. The full criteria are shown in 
Table 3-F. 
 
Table 3-F: The POPI UK tool 
DIVERSE ILLNESSES 
PAIN AND FEVER 
Inappropriate prescriptions 
Prescription of two alternating antipyretics as a first-line treatment 
Prescription of a medication other than paracetamol or ibuprofen as a first-line treatment for pain 
(except in the case of migraine) 
The combined use of two NSAIDs 
Doses of ibuprofen administered in more than three doses per day or exceeding maximum dose of 
30mg/kg over three doses per day 
Opiates to treat migraine attacks 
Omissions 




Antibiotic prophylaxis following an initial infection without complications (except in the case of 
uropathy) 
Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy) 
VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS 
Omissions 
Healthy Start vitamins for infants and children 6 months- 5 years or having less than 500mL infant 
formula per day 
Antibiotic prophylaxis with phenoxyethylpenicillin (penicillin V) from age 1 month until 5 years for 
children with sickle-cell anaemia at a dose of: 
x 125 mg twice a day for infants and children up to 5 years of age. 
x 250 mg twice a day for children from 6 to 12 years of age. 
x 500 mg twice a day for adults and children older than 12 years of age. 
OR Erythromycin for children who are allergic to penicillin, at a dose of: 
x 125 mg twice a day for infants and children up to 2 years of age. 
x 250 mg twice a day for children older than 2 years of age. 
DIGESTIVE PROBLEMS 
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Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube) 
Acid-suppressing drugs to treat overt regurgitation in the absence of feeding difficulties, distress, or 
faltering growth 
The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients 
without risk factors 
The use of H2 receptor antagonists for more than 4 weeks 
Erythromycin 
Omissions 
Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated (shock, red 
flag symptoms despite ORS, persist vomiting of ORS) 
DIARRHOEA 
Inappropriate prescriptions 
Loperamide before 4 years of age 
Loperamide in the case of invasive diarrhoea 
Omissions 
Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated (shock, red 






Failure to propose a whooping cough vaccine for pregnant women. 
BRONCHIOLITIS IN INFANTS 
Inappropriate prescriptions 
Antibiotics, ß2 agonists or corticosteroids to treat bronchiolitis 
H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis 
Omissions 
Palivizumab in high-risk cases, defined as: 
3) children < 2 years with chronic lung disease on home oxygen or who have prolonged use of 
oxygen 
4) infants < 6 months with left-to-right shunt haemodynamically significant congenital heart 
disease and/or pulmonary hypertension 
5) children < 2 years with severe congenital immunodeficiency 
ENT INFECTIONS 
Inappropriate prescriptions 
An antibiotic for < 4 days symptoms of acute upper respiratory tract infection (except: 
x bilateral acute otitis media in children younger than 2 years 
x acute otitis media in children with otorrhoea 
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x acute sore throat/acute pharyngitis/acute tonsillitis when three or more Centor criteria are 
present. 
Antibiotic treatment for a sore throat except in severe cases (anticipated to be no more than 20% of 
cases) 
Antibiotics to treat otitis media with effusion in the first 6-12 weeks 
Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat 
Nasal or oral decongestant (oxymetazoline (Aturgyl), pseudoephedrine (Sudafed), naphazoline 
(Derinox), ephedrine (Rhinamide), tuaminoheptane (Rhinofluimicil), phenylephrine (Humoxal)) 
Sedating antihistamines (pheniramine, chlorpheniramine) before 2 years (except for anaphylaxis) 
Ear drops in the case of acute otitis media 
Omissions 
Doses in mg for drinkable (solutions of) amoxicillin or josamycin 
Paracetamol combined with antibiotic treatment for ear infections to relieve pain 
ASTHMA 
Inappropriate prescriptions 
Ketotifen and other antihistamines 
Cough suppressants 
Omissions 
Asthma inhaler appropria e for he child s age (aged < 5 years, either Metered Dose Inhaler with spacer 
system or nebuliser; age 3-5 years Dry Powder Inhaler may be appropriate) 





The combined use of an oral and a local antibiotic 
Oral or local antibiotics as a monotherapy (not in combination with another drug) 
Cyproterone+ethinylestradiol (Diane 35) as a contraceptive to allow isotretinoin per os 
Omissions 
Contraception for menstruating girls taking isotretinoin 





A second application of permethrin or malathion one week after the first 
Decontamination of household linen and clothes and same day treatment of all members of the 
household 
LICE 
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Inappropriate prescriptions 




Oral treatment other than griseofulvin 
Omissions 
Topical treatment combined with an orally-administered treatment 
Griseofulvin taken during a meal containing a moderate amount of fat 
IMPETIGO 
Inappropriate prescriptions 
The combination of locally applied and orally administered antibiotic 
Fewer than two applications per day for topical antibiotics 




Topical agents containing corticosteroids 
Topical agents containing aciclovir before six years of age 
Omissions 
Paracetamol during an outbreak of herpes 
Orally administered aciclovir to treat severe herpetic gingivostomatitis 
ATOPIC ECZEMA 
Inappropriate prescriptions 
A potent topical corticosteroid applied to the face, or for > 14 days applied to the axilla or groin 
More than one application per day of a dermocorticoid, except in cases of severe lichenification 
Prescription of antihistamines except as a trial for severe itching or where sleep disturbance has a 
significant impact on the child or carers 
Topically applied 0.03% tacrolimus before 2 years of age 
Topically applied 0.1% tacrolimus before 16 years of age 




Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case 
of myoclonic epilepsy 
Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabaline, tiagabine, or vigabatrin in the case 
of epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence 
epilepsy) 
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Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL 
DEPRESSION 
Inappropriate prescriptions 
An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy) 
Tricyclic antidepressants to treat depression 
NOCTURNAL ENURESIS 
Inappropriate prescriptions 
Desmopressin administered by a nasal spray 
Desmopressin in the case of daytime symptoms 
An anticholinergic agent used as a monotherapy in the absence of daytime symptoms 
Tricyclic agents in combination with anticholinergic agents 
Tricyclic agents as a first-line treatment 
ANOREXIA 
Inappropriate prescriptions 
Prescription of medications as a sole or primary treatment for anorexia nervosa 
ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY 
Inappropriate prescriptions 
Pharmacological treatment before age 6 (before school), except in severe cases 
Antipsychotic drugs to treat attention deficit hyperactivity disorder 
Modified release methylphenidate as two doses per day, rather than only one dose 
Omissions 




The POPI criteria were modified to develop a list of PIMs and PIOs for children in the 
UK. The POPI tool was the first paediatric prescribing screening tool, and the modified 
tool was the first paediatric rational prescribing tool for use in the UK when it was 
developed for use in our research in 2016. It remains the only paediatric rational 
prescribing tool for application to paediatric practice outside primary care and is designed 
to closely reflect national clinical guidelines and prescribing practice. The POPI UK 
criteria have a number of potential applications: the tool could be used in a research 
context to estimate prevalence of irrational prescribing using basic prescribing data of 
medications and their indication on either a local or national level; it could also be used as 
a tool for service evaluation and quality improvement, for instance through use in audit. 
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3.4.1 Criteria modified for inclusion in POPI UK 
 
Twenty-nine of the propositions of the original POPI criteria were amended. The 
majority of these changes were subtle modifications to bring the wording of propositions 
more closely in line with the specific wording of UK clinical guidelines. For example, 
An ips cho ic dr gs o rea  a en ion defici  disorder i ho  h perac i i  as 
amended o An ips cho ic dr gs o rea  a en ion defici  h perac i i  disorder . 
 
In other cases, the criteria contained specific differences such as age ranges or first-line 
drug recommendations and were amended accordingly. Examples of these include some 
criteria where the amendment increased the specificity of the proposition, such as 
changing from The se of pe H2 an ihis amines for long periods of rea men  o The 
use of H2 recep or an agonis s for more han fo r eeks . In o her cases, he amendmen  
added complexity or subjectivity, in order to better reflect the UK guidance, for instance 
a criterion rela ing o a opic ec ema as changed from Local or s s emic an ihis amine 
d ring he rea men  of o breaks  o Prescrip ion of an ihis amines e cep  as a rial for 
severe itching or where sleep disturbance has a significan  impac  on he child or carers . 
 
In order for this tool to be useful in appraising rational prescribing in the UK, it is 
important that prescribers are being measured against the specific standards they are 
striving for, and this would also facilitate straightforward interventions using UK 
guidelines for education and service improvement. 
 
3.4.2 Criteria omitted from POPI UK 
 
For 22 criteria, there were no relevant UK clinical guidelines or guidelines were directly 
contradictory to the original POPI criterion. Absence from guidelines does not 
necessarily invalidate the recommendations of those criteria but they were omitted as they 
appeared to relate to irrational use of medicines that do not appear to be prevalent in the 
UK. In some cases, the propositions related to medications not available in the UK, for 
instance in the case of diosmectite for diarrhoea there is some emerging evidence 
supporting its use (145) but this is not reflected in UK availability of the product.  
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In other cases, differences in national clinical practices may explain the absence if the type 
of irrational prescribing described is already rare in UK practice. This explanation likely 
underlies guidance about rectally administered drugs including paracetamol per rectum 
for pain and suppositories for cough. The cultural difference that may give rise to this 
variance in clinical practice was recognised in the EMA Guideline on pharmaceutical 
development of medicines for paediatric use (146) when discussing medication acceptability in 
differen  co n ries, gi ing he e ample ha  he rec al ro e of adminis ra ion is no  
generall  fa o red in he UK . 
 
Two of the omitted criteria, in relation to sucrose for painful procedures in infants and 
nitrofurantoin as prophylaxis for urinary infection, may be absent from national UK 
guidelines because these are areas where there is not a national consensus of best practice. 
In reviewing these topics, local guidelines were found to differ. Some UK guidelines were 
found recommending nitrofurantoin for prophylaxis (147, 148). In guidelines relating to 
sucrose for painful procedures, some UK guidelines preferred breast- or bottle-feeding 
over sucrose, described contraindications, and qualified the guideline according to 
gestation and age of infant (149, 150). In the absence of a unifying national guideline on 
these topics, they were therefore not considered to be good candidates for screening 
prescribing practice nationally. 
 
Four criteria were omitted due to the existence of UK clinical guidelines that were in 
direct conflict with the original proposition (see   
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Table 3-B).  
 
Three of these appear to have been included as PIMs in the original French tool due to 
risk of interactions or side effects. One related to nitrofurantoin for treatment of urinary 
infections. According to the report describing the development of the original POPI tool, 
this criterion was derived from a statement issued by Agence Française de Sécurité 
Sanitaire des Produits de Santé (AFSSAPS, the French Agency for the Safety of Health 
Products) in 2011 warning of cases of severe hepatic and pulmonary complications 
following long-term treatment with nitrofurantoin (151).  
 
The BNFc does recommend monitoring liver function and for pulmonary symptoms if 
prescribing nitrofurantoin long-term, but it is licensed and indicated in acute 
uncomplicated urinary tract infections for children aged 3 months and older (120) and is 
second-line for children aged 3 months and older in the most recent NICE guideline 
NG109 (152).  
 
The second related to isotretinoin and tetracycline antibiotics. This appears to be derived 
from a Good Practice Recommendation from AFSSAP describing isotretinoin as 
contraindicated with tetracyclines due to the reported occurrence of benign intracranial 
hypertension with this combination (153). This risk is recorded in the BNFc as a possible 
in erac ion, ra ed as Serio s  i h an anecdo al e idence base (120). The combination is 
not recorded as a contraindication and combined topical retinoids and oral tetracyclines 
and recommended in the NICE Clinical Knowledge Summary.  
 
The third related to fluoride supplements before age 6 months. The related French 
guideline, an AFSAPPS statement in 2008, recommended that fluoride-containing 
supplements such as toothpaste be commenced when teeth erupt, on average at age 6 
months (154). This statement, like the relevant UK guidelines, discusses the risk of dental 
fluorosis with excess fluoride consumption during tooth development and recommends 
lower dose fluoride in toothpaste for young children. Both the NICE and SIGN 
guidelines quoted in   
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Table 3-B acknowledge the risk of dental fluorosis and state that the benefit of reduced 
caries favours starting fluoride supplementation as soon as teeth erupt with no definitive 
lower age limit of benefit to the child. 
These all appear to reflect differing risk tolerance between the French and UK guidelines. 
In order that the modified tool reflects what is considered nationally to be good practice, 
the criteria were therefore omitted from the modified tool. 
 
The fourth omitted criterion lis ed The se of se rons (5-HT3 antagonists) for 
chemotherapy-associa ed na sea and omi ing  as a PIP. It was not clear what evidence 
was used to develop this proposition as none of the references in the report describing 
the development of the original tool related to chemotherapy-associated nausea and 
vomiting. The only reference mentioning setrons in the section explaining the evidence-
base for each criterion was from the American Centers for Disease Control and 
Prevention, which recommended ondansetron as an effective anti-emetic for children, 
noting it is not usually required for gastroenteritis but not making any reference to 
chemotherapy (155).  
 
Chemotherapy-induced nausea and vomiting is one of the listed indications for 
ondansetron in the BNFc (120). It is possible that the inclusion of this criterion in the 
original tool constitutes a typographical error, and that it was intended to read as an 
inappropriate omission given the importance of treating chemotherapy-associated nausea. 
It was therefore felt not to accurately reflect rational prescribing and was omitted from 
the modified tool. 
 
3.4.3 Impact of the modification process on the criteria list 
 
Of the 105 criteria of the original POPI tool, the majority were amended or omitted, with 
49 remaining unchanged. 
 
One entire clinical category was removed from the list, relating to mosquitoes. Otherwise, 
the breadth of clinical indications covered by the criteria remains unchanged. In addition, 
the range of categories of irrational prescribing described in the criteria (discussed in 
Section 2.4.4, page 36) remains equally broad. Examples from both the original POPI and 
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POPI UK relating to various types of misprescribing, as well as over- and 
underprescribing, are shown over page in Table 3-G.  
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Table 3-G: Examples of criteria relating to different categories of irrational prescribing 
Aspect of rational 
prescribing 
Example of related PIM or PIO 
from original POPI (theme) 
Example of related PIM or PIO 
from POPI UK (theme) 
Drug Nitrofurantoin used as a curative 
agent in children under six years 
(Urinary infections) 
Loperamide in the case of invasive 
diarrhoea (Diarrhoea) 
Dosage Oral solutions of ibuprofen 
administered in more than three 
doses per day using a graduated 
pipette of 10mg/kg (Pain and fever) 
Doses of ibuprofen administered in 
more than three doses per day or 
exceeding maximum dose of 
30mg/kg over three doses per day 
(Pain and fever) 
Duplication The combined use of an oral and a 
local antibiotic (Acne vulgaris) 
The combined use of an oral and a 
local antibiotic (Acne vulgaris) 
Duration The use of H2 type antihistamines for 
long periods of treatment (Nausea, 
vomiting, or gastrooesophageal 
reflux) 
The use of H2 receptor antagonists 
for more than 4 weeks (Nausea, 




Isotretinoin in combination with a 
member of the tetracycline family of 
antibiotics (Acne Vulgaris) 
The combined use of two NSAIDs 
(Pain and fever) 
Drug-disease 
interaction 
ß2 agonists, corticosteroids to treat 
an infan s firs  case of bronchioli is 
(Bronchiolitis) 
Antibiotics, ß2 agonists or 
corticosteroids to treat bronchiolitis 
(Bronchiolitis) 
Overprescribing Antibiotic treatment for a sore 
throat, without a positive rapid 
diagnos ic es  (ENT infec ions) 
Antibiotic treatment for a sore throat 
except in severe cases (ENT 
infections) 
Underprescribing Omission: Oral rehydration solution 
(Diarrhoea) 
Omission: Preventative treatment 
(inhaled corticosteroids) in the case 
of persistent asthma (Asthma) 
 
 
There is also no evidence that the modification of the tool had any impact on the degree 
of complexity, as represented by the proportion of criteria with implicit features. All 
modifications shown in Table 3-D and Table 3-E either maintained implicit features (that 
is, reference to patient characteristics or clinical details) or in one case changed a criterion 
from implici  o e plici : from The applica ion of ben l ben oa e for periods longer 
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han eigh  ho rs for infan s and 12 ho rs for children or pregnan  girls  o Ben l 
ben oa e  as a PIM for children.  
 
In some cases, amendments increased the subjectivity of a criterion, such as the change to 
antibiotics for sore throats, shown as the example of overprescribing in Table 4-B above. 
However, others reduced subjectivity, such as the proposition relating to treatment of 
gastrooesophageal reflux with H2 receptor antagonists, shown as the example of 
misprescribing duration shown in Table 4-B, or he amendmen  of he PIO As hma 
inhaler appropria e for he child s age  b  adding specificall  aged <5 ears, ei her 
Metered Dose Inhaler with spacer system or nebuliser; age 3-5 years Dry Powder Inhaler 
ma  be appropria e  sho n in Table 3-E. 
 
Therefore, the POPI UK tool, like the original POPI tool, has mixed implicit and explicit 






The POPI UK criteria are the first rational prescribing tool designed to assess rational 
prescribing for children across any setting in the UK. The tool comprises 80 criteria 
describing PIMs and PIOs. 
 
Although the POPI UK criteria are founded in evidence-based practice, their usefulness 
and validity and usefulness required testing. As discussed in Chapter 2, both clinical 
validation and inter-rater reliability studies have been published for the original POPI 
tool.  
 
In order to assess the POPI UK criteria, two studies were undertaken to test, respectively, 
the clinical application and repeatability of the new criteria. Firstly, a clinical validation 
study was undertaken in which the criteria would be applied to inpatient and emergency 
depar men  prescrip ions in a UK children s hospi al o iden if  he propor ion of 
prescriptions that fall within the categories of the tool and any inappropriate prescriptions 
or omissions that it detects in that setting. This is described in Chapter 4. Secondly, a 
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repeatability study was completed in which inter- and intra-rater agreement would be 
assessed to study the reliability of scores produced by using the criteria is described in 
Chapter 5.  
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This chapter describes the clinical assessment of the POPI UK criteria, with an overview 
of how rational prescribing tools are validated followed by the methodology and results 
of the study designed to evaluate the usefulness of the POPI UK criteria in UK paediatric 
practice. 
 
4.1.1 Evaluating rational prescribing tools 
 
As discussed in Chapter 1, rational prescribing criteria enable research into the quality of 
prescribing. The reliability of any measurement can be described in terms of two 
paradigms: accuracy and precision. Accuracy (sometimes called validity) has been 
described as meaning he closeness of he meas remen s o some e ernal r e  al e, 
or else to the results of a previously established gold standard(156). In particular, accuracy 
should be applied specifically to the results of measurement, rather than the measurement 
tool itself, as it is considered a descriptor of the meaningfulness of test results in serving a 
specific purpose(157). Precision (sometimes called reliability), on the other hand, has been 
described as reflecting the agreement between repeated measurements, whether scored by 
a single assessor at different times or scored by different assessors. There has been 
criticism of conflating precision with reliability, which in fact should take into account 
true variance (the variability that exists in the ex ernal r e  al es) hereas precision 
usually only accommodates error variance (the variability that appears due to 
measurement error) (156). Nonetheless, for the purposes of this hesis, reliabili  and 
precision  are used to mean the agreement between repeated measurements, accepting 
that this excludes some nuance in statistical terms. 
 
The analog  of a b ll s e e arge  has of en been sed o is all  represen  acc rac  and 
precision. In his analog , he cen re of he b ll s e e arge  represen s he r e  al e of 
what is being measured, and marks on the target represent values produced by 
measurement. Accurate measurements are close to the centre of the target, and a precise 
Chapter 4: Clinically assessing the POPI UK criteria 
 92 
method of measurement will produce values that are close to one another. This is 
illustrated in Figure 4-1. 
 
 
Figure 4-1: The b ll -eye analogy of accuracy and precision 
A) Low accuracy, high precision; B) Low accuracy, low precision; C) High accuracy, low precision; D) 
High accuracy, high precision. Adapted from Streiner et al, 2006 (156). 
 
 
As discussed in Section 1.4, different types of rational prescribing tools have different 
utilities and may vary in terms of accuracy or usefulness. For example, implicit criteria 
may be more accurate than explicit criteria because they are patient-specific and take into 
account co-prescriptions and patient factors (59). However, implicit criteria rely upon 
subjective judgements or understanding of clinical context by the assessor (15) meaning 
that they necessitate skilled or even expert assessors and may have lower precision. 
Correspondingl , e plici  cri eria ma  be less acc ra e in iden if ing r e  ra es of 
rational prescribing due to inability to take into account individual patient factors or 
regional differences (for instance, in the case of differing patterns of antibiotic resistance 
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in different regions) (15), but these may have higher precision due to the objectivity of the 
criteria, represented by example A in Figure 4-1. Implicit criteria, which may be more 
accurate but less precise, are represented by example C. 
 
Also described briefly in Section 1.4, there are several potential approaches to testing the 
accuracy and precision of rational prescribing tools. Their accuracy can be considered in 
two different ways. Firstly, the accuracy of a rational prescribing tool could reflect the 
degree to which it detects true rates of rational and irrational prescribing, as compared to 
their true incidence (which is unknowable) or to their measurement by another tool. 
Alternatively, bearing in mind that accuracy relates to the test results in the context of a 
specific purpose, the accuracy of rational prescribing tools could be considered to reflect 
the degree to which a tool detects rates of rational and irrational prescribing as 
correspond with adverse drug events or patient outcomes. In other words, the accuracy 
of a rational prescribing tool could be considered either its sensitivity to detecting non-
gold standard prescribing, or its closeness of correlation with patient outcomes. 
 
In order to be amenable to a clinical validation study, rational prescribing tools must 
either be limited to criteria that can be applied to large datasets that are already available, 
or authors must carry out a large, complex and costly study to collect all data required 
prospectively and follow-up patient outcomes. In their 2013 systematic review of rational 
prescribing tools for adults, Kaufmann et al found that 39 of the 46 tools they described 
had not had any clinical validation studies assessing correlation with patient outcomes 
(60). These studies had demonstrated correlation between potentially irrational 
prescribing as indicated by the tools and adverse patient outcomes, including probability 
of hospitalisation and risk of adverse drug reactions.  
 
Many rational prescribing tools without clinical validation studies have instead been 
studied in their ability to detect potentially irrational prescribing in an appropriate clinical 
context. Without a comparator, these studies cannot be considered assessments of the 
acc rac  of he ools, as he r e  al e for potentially irrational prescriptions in those 
populations is not known. However, these studies do provide evidence of the potential 
usefulness of the tools by demonstrating their ability to highlight some inappropriate 
prescriptions and identifying the types of PIMs or PIOs the tool finds. They could 
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therefore be used to study these types of irrational prescribing futher, for instance 
investigating causative factors or interventions designed to improve rational prescribing. 
 
As the POPI criteria were the first rational prescribing tool published for paediatric 
applications, and the only extant tool at the time of this work, it was not possible to 
design a protocol that compared the POPI UK criteria to an alternative measurement. 
Since the completion of the study reported in this chaper, a clinical validation study of the 
original POPI criteria has been published; this is discussed in comparison with the POPI 





The purpose of this study was to evaluate the applicability of the POPI UK criteria in 
clinical prac ice in a UK children s hospi al. 
 
The primary objective was to identify what proportion of children received prescriptions 
that can be assessed using the POPI UK criteria, and thereby to test the relevance of the 
tool in a UK paediatric population. 
 
The secondary objectives were to assess rational prescribing according to the POPI UK 
criteria by:  
x recording instances of PIMs or PIOs in screened prescriptions 
x recording the setting of prescription and test whether there is any difference in 
rates of rational prescribing between settings, with the null hypothesis that there 
will be no difference between settings 
x recording the age of patients and test whether there is any difference in rates of 
rational prescribing between age groups (infant, child and adolescent), with the 
null hypothesis that there will be no difference between patient groups 
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4.3 Methods 
4.3.1 Study design 
 
The POPI UK tool was used to prospectively assess paediatric prescriptions with a cross-
sec ional approach (i.e. each child s dr g char  as scored agains  he POPI cri eria a  a 
single point in time), with reference to patient notes for information on symptoms and 
diagnoses, in inpatient and emergency department settings in the Royal Derby Hospital, 
Derby. This did not replace any usual practice of on-going review of prescriptions, for 
instance by clinical pharmacists.  
 
Using retrospective pre-anonymised data was considered as an alternative to prospective 
data collection, however the POPI criteria require contemporaneous information about 
par icipan s  s mp oms and heir prescrip ions. As a combina ion of paper and elec ronic 
prescribing and paper and electronic medical record-keeping was in use in the Royal 
Derby Hospital at the time of data collection, prospective recruitment was felt to be a 
more reliable method of ensuring complete data collection. For example, some patients 
received handwritten outpatient prescrip ions from he Children s Emergenc  
Department; these did not automatically produce copies for filing on discharge and 
therefore information of how the prescription was written would not be available for 
retrospective analysis. This was necessary for full evaluation under the POPI criteria, for 





Participants were recruited from current inpatients in the paediatric inpatient wards and 
he Children s Emergency Department (children s ED) at the Royal Derby Hospital. All 
children in these departments were eligible for recruitment whether or not they presented 
with illnesses within the remit of the POPI criteria, and whether or not any medications 
were prescribed. The aim was to recruit 300 participants in each setting (sample size is 
discussed in 4.5.2). 
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Recruitment was undertaken between August 2016 and February 2017. All recruitment 
was undertaken during the day, including all days of the week. 
 
4.3.3 Eligibility criteria 
4.3.3.1 Inclusion criteria 
 
x Age 0-15 years with parent/carer consent and optional assent or 16-18 with their 
own informed consent 
x Inpatient in a paediatric ward or a endee o he Children s Emergenc  
Department (children s ED) at the Royal Derby Hospital 
 
4.3.3.2 Exclusion criteria 
 
x Lack of good English language skills in the consenting parent/guardian and 
patient. 
x Lack of informed consent given by parent/guardian in children aged 0-15 years, 
declining to assent aged 6-15 years or lack of consent in participants aged 16-18 
years 
4.3.4 Participant information literature 
 
Parental participant information sheets and age-appropriate leaflets were developed to 
provide families with information about the study prior to obtaining consent. There is 
evidence that participant information provided in the course of research studies is often 
difficult for participants to read(158), which presents ethical challenges in ensuring 
consent is fully informed.  
 
As discussed in Chapter 1.8.2, research that involves children may be perceived as more 
challenging because is likely to include children with varying developmental ages and 
literacy levels, all of whom must be catered for in the process of providing participants 
i h informa ion. Ho e er, hile children s differing de elopmen al ages are likel  o be 
taken into account, it is often not considered that more than a quarter of adults in the UK 
ha e lo  li erac  or n merac  skills, meaning ha  he  s r ggle i h basic q an i a i e 
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reasoning or ha e diffic l  i h simple ri en informa ion (97). Readability assessments 
of sample educational materials intended to support informed consent have shown that 
texts produced in institutions with guidelines recommending language at a set reading 
level- the most common standard was eighth grade, the average reading level of adults in 
the US (159)- less than 10% meet this standard (160).  
 
Strategies such as improving the readability of educational materials through ensuring that 
they use simple language, are short, clearly organised, and illustrated with images, and 
providing concurrent verbal information with the written information have been shown 
to improve understanding, although they do not entirely mitigate the effects of low 
literacy (91). These strategies are equally appropriate in research involving children as in 
adult s dies, and i  is impor an  o consider paren al li erac  as ell as he child s 
developmental stage and literacy. 
 
For these reasons, in order to design information sheets that were accessible and useful to 
families, several steps were taken to maximise the readability and usefulness of the 
participant information sheets. All of the development and design of leaflets was 
undertaken by the author. 
 
Firstly, parental information leaflets and information posters were designed. The drafts 
were then tested for accessibility and usefulness by attendance at the paediatric outpatient 
department and discussion of their design and content with families attending clinics, 
which included children of ages ranging from 1 year to 15 years. The majority of feedback 
was posi i e, s ch as commen s of, I  e plains e er hing  and I  is self-e plana or . 
Specific positive features included the detail about data storage, and a comment on the 
language being accessible for a family for whom English was a second language. 
However, one paren  fo nd ha  he informa ion as a bi  orr ing , as i  made her 
concerned that her child might be being exposed to medication errors. Another parent 
fel  ha  he ord ool  as misleading and commen ed ha  e amples of POPI cri eria 
would be helpful. 
 
Taking into account participant and parent feedback, parental leaflets were redesigned, 
and then further designed leaflets containing the same information in simplified language 
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and with additional pictures for children. These were designed by age group, for 
participants aged 16-18 years, 13-15 years, and 6-13 years. 
 
All leaflets were evaluated using Microsoft Word in-built readability statistics, which 
provide a Flesch-Kincaid reading grade level. This is a score that is used to reflect the 
number of years of education that might be required to understand a text, and it has been 
widely used to evaluate patient information material (160-162). The score takes into 
account length of sentences and average number of syllables in words to represent 
complexity of text. All leaflets were designed with the aim of a reading grade level less 
than 8.0, which corresponds approximately to an age of thirteen years. Work was then 
undertaken to amend the parent information sheets to achieve a Kincaid reading grade of 
8.8 (see Appendix 9); this was partly limited by needing to include contact information for 
researchers including many pol s llabic ords, e.g. ni ersi  and depar men . 
 
The age-appropriate leaflets for ages 6-13 years were designed aiming for a lower age 
grade. Although grade 1 would approximately correspond to age six, this readability level 
was not targeted as it is extremely limiting given that polysyllabic words such as 
medicines  and children  needed o appear in he shee . The draf  of he age 6-13 
participant information leaflet achieved a Kincaid reading grade of 4.1 (see Error! 
Reference source not found.10). The draft of the age 13-15 years leaflet and 16-18 
leaflet (which used the same body text) achieved a Kincaid reading grade of 8.4, 
corresponding approximately to a reading age of 13 years (see Appendices 11 and 12). 
 
However, subsequent to the design of the participant and parental information sheets, 
after submission to the University ethics board, required phrasing had to be introduced 
for many sections to meet University requirements of specific language that had to be 
included in any participant information sheets used in University research. These rules did 
not mandate changing the information sheets for children under the age of 16 years but 
required inclusion of mandatory phrases in all parental information sheets and those for 
participants aged 16-18 years who might be consenting for themselves. The leaflets were 
therefore redesigned using the University mandated language (see Error! Reference 
source not found. 13). As a result, the Kincaid reading grade of each was 9.5, 
corresponding approximately to a reading age of 15 years, above the recommended 
readability standard of most institutions. 
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4.3.5 Data collection 
 
Families were approached by a researcher, who explained the study and sought informed 
consent for participation. As discussed in 4.3.4 written participant information sheets 
were provided to parents, with age-appropriate information leaflets for children (see 
Appendices 10, 11, and 13). After consent was given, there was no further active 
involvement with the participant.  
 
The author fulfilled the role of researcher for the majority of recruitment (86%), with 
assistance from two research nurses, Janine Abramson and Coral Smith, who recruited 
14% of participants. 
 
The researcher re ie ed he par icipan s  records in he depar men  and ranscribed da a 
from he par icipan s  prescriptions and medical notes onto a case report form (CRF), see 
Figure 4-2. POPI UK criteria were recorded using codes for relevant diagnoses and PIMs 
or PIOs with reference to a POPI UK criteria code document (see Appendix 8). 
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Figure 4-2: Case report form  
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Figure 4 2: Case report form   
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Figure 4 2: Case report form   
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4.4 Ethics approval 
 
Ethics approval was secured from the Brighton & Sussex Research Ethics Committee 
(REC reference 15/LO/2191), see Appendix 14. In addition, the University of 
Nottingham Research & Development department approved and sponsored the study 
(Appendix 15). Trust approval was granted by the Derby Hospitals NHS Foundation 
Trust (Appendix 16). 
 
4.5 Statistical analysis 
4.5.1 Methods of statistical analysis 
 
All data were analysed in Microsoft Excel. Analysis included calculation of mean and 
median number of prescriptions per child, rates of inappropriate prescribing types 
according to the POPI screening tool, and calculation of difference between mean rates 
of inappropriate prescribing in different age groups, sex, and by types of prescribers using 
the chi-squared test. 
 
4.5.2 Sample size and justification 
 
A sample size power calculation was not calculated, as there are no relevant data available 
about expected proportions of participants who will fall within the POPI UK criteria to 
inform a power calculation. The WHO have recommended a sample size of 600 clinical 
encounters in total in studies evaluating rational prescribing (54) Therefore, the target was 




4.6.1 Population characteristics 
 
In total, 598 participants were recruited (due to erroneous numbering of consecutive 
consented patients) with 299 patients recruited from the paediatric inpatient wards and 
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299 from he Children s Emergenc  Depar men  (children s ED). A total of 1,608 
prescriptions were analysed, of which 1,279 were prescribed for the inpatient population, 
and 329 in the ED. Patient demographics including clinical (diagnostic) codes and 
common medications prescribed are shown in Table 4-A. 
 
Table 4-A: Patient demographics 
 Number of participants 
 Inpatient ED Total 
Age (years) 
<1 109 42 151 
1-5 97 112 209 
6-10 42 73 115 
11-15 33 64 97 
>15 18 8 26 
Number of medications prescribed 
0 23 103 126 
1-5 202 195 397 
6-10 60 1 61 
11-15 9 0 9 
>15 5 0 5 
Clinical indications (affecting five or more participants) 
Pain and fever 183 190 373 
Vitamin supplements and antibiotic prophylaxis 115 127 242 
Nausea, vomiting, or gastrooesophageal reflux 97 65 162 
Cough 65 37 102 
ENT infections 20 31 51 
Diarrhoea 29 17 46 
Urinary infections 17 3 20 
Bronchiolitis 13 2 15 
Asthma 7 4 11 
Atopic eczema 4 3 7 
Epilepsy 5 1 6 
Medications (prescribed to 20 or more participants) 
Paracetamol 223 93 316 
Ibuprofen 130 75 205 
Salbutamol 54 19 73 
Amoxicillin 60 5 65 
Morphine 54 5 59 
Co-amoxiclav 42 9 51 
Cefotaxime 42 0 42 
Ondansetron 38 1 39 
Ipratropium 26 4 30 
Prednisolone 26 3 29 
Oral fluids 9 17 26 
Cefuroxime 25 0 25 
Cyclizine 24 1 25 




Patient age ranged from 3 days to 17 years; distribution of patient age is shown in Figure 
4-3 and Figure 4-4. 
 
 
Figure 4-3: Age of recruited participants 
 
Figure 4-4: Age of recruited participants under 1 year 
  
The mean age in the inpatient group was 4 years and 4 months, the mean age in the ED 
group was 6 years and 2 months, with an overall mean for the population of 5 years and 3 
months. The median age in the inpatient group was 2 years, the median in the ED group 
was 5 years, and the overall median age was 3 years. 
36
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The most common clinical category from POPI UK observed in the population was pain 
or fever, affecting 373 participants. Corresponding with this finding, the two most 
common prescriptions were paracetamol and ibuprofen, prescribed to 316 and 205 
participants respectively. Alongside analgesia, common medication groups included 
antibiotics, bronchodilators and antiemetics, as well as prednisolone and oral fluids. The 
latter, oral fluids, are not prescription-only or even medication in the usual definition. 
However, documentation of oral fluid challenges or treatment was documented alongside 
prescribing data in order to assess relevant criteria related to oral rehydration solution for 
diarrhoea or vomiting. 
 
Prescriber background could not be recorded for all prescriptions, but prescribers 
included a range of backgrounds and experience including paediatric consultants, 
paediatric specialty trainees, GP trainees, and nurse practitioners. 
 
4.6.2 Evaluation of POPI UK criteria: relevance to study population 
 
The primary aim of this study was to identify what proportion of children received 
prescriptions that can be assessed using the POPI UK criteria. 
 
Out of 598 patients, 574 had at least one documented symptom or diagnosis included in 
the POPI UK criteria; 292 patients in the inpatient group and 282 in the emergency 
department group. The most frequent was pain or fever (373), with other frequent 
indications being vitamin supplements and antibiotic prophylaxis (242), nausea, vomiting 
or gastro-oesophageal reflux (162), cough (102), and ENT infections (51). Some patients 
had symptoms or diagnoses that related to multiple categories. Six categories were not 
relevant to any patients in the study population. The number of patients presenting with 
symptoms or diagnoses relevant to each of the categories in the tool is shown over page 
in Table 4-B.   
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Table 4-B: Patients with symptoms or diagnoses related to each POPI UK category 
POPI UK tool category Number of patients presenting with related symptoms or diagnosis (by 
setting) 
Inpatient ED Total 
Pain and fever 183 190 373 
Vitamin supplements and 
antibiotic prophylaxis 
115 127 242 
Nausea, vomiting, or 
gastrooesophageal reflux 
97 65 162 
Cough 65 37 102 
ENT infections 20 31 51 
Diarrhoea 29 17 46 
Urinary infections 17 3 20 
Bronchiolitis 13 2 15 
Asthma 7 4 11 
Atopic eczema 4 3 7 
Epilepsy 5 1 6 
Herpes simplex 1 0 1 
Depression 0 1 1 
Anorexia 1 0 1 
ADHD 1 0 1 
Acne vulgaris 0 0 0 
Scabies 0 0 0 
Lice 0 0 0 
Ringworm 0 0 0 
Impetigo 0 0 0 
Nocturnal enuresis 0 0 0 
 
 
There were a number of frequent diagnoses that are not contained within any of the 
categories of the POPI UK criteria. Uncoded diagnoses with at least fifteen cases in the 
study population were: lower respiratory tract infections (LRTI), viral-induced wheeze, 
appendicitis, sepsis, soft tissue injury, and fracture. These are listed in Table 4-C. 
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Table 4-C: Common diagnoses in study population that are not contained in the POPI UK criteria 
Diagnosis Number of cases in 
study population 
Viral-induced wheeze 50 
Sepsis 46 
Soft tissue injury 39 
Lower respiratory tract infection 34 
Appendicitis 20 




The most common uncoded diagnosis found in the study population was viral-induced 
wheeze, followed by sepsis and soft tissue injury. Only seven of the original categories in 
the tool had more cases than those listed in Table 4-C. 
 
4.6.3 Potentially inappropriate medicines and omissions detected by the POPI 
UK criteria 
 
One secondary aim was to identify any instances of PIMs or PIOs in the study 
population. There were 282 instances of PIMs and PIOs identified in 261 of the 598 
(44%) participants, with more than one PIP/PIO for some participants. The categories of 
identified potentially inappropriate prescribing are shown in Table 4-D.  
 
Table 4-D: Categories of identified PIMs and PIOs 
Clinical category Number  
Vitamins and Antibiotic Prophylaxis 242 
Pain and fever 30 
Bronchiolitis 4 
Nausea, vomiting and gastro-oesophageal 
reflux 
2 
Atopic eczema 2 
ENT infection 1 
Asthma 1 
Total  282 
 
Chapter 4: Clinically assessing the POPI UK criteria 
 110 
As shown in Table 4-D, the majority of PIMs and PIOs fell within just two categories: 
242 related to vitamins and antibiotics prophylaxis, 30 related to pain and fever. The 
related clinical categories of all identified PIMs/PIOs are further broken down in Table 
4-E. 
 
Table 4-E: Specific PIMs and PIOs detected 




Omission: Healthy Start vitamins for infants and children 6 months- 5 
years or having less than 500mL infant formula per day 
242 
Pain and fever Omission: Failure to give an osmotic laxative to patients being treated 
with morphine for a period of more than 48 hours 
22 
Inappropriate prescription: Prescription of two alternating antipyretics 
as a first-line treatment 
7 
Inappropriate prescription: Prescription of a medication other than 
paracetamol or ibuprofen as a first-line treatment for pain (except in 
the case of migraine) 
1 
Bronchiolitis Inappropriate prescription: Antibiotics, ß2 agonists or corticosteroids 







Inappropriate prescription: Acid-suppressing drugs to treat overt 
regurgitation in the absence of feeding difficulties, distress, or faltering 
growth 
1 
Omission: Oral rehydration solution (ORS) for dehydrated children 
unless IV fluid therapy is indicated (shock, red flag symptoms despite 
ORS, persist vomiting of ORS) 
1 
Atopic eczema Inappropriate prescription: More than one application per day of a 
dermocorticoid, except in cases of severe lichenification 
1 
Inappropriate prescription: Prescription of antihistamines except as a 
trial for severe itching or where sleep disturbance has a significant 
impact on the child or carers 
1 
ENT infection Inappropriate prescription: An antibiotic for < 4 days symptoms of 
acute upper respiratory tract infection except: 
x bilateral acute otitis media in children younger than 2 years 
x acute otitis media in children with otorrhoea 
x acute sore throat/acute pharyngitis/acute tonsillitis when 
three or more Centor criteria are present. 
1 
Asthma Omission: Preventative treatment (inhaled corticosteroids) in the case 
of persistent asthma 
1 
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As Table 4-E shows, a single criterion relating to vitamins dominated, with 242 cases 
related to that criterion alone. There were several other criterion with multiple identified 
instances, two in the category of pain and fever, and one relating to bronchiolitis. 
 
In 38 prescriptions, it was not possible to determine whether or not an inappropriate 
prescription or omission had occurred according to the POPI UK criteria. In some cases, 
there was uncertainty about a PIM or PIO in more than one category. The specific 
criteria cited and reasons for uncertainty are listed in Table 4-F.  
 
Table 4-F: Cases where it was not possible to determine whether a PIM/PIO had been made 
according to the POPI UK criteria 
Clinical category Criterion Reason for uncertainty Number 
of cases 
Nausea, vomiting, or 
gastro-oesophageal 
reflux 
Omission: Oral rehydration 
solution (ORS) for dehydrated 
children unless IV fluid therapy 
is indicated (shock, red flag 
symptoms despite ORS, persist 
vomiting of ORS) distress, or 
faltering growth 
Types of oral fluids used 
for oral fluid challenge 
not specified  
12  





Acid-suppressing drugs to treat 
overt regurgitation in the 
absence of feeding difficulties, 
Hydration status not 
specified 
2 
S bjec i e: dis ress  1 
Diarrhoea Omission: Oral rehydration 
solution (ORS) for dehydrated 
children unless IV fluid therapy 
is indicated (shock, red flag 
symptoms despite ORS, persist 
vomiting of ORS) 
Type of oral fluids used 
for oral fluid challenge 
not specified 
4 
Hydration status not 
documented 
2 
ENT infections Inappropriate prescription: An 
antibiotic for < 4 days 
symptoms of acute upper 
Centor criteria not 
documented 
4 
Duration of symptoms 
not documented 
1 
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respiratory tract infection 
(except: 
x bilateral acute otitis 
media in children 
younger than 2 years 
x acute otitis media in 
children with otorrhoea 
acute sore throat/acute 
pharyngitis/acute tonsillitis 
when three or more Centor 
criteria are present. 
Specific indication for 




Antibiotic treatment for a sore 
throat except in severe cases 
(anticipated to be no more than 
20% of cases) 
Subjective: definition of 
se ere  
1 
Pain and fever Omission: Failure to give an 
osmotic laxative to patients 
being treated with morphine for 
a period of more than 48 hours 
On-going loose stools 4 
Duration morphine not 
specified 
1 
Bronchiolitis in infants Inappropriate prescription: 
Antibiotics, ß2 agonists or 
corticosteroids to treat 
bronchiolitis 
Antibiotics given but 
indication documented as 
chest infection although 
only listed diagnosis 
bronchiolitis 
2 
Atopic eczema Inappropriate prescription: 
More than one application per 
day of a dermocorticoid, except 
in cases of severe lichenification 






Omission: Recording a growth 
chart (height and weight) if the 
patient is taking 
methylphenidate 
Not documented whether 
growth chart being 
completed for patient 
1 
Total   40 
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In some of the instances described in Table 4-F, the reason for the case being 
doc men ed as Uncer ain  as d e o clinical reasoning making he criterion irrelevant, 
while the proposition itself did not give room for subjective reasoning. For instance, 
laxatives would clearly be inappropriate in the context of diarrhoea, despite ongoing 
prescription of potentially constipating opiates. In other instances, overview of clinical 
documentation and prescriptions did not provide adequate information, such as 
frequency of application of a topical prescription, or the presence or absence of growth 
documentation elsewhere. 
 
4.6.4 Settings of prescribing and rates of potentially inappropriate prescribing 
 
Another secondary aim of this study was to evaluate whether there was any difference in 
rates of rational prescribing between settings. A null hypothesis of no difference was not 
assessed with statistical testing as it was deemed that the numbers were not sufficient for 
meaningful testing. However, the rates of PIMs and PIOs detected did differ between the 
two settings s died, a children s emergenc  depar men  and an inpa ien  ard. 
 
As discussed above, the distribution of age of participants presenting to the two settings 
was quite different, as illustrated in Figure 4-3 and Figure 4-4, with many more patients 
aged less than 1 year in the inpatient population (36%) compared with the emergency 
department (14%). Another important difference between settings was the number of 
medicines prescribed. A total of 1,608 medications were prescribed for the study 
population as a whole. 1,279 were prescribed for patients in the Inpatient setting, and 
only 329 for patients in the ED. The rates of potentially irrational prescribing in each 
setting therefore need to be evaluated in the context of the number of children with 
relevant indications and the total number of medicines prescribed. 
 
In total, 14 PIMs were identified in the inpatient setting and two in the ED. These are 
further subdivided by clinical category in Table 4-G. PIOs were again affected by the high 
rates in the vitamins category, with 138 PIOs in the inpatient setting and 128 in the ED. 
Excluding the vitamins category, there were 23 PIOs identified in the inpatient group and 
one in the ED. 
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Clinical category Inpatient ED Inpatient ED 
Vitamins and antibiotic prophylaxis 0 0 115 127 
Pain and fever 7 1 21 1 
Bronchiolitis 4 0 0 0 
Nausea, vomiting and gastro-oesophageal 
reflux 
1 0 1 0 
Atopic eczema 2 0 0 0 
ENT infection 0 1 0 0 
Asthma 0 0 1 0 
Total  
(excluding vitamins) 





As this shows, the inpatient population had more potentially inappropriate prescribing 
identified in both categories, whether the vitamins category was included or not. Most 
striking were the higher number of PIMs, half of which were due to PIMs relating to pain 
and fever. 
 
In order to take into account the different numbers of patients within relevant categories 
in the different settings, the numbers of PIMs/PIOs identified need to be considered in 
the context of total numbers of prescriptions. The number of PIMs/PIOs as compared 
with total number of medicines prescribed is shown below in Table 4-H. 
 
Table 4-H: Numbers of prescriptions and potential irrational prescribing by setting 
Setting Number of 
prescriptions 
PIMs PIOs Total PIMs and 
PIOs 
Inpatient 1,279 14 138 152 
ED 329 2 128 130 
 
 
The higher rates of potentially inappropriate describing identified in the inpatient group 
and possible reasons for this finding are discussed further in 4.7.2.3. 
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4.6.5 Age of participants and potentially inappropriate describing  
 
Identified instances of either type of potentially inappropriate prescribing were not evenly 
distributed across the age groups, with a much higher proportion occurring in the 1 to 5 
year age group, as shown in Table 4-I below.  
 
Table 4-I: Rates of potentially inappropriate prescribing by age group 
Age group Number of 
participants 
Number with potentially 
inappropriate prescribing 
identified (%) 
<1 year 152 38 (25) 
1 to 5 years 208 208 (100) 
6 to 10 years 115 6 (5) 
11 to 15 years 97 5 (5) 
> 15 years 26 4 (15) 
 
 
Clearly, this result is significantly affected by the fact that the vitamin criterion related to 
all participants between age 6 months and 5 years. Excluding this criterion, rates by age 
group are shown in Table 4-J. 
 
Table 4-J: Rates of potentially inappropriate prescribing excluding vitamin criterion by age group 
Age group Number of 
participants 
Number with potentially 
inappropriate prescribing 
(%) 
<1 year 152 8 (5) 
1 to 5 years 208 14 (7) 
6 to 10 years 115 6 (5) 
11 to 15 years 97 5 (5) 
> 15 years 26 4 (15) 
 
This shows that while potentially inappropriate prescribing occurred most often in the 1-
5 years age group, as a proportion of the population the group over 15 years was more 
affected, with 15% of this group having either a PIP or PIO. 
 
 




4.7.1 Appropriateness of clinical categories in the POPI UK criteria to the study 
population 
 
This study demonstrated that the POPI UK criteria were applicable to a large majority of 
patients (574/598, 96%). However, two categories contributed a large number of patients 
to this finding. The category of vitamin supplements and antibiotic prophylaxis was 
relevant to 242 patients, all of which were due to patient age (with one criterion stating 
that an inappropriate omission would be the omission of Healthy Start vitamins for 
infants and children aged 6 months to 5 years or having less than 500mL infant formula 
per day). This captured a large proportion of the study population, of which a quarter 
were aged under 1 year and 60% under 6 years. Forty-three of these patients presented 
with vitamin supplements and antibiotic prophylaxis as their only relevant clinical 
condition, while 199 had concurrent symptoms or diagnoses relevant to other categories. 
 
Pain and fever was also a category relevant to many patients (373/598) with a range of 
diagnoses that presented with the symptoms of pain or fever. Of these, 232/373 
presented with other categories included in the criteria and 141/373 presented with pain 
and fever as their only included clinical condition.   
 
Excluding these two categories, only 35% (390/598) still had a symptom or condition 
that is included in the tool. 
 
In the category of vitamins and antibiotic prophylaxis, every patient between 6 months 
and 5 years of age was considered as having a PIO, in that Healthy Start vitamins were 
not prescribed for any child in this study, as per the criterion. However, in collecting data 
from clinical notes, it was not possible to determine whether patients were receiving 
infant formula, or the volume if so. Coding this as a PIO unknown for all patients under 
two years was considered, as a diet high in infant formula was considered possible, but 
the precise cut-off would have been chosen without good evidence base. Absence of 
recording adequate infant formula in the diet was therefore accepted as evidence that the 
omission was not a rational decision and so falls within irrational prescribing.  
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While alternative data collection methods would be able to access detailed dietary 
information, for instance via data collection from parents, this is a serious limitation for a 
tool aiming to assess quality of prescribing, as it cannot be scored from prescribing and 
clinical coding data. This limitation is also true of a number of other criteria, for instance 
the omission Recording a growth chart (height and weight) if the patient is taking 
methylphenidate  for patients with ADHD as shown in Table 4-F. A full list of criteria 
that may not be measurable from prescribing and clinical coding data alone is shown in 
Table 4-K. Some of these criteria could have been coded as PIOs on the same basis, for 
the 102 patients presenting with cough, one with anorexia and one with ADHD.  
 
Table 4-K: POPI UK criteria that cannot be scored using only prescribing and clinical coding data 
Clinical category Criterion 
Vitamin Supplements and Antibiotic Prophylaxis Healthy Start vitamins for infants and children 6 
months- 5 years or having less than 500mL infant 
formula per day 
Cough Failure to propose a whooping cough vaccine for 
pregnant women. 
Scabies Decontamination of household linen and clothes 
and same day treatment of all members of the 
household 
Anorexia Prescription of medications as a sole or primary 
treatment for anorexia nervosa 
ADHD Recording a growth chart (height and weight) if 
the patient is taking methylphenidate 
 
In the case of the criterion related to scabies, no patients were recorded with this 
indication. The one patient with anorexia nervosa did not have any medications 
prescribed, making i  clear he PIM of Prescription of medications as a sole or primary 
treatment for anorexia nervosa  did not apply. In other cases, the decision against this 
approach was subjective. For instance, in no instance was the presence of a pregnant 
woman noted in the patient records of cases of cough, therefore it seemed unreasonable 
to record absence of documentation about advice for whooping cough vaccine as a PIO.  
 
The results demonstrate that pain and fever are highly prevalent conditions in the 
paediatric population attending the emergency department and those admitted as 
inpatients and are therefore appropriate targets for studying rational prescribing. 
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However, when the categories of pain and fever and vitamin supplements and antibiotic 
prophylaxis are excluded, approximately two-thirds (65%) of patients in this population 
had no presenting symptoms or diagnoses that are contained within the tool.  
 
The diagnoses in Table 4-C may represent further appropriate conditions to consider 
when assessing quality of prescribing, if a broadly inclusive strategy such as POPI is being 
used. For example, viral-induced wheeze is a condition for which the management has 
changed substantially and repeatedly in recent years (163, 164). While controversy 
remains around some approaches to treatment, other treatments are known to be 
ineffective but continue to be prescribed (165). Sepsis is also a frequent condition 
observed in the study population that is not included in POPI UK. This is a condition 
known to be time-critical in terms of pharmaceutical management with antimicrobial 
therapy in both adults (166) and children (167), with strong evidence for reduced 
mortality and organ failure resulting from optimal prescribing (i.e. antimicrobial therapy 
within one hour of recognition of sepsis), suggesting this would be a valuable target for 
improving prescribing practice. 
 
4.7.2 Potentially inappropriate medicines and omissions detected in this study 
 
In total, 282 PIOs or PIOS were detected, out of 1,607 prescriptions, with a rate of 
17.5%. These occurred in 258 of the 598 participants (43%), with more than one 
PIM/PIO in some cases.  
 
Ho e er, he ra e  m s  be in erpre ed i h he nders anding ha  i  is possible for 
there to be more than one PIM/PIO for a single prescription within the POPI UK 
criteria. For example, a patient prescribed morphine as the only treatment for pain for 
several days would have both a PIM and a PIO (Inappropriate medicine: Prescription of a 
medication other than paracetamol or ibuprofen as a first-line treatment for pain (except in the case of 
migraine) and Omission: Failure to give an osmotic laxative to patients being treated with morphine for 
a period of more than 48 hours). If this patient were the only participant studied, this would 
generate a PIM/PIO rate of 200%. 
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4.7.2.1 Comparing potentially inappropriate medicines and potentially 
inappropriate omissions 
 
Of the 282 PIM/PIOs, only sixteen comprised PIMs, while 266 were PIOs. Out of 1,607 
prescriptions, this represents a 1% rate of PIMs and 16.4% rate of PIOs. However, a 
large majority of omissions related to a single vitamin-related criterion (discussed in detail 
below); excluding the Health Start vitamin criterion, there were 24 PIOs, a rate of 1.5%. 
 
4.7.2.2 Comparing potential irrational prescribing within each clinical category 
 
The most common category in which potentially irrational prescribing was detected was 
vitamin supplements and antibiotic prophylaxis, specifically in prescription of Healthy 
Start vitamins (239 cases). There were no prescriptions of Healthy Start vitamins to any 
patient in the study population. Given this complete omission, it seems possible that 
rather than this representing a 100% PIO rate in the study population, this may instead 
demonstrate that the criterion is not appropriate for evaluation of prescriptions. The 
NHS website with patient and healthcare professional information about Healthy Start 
vitamins (168) describes distribution points in England, Scotland, Wales, and Northern 
Island, including inviting parents to apply for coupons by post or by contacting midwives 
or health visitors. This highlights that the usual source of Healthy Start vitamins is 
unlikely to be via prescription and might not therefore be detected in an inpatient setting 
if parents continue to give these to their children even in hospital. Alternatively, this may 
demonstrate a genuine deficit; it would be useful to evaluate the nutritional guidelines of 
UK paediatric hospitals to assess whether nutritional supplements are considered and 
whether vitamins are provided as non-prescribed nutritional supplements, intentionally 
omitted during inpatient stays, or unintentionally omitted during inpatient stays. 
 
Excluding the vitamin PIO from analysis, there were 40 PIMs/PIOs identified, with a 
rate of 2.5%. Thirty-seven of these were in the inpatient group (a rate of 2.9%) and three 
in the emergency department (a rate of 0.9%).  
 
The second most frequently detected potentially irrational prescribing was the PIO of 
Fail re o gi e an osmo ic la a i e o pa ien s being rea ed i h morphine for a period 
of more han 48 ho rs , hich occ rred in 22 cases. Of those cases, 21 occurred in the 
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inpatient setting and one in the emergency department, which may reflect the increased 
likelihood of s rong analgesia being gi en as a s a  or one-off prescription in the 
emergency setting, as compared with patients receiving more than 48 hours of care in the 
inpatient setting.  
 
The third most frequent potentially irrational prescribing was also in the category of Pain 
and Fe er, Prescrip ion of o al erna ing an ip re ics as a firs -line rea men . All 
seven instances of this PIM occurred in the inpatient setting, which may again highlight 
that this is a type of irrational prescribing to which patients may be more vulnerable 
during on-going periods of treatment compared to periods of assessment and initial 
management. However, this may also reflect difficulty in capturing data about use of non-
prescribed medicines in an outpatient population, as two commonly used antipyretics in 
the UK, ibuprofen and paracetamol, are both available without prescription. Therefore 
parental use of these medications would be important contributors to their use, both 
rational and irrational, but would not be captured through analysis of prescribing. 
 
The only other potentially irrational prescribing detected more than once was in the 
category of Bronchiolitis, the PIM of An ibio ics, ß2 agonists or corticosteroids to treat 
bronchioli is . This as detected in four cases, again all in the inpatient setting. The 
specific potentially inappropriate medicines prescribed for patients with the diagnosis of 
bronchiolitis were antibiotics (cefuroxime, amoxicillin, azithromycin, clarithromycin, and 
co-amoxiclav) and salbutamol (ß2 agonist). This may relate to the diagnostic uncertainty 
between severe bronchiolitis and bacterial lower respiratory tract infection, however these 
cases were only coded as potentially irrational prescribing if there were no alternative 
diagnoses lis ed in he pa ien s case no es ha  demons ra ed clinician diagnos ic 
uncertainty. For example, two cases ere coded as possible G1  b  rejec ed d e o 
pa ien  diagnoses incl ding in one case ? sepsis, ? bronchioli is  and in he second case, 
? chest infection, ? bronchioli is , documenting clinical uncertainty around the diagnosis. 
 
4.7.2.3 Comparing inpatient versus emergency department populations 
 
There was a substantial difference in the number of prescriptions between the two 
populations. There were 1,279 prescriptions for the patients in the inpatient population, 
compared with 329 prescriptions for the patients in the emergency department. This may 
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reflect the higher complexity and morbidity of children who require inpatient admission, 
as well as some participants being on regular medications that were not required to be 
prescribed while in the emergency department, but which would have appeared in their 
prescriptions once admitted.   
 
There were 152 PIMs/PIOs in a total 1,279 prescriptions (12%) in the inpatient 
population, and 130 PIMs/PIOs in the emergency department out of 329 prescriptions 
(40%). This shows that while there were more PIMs/PIOs detected in the inpatient 
group, there was a much higher rate in the emergency department when the lower 
number of prescriptions per patient is taken into account.  
 
However, excluding the vitamin category, there were only 37 instances of potentially 
irrational prescribing in the inpatient population and three in the emergency department 
population. This is due to the effect of differences in the age of participants in the 
different settings, as the vitamin-related PIO applied to all patients age 6 months to 5 
years. There were many more participants in this category in the inpatient compared with 
the emergency department population. 
 
The clinical categories in which potentially irrational prescribing was detected also 
differed between the populations. These are shown below in Table 4-L.  
 
Table 4-L: Clinical categories of potential PIMs and PIOs in the inpatient and emergency 
department populations 
Clinical category Number of PIMS and PIOs/number of patients with relevant 
clinical category (%) 
Inpatient Emergency department 
Vitamin supplements and 
antibiotic prophylaxis 
115/206 (56) 127/154 (82) 
Pain and fever 28/174 (16) 2/199 (1) 
Bronchiolitis 4/7 (57) 0/8 (0) 
Nausea, vomiting, or 
gastroesophageal reflux 
2/93 (2) 0/69 (0) 
Atopic eczema 2/3 (67) 0/4 (0) 
ENT infections 0/24 (0) 1/27 (4) 
Asthma 1/8 (13) 0/3 (0) 
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These data demonstrate that the higher rate of identified potentially irrational prescribing 
in the inpatient population (excluding the vitamin category) does not correlate with higher 
numbers of patients with a relevant clinical indication. That is to say that there are 
patients present in the emergency department population with the same indications for 
prescribing in whom potentially irrational prescribing has not been detected. There are 
several possible explanations for this observation. 
 
The higher numbers of medicines prescribed in the inpatient population may have 
increased observed rates of PIMs. In addition, it may be that children in this group had 
greater morbidity, e.g. anti-emetics for nausea or vomiting may be considered clinically 
indicated for patients whose severity warrants admission, or inpatients may be more likely 
to have other causes for nausea and vomiting besides gastroenteritis, thereby justifying 
use of anti-emetics. Bronchiolitis was an area with a 57% rate of PIM compared with 
none in the ED group; again, more severe morbidity may account for patients having 
been prescribed antibiotics, for example, in case of an alternative diagnosis of bacterial 
infection. However, cases were only rated as PIMs if bacterial infection was not stated as 
a diagnosis, which may suggest these are cases of true inappropriate prescribing. 
 
4.7.3 Usefulness of the POPI UK criteria in identifying potentially inappropriate 
prescribing 
 
This study demonstrated the POPI UK criteria were used to successfully identify a 
number of PIMs and PIOs in the study population. However, 242/282 of these related to 
the single vitamin criterion, with 39 other PIMs or PIOs identified. In addition, there 
were 30 cases where it was undeterminable whether or not a PIM or PIO had occurred.  
 
In most cases where a PIM or PIO could not be determined, this was due to the highly 
detailed nature of the POPI UK s implici  cri eria, s ch as req iring kno ledge of he 
pa ien s comple e die , or doc men a ion no  incl ded on ei her elec ronic or paper 
prescribing nor in clinical notes. These included examples such as the presence or 
absence of a growth chart, the hydration status of the patient at the time of prescribing, 
or all examination features needed to calculate a Centor score in tonsillitis. In other cases, 
the issue was subjectivity of terms in the criteria s ch as se ere  and dis ress , hich, if 
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not explicitly documented by the prescribing clinician, could not readily be inferred by the 
POPI UK coder. 
 
These cases of indeterminate criteria highlighted that a comprehensive view of patient 
data is required to code patient data using the POPI UK criteria. In comparison, explicit 
criteria such as the STOPP/START criteria for geriatric medicine can be applied to more 
limited datasets such as prescribing databases with only coded diagnoses and 
prescriptions(169). This facilitates application of the criteria to potentially very large 
datasets, including previously acquired data and data matched to patient outcome 
measures, such as a 2015 population-based cohort study of older adults in Ontario using 
Beers and STOPP/START criteria(110). PIPc was also designed to be applicable to 
retrospective prescribing datasets, although there may be limitations in their application, 
as discussed in Section 2.5.4.  
 
The highly detailed criteria of the POPI UK tool are also likely to necessitate a clinically 
trained coder who is able to understand the specific clinical terminology of inclusions and 
exclusions described within criteria. Some criteria require good knowledge of technical 
lang age, e.g. o orrhoea , and o hers specific kno ledge of s mp oms, e.g. he 
presentation of o er  reg rgi a ion  in infan s, or red flag s mp oms  of deh dra ion. 
 
The fact that indeterminate cases almost equalled identified PIMs and PIOs appears to 
highlight a significant limitation to the POPI UK tool. However, as discussed in 4.1.1, 
this is a limitation that may be expected in highly detailed implicit criteria, where the detail 
allows for more accurate results but makes scoring the tool more challenging. It may be 
expected that therefore the precision, or repeatability, of the POPI UK tool might be low, 
given the difficulty of coding using the POPI UK criteria as revealed in this study. 
 
4.7.4 Comparison with published clinical evaluation of French POPI criteria 
 
There is one published validation study of the French POPI criteria, published as an 
abstract (129) and subsequently in the British Medical Journal Open (123). 
 
Similar to this clinical evaluation of the POPI UK criteria, the POPI criteria were 
evaluated in their usefulness to detect potential irrational prescribing, without directly 
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studying association with adverse drug effects or patient outcomes. Unlike the evaluation 
of the POPI UK criteria, the French POPI criteria were conducted as retrospective 
analysis of prescription data. Patient data were drawn from two study populations: an 
emergency department and a community pharmacy. A total of 18,562 prescriptions for 
15,973 patients in the emergency department and 4,780 prescriptions for 2,225 patients in 
the community pharmacy were analysed. 
 
One important difference in study protocol was that, despite the POPI criteria assessing 
for PIOs, their clinical validation study inclusion criteria mandated inclusion only of 
children who had been prescribed one or more medications. This is in contrast to the 
approach to the validation of the POPI UK tool, where participants were eligible even 
without any prescriptions, in order to enable greater capture of potentially inappropriate 
omissions. As the tools both assess for PIOs as well as PIMs, this may cause a falsely low 
rate of omissions being identified. In addition, in the original POPI study only primary 
diagnoses and their related prescriptions were evaluated, rather than all diagnoses and 
prescriptions (123). 
 
In the French POPI study, PIMs and PIOs were analysed separately. The rate of PIMs 
was 2.9% in the emergency department and 12.3% in the community pharmacy. PIOs 
were detected in 2.3% of prescriptions in the emergency department and 6.1% in the 
community pharmacy.  
 
In comparison, the UK POPI UK criteria study demonstrated overall rates of PIMs in 
1% and PIOs in 16.4%, which falls to 1.5% excluding the criterion mandating Healthy 
Start vitamins.  
 
The close equivalent criterion in the original POPI criteria to the Healthy Start vitamin 
criterion in the POPI UK tool is a criterion advising a PIO of vitamin D 
supplementation. These are compared in Table 4-M. 
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Table 4-M: Comparison of original POPI and POPI UK criteria relating to vitamins 
Original POPI criterion POPI UK criterion 
Insufficient intake of vitamin D. Minimum vitamin 
D intake: Breastfed baby = 1,000 to 1,200 IU/day; 
Infant, 18 months of age (milk enriched in vitamin 
D) = 600 to 800 IU/day; Child aged between 18 
months and 5 years, and adolescents aged between 
10 and 18 years: two quarterly loading doses of 
80,000 to 100,000 IU/day in winter (adolescents 
can take this dose in one go) 
Healthy Start vitamins for infants and children 6 
months- 5 years or having less than 500ml infant 
formula per day 
 
This criterion was excluded from analysis in both populations of the original POPI 
clinical study, meaning that the comparison between studies is more pertinent when 
excluding the vitamin criterion from the POPI UK study results.  
 
The categories with the most frequent potentially irrational prescribing in the study of the 
original POPI tool were in respiratory and digestive medicine, in contrast with the study 
of the POPI UK criteria, where vitamins and antibiotic prophylaxis and pain and fever 
were the most common categories of potentially irrational prescribing. This difference is 
likely due to the original POPI study only including three of the criteria related to pain 
and fever in fact, only one was applied to the hospital population (a PIM relating to 
opiates used to treat migraine) and two in the community population (relating to dosage 
of ibuprofen and the combined use of two NSAIDs). 
 
The selective use of criteria in the study using the original POPI tool therefore limits the 
usefulness of direct comparisons. 
 
4.7.5 Study population and risk of bias 
 
As stated in section 4.3.3, fluency in the English language was a mandatory inclusion 
criterion due to resource constraints. As demographic data around ethnicity was not 
collected, it is not possible to state to what extent the study population was representative 
of the catchment population of the Royal Derby Hospital. However, the three groups 
likely to have been excluded by this criterion- first- or second-generation immigrants, 
international travellers and children of parents with disability (e.g. native sign language 
users)  are likely to have relevant characteristics that affect the results of the study. 
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In terms of evaluating the applicability of the POPI UK criteria to a population, some 
heritable conditions are more prevalent in people of particular ethnic origins, for instance 
African or Caribbean origins in the case of sickle cell anaemia (of which no cases were 
identified in the study population). Other acquired conditions, such as malaria (not 
included in POPI UK), are likely to be acquired in endemic regions and may therefore be 
more common in international travellers or immigrant families with travel from such 
areas. 
 
In addition, all recruitment and data collection were conducted during the day. Although 
patients admitted overnight to the inpatient ward were likely to be captured, this will have 
excluded patients seen in the ED overnight. It is possible that certain conditions were 
over- or under-represented as a result, if they are more likely to present at night. 
Recruitment was undertaken between August and February and therefore captured both 
summer and winter populations. 
 
In future work using POPI UK, further evaluation of the applicability of the criteria to 
the full population would be valuable to ascertain whether the criteria are equally 




4.8.1 Strengths and limitations of the POPI UK criteria 
 
These results demonstrate that the POPI UK criteria have reasonably broad scope and 
are relevant to the majority of children presenting to the Emergency Department and 
admitted to the inpatient paediatric ward in this study. Even excluding the PIO related to 
vitamins, the criteria related to at least one condition seen in the majority patients in the 
population. The criteria were able to detect a number of potentially clinically significant 
inappropriate PIMs or PIOs that might have adverse effects on patients, such as omission 
of laxatives with over 48 hours of morphine administration (which may lead to 
constipation with both patient discomfort and the risk of secondary complications), PIMs 
of non-indicated therapies such as acid-suppressing medications, antibiotics, or inhaled ß2 
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agonists (which therefore carry the risk of adverse effects of therapy without likelihood of 
patient benefit). 
 
The findings also highlighted a number of prevalent symptoms and conditions that are 
not included within the POPI UK, including sepsis and viral-induced wheeze. As 
discussed in Section 4.7.1, these are areas where there is evidence suggesting that they 
may be valuable areas in which to study irrational prescribing. 
 
This study also exposed a significant weakness in the POPI UK criteria in that the degree 
of specificity in the criteria required access to very detailed patient information, which 
was not always available from written patient records even contemporaneously. This 
limitation would limit the ability to apply the POPI UK criteria to any retrospective 
dataset and even with contemporaneous data collection it was not possible to code all 
criteria for all patients, with 38 cases with indeterminate coding. This limitation would 
apply equally to the original POPI criteria, and the published evaluations of the original 
POPI criteria have not addressed this limitation. 
 
In addition, the complexity of the criteria makes them time-consuming to apply. In each 
case, da a collec ion req ired re ie  of all of he pa ien s clinical notes as well as their 
current and historic prescriptions since the time of admission in order to identify 
potential indications or contra-indications to medications, or clinical reasoning that might 
influence interpretation of criteria. Depending on the leng h of he pa ien s admission a  
the time of data collection, this took up to 45 minutes per patient. Analysis with cross-
reference to the POPI UK codes became quicker with experience using the tool and once 
experienced with the tool took approximately ten minutes per patient. 
 
4.8.2 Further research needs identified 
 
This study highlighted several limitations in the clinical application of the POPI UK 
criteria. Several frequent clinical indications are not included within the tool, and as 
discussed some of the complex implicit criteria were challenging to apply to the data. The 
high degree of complexity and nuance in implicit criteria may increase their accuracy but 
compromise their precision. To test this hypothesis, and evaluate the precision of the 
POPI UK criteria, an inter-rater and intra-rater repeatability study was felt to be of great 
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value. This study is detailed in Chapter 5.  Other future work could address the clinical 
areas not covered by the POPI UK criteria, either by further modifying the tool or 
considering alternative approaches to evaluate rational prescribing in these areas.
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5 Inter- and intra-rater repeatability study of the POPI 
UK criteria  
 
5.1 Introduction 
5.1.1 Repeatability studies 
 
As discussed in Section 1.4.2 and in more detail in Section 4.1, a es s reliabili  can be 
described through two aspects: repeatability, which evaluates precision, and accuracy, 
which describes closeness to a true value.   
 
Repeatability studies evaluate the similarity of results between different observers, or by 
the same observer when the test is performed multiple times. A high degree of precision 
is therefore reflected in a high degree of agreement between observers (inter-rater 
variability) or between scores by the same observer (intra-rater variability). 
 
Repeatability studies do not provide any measure of the accuracy of a test. Supposing a 
true value is known, even if both raters gave incorrect answers, if their responses were in 
agreement then this would support a high level of repeatability.  
 
Cohen s Kappa (𝜅) coefficient is an index of inter-observer agreement in categorical data. 
Although there is no universally accepted value of Kappa that equates to an acceptable 
degree of agreement, by one widely used convention a Kappa of < 0.4 is considered 
poor, 0.4-0.7 fair to good, and > 0.7 excellent (170).  
 
 
5.1.2 Repeatability studies of other rational prescribing tools 
 
Repeatability studies have often been used to evaluate the precision of rational 
prescribing tools, including the MAI (171), STOPP/START criteria (72),  and ACOVE 
criteria (172). Precision is a valuable characteristic of a rational prescribing tool as it 
increases the likelihood that values obtained in different studies, settings, or simply by 
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different raters are comparable, and therefore enables the tool to be used to make valid 
comparisons. 
 
A 2013 review of the MAI provides a cross-section of different methodologies that have 
been used in eight separate repeatability studies of the MAI. These are summarised in 
Table 5-A, adapted from Hanlon et al, 2013 (171).  
 
Table 5-A: Methodology of inter-rater reliability studies of the MAI 
Reference Raters Number of 
patients 
Hanlon et al, 1992 (128) Physician and pharmacist; two pharmacists 
Intra-rater reliability also evaluated 
10 
Samsa et al, 1994 (173) Physician and pharmacist 10 
Fitzgerald et al, 1997 (174) Two pharmacists 10 
Kassam et al, 2003 (175) Two pharmacists 32 
Bregnhøj et al, 2005 (176) Two clinical pharmacologists, a clinical 
pharmacologist and a pharmacist (in pairs) 
Intra-rater reliability also evaluated 
30 
Spinewine et al, 2006 (177) Physician and pharmacist 16 
Stuijt et al, 2009 (178) Three pairs of pharmacists 
Intra-rater reliability also evaluated 
15 
Gallagher et al, 2011 (179) Two physicians 40 
 
 
The original POPI tool has also been evaluated in terms of inter-rater reliability in a study 
published as a conference abstract (180). In this study, twenty cases from the prior clinical 
validation study of children treated in an emergency department were selected. This 
included cases with or without PIMs/PIOs, but all cases had some medicines prescribed. 
One doctor and one pharmacist, who were involved in the creation of the POPI tool, 
e al a ed he cases and composed s andard ans ers . The cases ere hen re iewed 
separately by eleven clinicians (including generalists, paediatricians, pharmacists, residents, 
and general practitioners) not experienced with the tool. Inter-rater agreement was tested 
b  calc la ing Cohen s Kappa coefficient. 
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In the evaluation of the original POPI inter-rater reliability, the results were analysed 
separately for PIMs and PIOs, with Kappas of 0.8 and 0.71 respectively (180). Intra-rater 
reliability was not tested. 
 
5.2 Aims 
The aims of this study were to measure the inter-rater and intra-rater reliability of the 




5.3.1 Study design 
 
The methodology chosen was designed for similarity to other studies assessing the 
reliability of rational prescribing tools in order to allow comparisons. The majority of 
studies assessing the MAI used the methodology of two raters, with a range of patient 
numbers from ten to 40. For this study, two junior doctors from relevant specialties 
(emergency medicine and general practice) were selected as raters. This meant that each 
worked in roles with paediatric patients. The junior doctors had trained and worked in 
different locations and were both ST1 grade at the time of the study.  Junior doctors were 
chosen as the POPI UK criteria contain technical language and are likely to require both 
clinical knowledge and familiarity with medical notes and terminology to apply. 
Furthermore, as junior doctors are often highly involved in audit and quality 
improvement work(181), junior doctors are a group that is likely to make use of the POPI 
UK criteria in future.   
 
Twenty cases were selected at random from the data collected for the clinical validation 
study of the POPI UK tool (see Chapter 4), with ten cases drawn from each clinical 
setting of a paediatric emergency department and a paediatric inpatient ward. These case 
data were transcribed to new Case Report Forms to match the form of data that users of 
the tool might be using to evaluate prescribing; these case report forms were anonymous 
and the only patient identity information provided was age and sex. 
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The cases were selected according to Participant Identification Numbers using a random 
number generator from 1-300 for ten cases and from 301-600 for ten cases, in order to 
select ten cases from each clinical setting. In order to ensure these cases were 
representative of the dataset as a whole and gave an opportunity for raters to apply a 
range of the POPI UK criteria, the rates of PIMs or PIOs in these cases was checked and 
was proportionate to the overall results of the dataset. This meant that there were some 
cases with no identified PIMs or PIOS, some cases with identified PIMs or PIOs, and 
some cases which had been rated as nkno n  d e o s bjec i i  or ins fficien  
information. The case information was supplied in the form of a completed Case Report 
Form (see Figure 4-2). 
 
Both raters were provided with the POPI UK criteria and given the opportunity to read 
through the criteria in advance. They were then provided with the twenty case details and 
asked to identify PIMs or PIOs as defined in the POPI UK criteria. The order of cases 
was randomised. 
 
After a two-week interval, the raters were asked to repeat the same exercise, again with 
randomised case order, in order to evaluate intra-rater reliability.  
 
5.3.2 Characteristics of selected cases 
 
The twenty randomly selected cases are shown over page in Table 5-B.  
 
The average number of medications per patient in the group was 3.1, compared with 2.7 
in the population of the POPI UK clinical study as a while. Thirteen (65%) of the group 
had no PIMs/PIOs detected in the original study, which is comparable to the 66% of the 
whole population in the original study with no possible PIMs/PIOs identified. The 
median age of the selected cases was 4 years 6 months, slightly older than the overall 
population, which had a median age of 3 years. 
  
Chapter 5: Inter- and intra-rater repeatability study of the POPI UK criteria 
 133 
 
Table 5-B: Characteristics of selected cases for the reliability study of POPI UK 







286 1 3y 6 Y 
89 1 1y 4 Y 
181 1 5m 8 N 
144 1 2m 3 Y 
27 1 9y 0 N 
180 1 11y 6 N 
57 1 12y 7 N 
188 1 6y 5 Y 
76 1 6y 7 Y 
83 1 8y 4 U 
500 2 12y 1 N 
477 2 3y 2 U 
448 2 3m 2 N 
322 2 3y 0 N 
381 2 15y 1 N 
418 2 1y 2 N 
554 2 13y 1 N 
457 2 2y 1 N 
471 2 12y 0 N 
348 2 2m 2 N 
 
 
5.4 Statistical analysis 
Results were assessed for both inter-rater and intra-rater agreement. The indicator used 
for each case was whether the rater identified a PIM or PIO according to the POPI UK 
cri eria. The o comes ere recorded as Yes  (PIM/PIO de ec ed), No  (no PIM/PIO 
de ec ed), or Uncer ain  ( i h free e  pro ided o e plain he so rce of ncer ain ). 
As there were two raters and two sessions, this produced two Kappa figures for each 
inter- and intra-rater agreement, of which the mean was taken. 
 
Statistical analysis as carried o  in Microsof  E cel b  calc la ing Cohen s Kappa. 
 




5.5.1 Inter-rater reliability 
The Kappas for session one and session two were substantially different, 0.58 and 0.30 
respec i el , i h a mean of 0.44. This corresponds o a fair o good  ra e of agreemen . 
The results for each session are shown in Table 5-C. The category and potential irrational 
prescribing codes were provided (see Appendix 8). 
 
Table 5-C: Results of each session  
Session 1 Session 2 








1 1 N 1 1 N 
2 N 2 U 
2 1 U 2 1 U 
2 U 2 Y 
3 1 N 3 1 N 
2 N 2 N 
4 1 N 4 1 N 
2 N 2 N 
5 1 N 5 1 N 
2 N 2 N 
6 1 N 6 1 N 
2 N 2 N 
7 1 U 7 1 N 
2 U 2 U 
8 1 U 8 1 U 
2 U 2 U 
9 1 U 9 1 N 
2 N 2 N 
10 1 N 10 1 N 
2 N 2 N 
11 1 N 11 1 N 
2 N 2 U 
12 1 N 12 1 N 
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2 N 2 N 
13 1 N 13 1 N 
2 N 2 N 
14 1 Y 14 1 Y 
2 Y 2 U 
15 1 N 15 1 N 
2 U 2 U 
16 1 N 16 1 N 
2 N 2 N 
17 1 Y 17 1 Y 
2 Y 2 Y 
18 1 Y 18 1 N 
2 U 2 N 
19 1 Y 19 1 U 
2 U 2 Y 
20 1 U 20 1 U 
2 Y 2 Y 
(Y=yes, N=no, U=uncertain) 
 
The table shows the cases and each rater s identification of a PIM/PIO i h Y , no 
PIM/PIO i h N , or ncer ainty i h U .  
 
Results were then tabulated to count instances of agreement and disagreement in order to 
calc la e Cohen s Kappa, as demons ra ed for session one in Table 5-D below. 
 
Table 5-D: Session one inter-rater reliability results 
  Rater 2   
Rater 1 Y N U Total 
Y 2 0 2 4 
N 0 10 1 11 
U 1 1 3 5 
Total 3 11 6 20 
Agreement 2 10 3 0.75 
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In Table 5-D, instances of agreement are counted in the cells running diagonally from top 
left to bottom right, showing two instances where raters agreed there was a PIM/PIO 
present, ten where they agreed there was no PIM/PIO, and three where both raters were 
uncertain. The rates of counted agreement as compared to what would be expected by 
chance are sed o calc la e Cohen s Kappa by the formula: 
 
Cohen’s Kappa =    
1   
 
 
Where Po is the observed agreement and Pe is the hypothetical probability of agreement 
by chance. 
 
Using the data from session one as a worked example, Po is calculated as the number of 
cases in agreement divided by the total number of cases, shown as the total in the 
agreement row, i.e.  
 
Po = 15 / 20 = 0.75 
 
Pe is calculated as the probability that instances of yes, no, or uncertain were in agreement 
by chance. These are calculated individually and then summed. Again, using the data from 
session one: 
 
‘Yes’   Pe = (4 / 20) x (3 / 20) = 0.03 
‘No’   Pe = (11 / 20) x (11 / 20) = 0.3025 
‘Uncertain’  Pe = (5 / 20) x (6 / 20) = 0.075 
Total   Pe = 0.4075 
 
Therefore, Kappa can be calculated for the inter-rater reliability of session one as: 
 
𝜅 =    
1   




The results for session two are shown in Table 5-E. 
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Table 5-E: Session two inter-rater reliability results  
  Rater 2   
Rater 1 Y N U Total 
Y 1 0 1 2 
N 0 10 4 14 
U 3 0 1 4 
Total 4 10 6 20 
Agreement 1 10 1 0.6 
By Chance 0.02 0.35 0.06 0.43 
Kappa 0.30 
 
5.5.2 Intra-rater reliability 
 
The full results for each rater are shown in Table 5-F and Table 5-G respectively.  
 
Table 5-F: Intra-rater reliability of rater 1 
  Session 2   
Session 1 Y N U Total 
Y 2 1 1 4 
N 0 11 0 11 
U 0 2 3 5 
Total 2 14 4 20 
Agreement 2 11 3 0.8 
By Chance 0.02 0.385 0.05 0.455 
Kappa 0.63 
 
Table 5-G: Intra-rater reliability of rater 2 
  Session 2   
Session 1 Y N U Total 
Y 2 0 1 3 
N 0 9 2 11 
U 2 1 3 6 
Total 4 10 6 20 
Agreement 2 9 3 0.7 
By Chance 0.03 0.275 0.09 0.395 
Kappa 0.50 
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The Kappa for intra-rater agreement was on average higher than that of inter-rater 
agreement, at 0.63 for rater 1 and 0.50 for rater 2, with a mean of 0.57. Like the inter-rater 
reliabili  fig re, his corresponds i h fair o good  agreemen . 
 
5.5.3 Criteria rated as uncertain 
 
Free e  responses ere req es ed for codings of ncer ain . The responses ha  
highlighted the reason for uncertainty are shown over page in Table 5-H with the related 
POPI UK criterion, grouped into four categories of reasons for rater uncertainty.  
 
As Table 5-H shows, the free-text comments could be grouped into the categories: more 
information required; subjective criterion; undefined timing or duration of prescription, 
and; specialist knowledge required. These categories highlight the challenges that 
prevented raters being able to apply the POPI UK criteria to the clinical information and 
prescriptions provided to them.  
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Table 5-H: Free text responses explaining responses of uncertainty 
Category Free text response Related POPI UK criteria 
More information 
required 
No past medical history, ?risk factors Nausea, vomiting and gastroesophageal 
reflux (inappropriate prescription):  
The combined use of proton pump 
inhibitors and NSAIDs, for a short period 
of time, in patients without risk factors 
Not enough information Nausea, vomiting and gastroesophageal 
reflux (omission): Oral rehydration 
solution (ORS) for dehydrated children 
unless IV fluid therapy is indicated 
(shock, red flag symptoms despite ORS, 
persist vomiting of ORS) 
Don  kno  if he  ha e risk fac ors 
for pavilizumab 
Bronchiolitis (omission): Palivizumab in 
high-risk cases, defined as: 
1) children < 2 years with chronic 
lung disease on home oxygen or 
who have prolonged use of 
oxygen 
2) infants < 6 months with left-to-
right shunt haemodynamically 
significant congenital heart 
disease and/or pulmonary 
hypertension 
children < 2 years with severe 
congenital immunodeficiency 
Need more information. 
Not enough information 
Unclear indication as more than one 
diagnosis 
Bronchiolitis (inappropriate prescription): 
H1-antagonists, cough suppressants, 
mucolytic drugs, or ribavirin to treat 
bronchiolitis 
Cannot know if this was proposed. Cough (omission): Failure to propose a 
whooping cough vaccine for pregnant 
women. 
 
Not enough information 




Unclear if symptom of limp = pain Pain and fever (inappropriate 
prescription): Prescription of a medication 
other than paracetamol as a first line 
treatment (except in the case of migraine  
Unclear whether this qualifies as 
se ere  
ENT infections (inappropriate 
prescription): Antibiotic treatment for a 
sore throat except in severe cases 
(anticipated to be no more than 20% of 
cases) 
Unclear how severe. 
Undefined timing 
or duration of 
prescription 
Unclear time on morphine Pain and fever (omission): Failure to give 
an osmotic laxative to patients being 
treated with morphine for a period of 
more than 48 hours 
Morphine and paracetamol 
prescribed, looks like morphine was 
first-line? 
Pain and fever (inappropriate 
prescription): Prescription of a medication 
other than paracetamol or ibuprofen as a 
first-line treatment for pain (except in the 




I don  kno  his brand name, is i  a 
steroid? 
Atopic eczema: A potent topical 
corticosteroid applied to the face, or for > 
14 days applied to the axilla or groin 
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Two criteria were mentioned three times by raters as requiring more information than 
was available to them, in the case of the criterion relating to bronchiolitis, the full past 
medical history of the child was required to rate it. In the criterion relating to pertussis 
vaccination, information was required about all adults accompanying the child in 
consultations. 
 
Two criteria were mentioned twice, relating to analgesia and antibiotics prescribing. In 
these cases, raters highlighted areas of subjectivity and the high level of details required 
specifying indications and intended timings of prescriptions. 
 
5.6 Discussion 
5.6.1 Reliability of the POPI UK criteria 
 
Both the inter-rater and intra-rater agreement in this study were > 0.4, being 0.44 and 
0.57 respectively. In the review of reliability studies of the MAI by Hanlon et al, a Kappa 
of > 0.4 as considered good  reliabili  (171).  
Table 5-I shows the inter-rater and, where it was measured, intra-rater Kappa scores for 
the MAI in the eight studies they reviewed. 
 
Table 5-I: Kappa score for the inter-rater and, where it was measured, intra-rater reliability of the 
MAI in eight studies (171) 
Reference Raters Kappa 
Inter-rater Intra-rater 





Samsa et al, 1994 (173) Physician and pharmacist 0.74*  
Fitzgerald et al, 1997 (174) Two pharmacists 0.64  
Kassam et al, 2003 (175) Two pharmacists 0.65  
Bregnhøj et al, 2005 (176) Two clinical pharmacologists, a 
clinical pharmacologist and a 
pharmacist (in pairs) 
0.50 0.71 
Spinewine et al, 2006 (177) Physician and pharmacist 0.84  
Stuijt et al, 2009 (178) Three pairs of pharmacists 0.47 0.84 
Gallagher et al, 2011 (179) Two physicians > 0.85  
*The intra-class correlation coefficient was calculated rather than Kappa in one study. 
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Like the POPI UK repeatability study, these results show higher intra-rater compared to 
inter-rater reliability. A higher intra-rater agreement may be expected, as a rater may have 
an individual interpretation of criteria, which they reliably apply, compared to a different 
interpretation by another rater. 
 
The MAI is an apposite comparator to the POPI UK because it also had three different 
outcomes or ratings, A  indica ing appropria e, B  marginall  appropria e, and C  
inappropriate (171). However, the MAI consists of only ten criteria, which makes it much 
simpler for raters to apply compared with the 80 criteria of POPI UK. This may account, 
at least in part, for the higher levels of reliability found in the studies of the MAI. 
 
5.6.2 Comparison with the reliability of the original POPI tool 
 
The original POPI tool was reported to have inter-rater reliability of 0.8 (for PIMs) and 
0.71 (for PIOs) (180). The study also reported a median time of use of 2 mins 45s per 
case and user satisfaction with the tool (82%). Given the very close similarity between the 
POPI UK and the original POPI criteria, it is not clear how this very fast rate of use was 
achieved compared with the time taken to apply the POPI UK (from 10 to 45 minutes) as 
discussed in 4.8.1, although this may be partly due to differences in methodology. 
 
It is not stated in the report of the inter-rater reliability study, however in the clinical 
validation study of the original POPI criteria from which the cases were selected, it was 
stated that only 82 of the POPI criteria were applied to the emergency department 
population. Furthermore, other criteria were only applied selectively, for instance only 
three of five criteria related to analgesia and antipyrexics were evaluated, and not all 
prescriptions of amoxicillin were assessed according to the relevant criterion (123). A 
selective approach to application of criteria would likely decrease the time taken to apply 
the criteria and would also be likely to increase the observed repeatability due to there 
being fewer opportunities for disagreement between raters.  
 
In addition, only primary diagnoses and their related prescriptions were evaluated in the 
original POPI study, as opposed to all prescriptions and documented indications in the 
POPI UK study. Furthermore, the clinical study of POPI UK showed greater complexity 
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in the inpatient group studied. While the original POPI was tested against an emergency 
department population only, the POPI UK was tested against both emergency and 
inpatient populations. This is supported by the measure of number of prescriptions 
evaluated. In total, 57 medication prescriptions were evaluated in the original POPI 
repeatability study, as compared with 62 in the POPI UK study (including three cases 
with no prescriptions, meaning some more complex cases with greater polypharmacy). 
 
The inter-rater reliability study of the original POPI tool also used different methodology 
to that of other rational prescribing tools discussed above. As the repeatability study for 
the original POPI tool was published after the POPI UK repeatability study was carried 
out, it was not possible to match methodologies for closer comparison. Developers of the 
original POPI tool rated twenty cases, and these ratings were used as a gold standard 
against which eleven other raters were individually compared. This is in contrast to the 
usual application of Cohen s Kappa as a s a is ical meas re, hich ass mes ha  no r e  
al e can be iden ified and ha  all ra ers  j dgemen s are eq all  alid (182). The reported 
reliability figures are therefore median values of eleven Kappa values comparing each 
rater against the gold standard answer, rather than comparing raters with one another. 
Inter-rater reliability for PIMs ranged between 0.61-0.96, while reliability for PIOs ranged 
between 0.41-1.0. 
 
There are a number of factors that could contribute to the POPI UK criteria scoring less 
highly for inter-rater reliability than the original POPI criteria.  
 
Firstly, it should be considered whether there is evidence that the modifications to the 
tool have reduced its reliability. Compared with the original tool. Forty-nine criteria are 
unchanged, 29 modified, four simplified into two, and 23 omitted altogether. As a result, 
over half (49/80) of the modified criteria are identical to the original tool. Of the criteria 
associa ed i h ra ers  ncer ain , in Table 5-J, five were associated with unchanged 
criteria, eight associated with criteria where modifications did not affect the cause for 
uncertainty (needing additional information related to severity, risk factors or people 
accompanying the child), and two associated with modifications that may have introduced 
cause for uncertainty due to subjectivity in the criterion. This is shown below in Table 5-J.  
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Table 5-J: POPI UK criteria associated with uncertainty in comparison to the original POPI 
criteria 
Related POPI UK criteria Comparison to original POPI 
criterion 
Expected impact on 
rater uncertainty 
Nausea, vomiting and 
gastroesophageal reflux (potentially 
inappropriate): 
The combined use of proton pump 
inhibitors and NSAIDs, for a short 





H1-antagonists, cough suppressants, 
mucolytic drugs, or ribavirin to treat 
bronchiolitis 
Unchanged Unchanged 
Pain and fever (potentially 
inappropriate): 
Prescription of a medication other 
than paracetamol as a first line 




Pain and fever (omission): 
Failure to give an osmotic laxative to 
patients being treated with morphine 
for a period of more than 48 hours 
Unchanged Unchanged 
Bronchiolitis (omission): 
Palivizumab in high-risk cases, defined 
as: 
1) children < 2 years with 
chronic lung disease on home 
oxygen or who have 
prolonged use of oxygen 
2) infants < 6 months with left-
to-right shunt 
haemodynamically significant 




Palivizumab in the following 
cases:  
 
(1) babies born both at less than 
35 weeks of gestation and less 
than six months prior to the onset 
of a seasonal RSV epidemic;  
(2) children less than two years 
old who have received treatment 
Unchanged 
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children < 2 years with severe 
congenital immunodeficiency   
(x3) 
for bronchopulmonary dysplasia 
in the past six months;  
(3) children less than two years 
old suffering from congenital 
heart disease with hemodynamic 
abnormalities  
Cough (omission):  
Failure to propose a whooping cough 
vaccine for pregnant women. 
(x3) 
Modified from: 
Failure to propose a whooping 
cough booster vaccine for adults 
who are likely to become parents 
in the coming months or years 
(only applicable if the previous 
vaccination was more than 10 
years ago). This booster 
vaccination should also be 
proposed to the family and 
entourage of expectant parents 
(parents, grand-parents, 
nannies/child minders)  o 
Fail re to propose a whooping 
cough vaccine for pregnant 
women. 
Unchanged 
Atopic eczema (potentially 
inappropriate): 
A potent topical corticosteroid applied 
to the face, or for >14 days applied to 
the axilla or groin 
Modified from:  
A strong dermocorticoid 
(clobetasol propionate 0.05% 
Dermoval, betamethasone 
dipropionate Diprosone) applied 
to the face, the armpits or groin, 
and the backside of babies or 
young children  
Unchanged 
Nausea, vomiting and 
gastroesophageal reflux (omission):  
Oral rehydration solution (ORS) for 
dehydrated children unless IV fluid 
therapy is indicated (shock, red flag 
symptoms despite ORS, persist 
vomiting of ORS) 
Modified from:  
Oral rehydration solution (ORS) 
Increased (subjective 
assessment of indications 
for IV fluids) 
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ENT infections (potentially 
inappropriate): 
Antibiotic treatment for a sore throat 
except in severe cases (anticipated to 
be no more than 20% of cases) 
(x2) 
Modified from:  
Antibiotic treatment for a sore 
throat, without a positive rapid 
diagnostic test result, in children 
less than three years old  
 
Increased (subjective 
assessment of severity of 
case) 
 
Given that seven out of the nine criteria for which uncertainty was rated had not been 
modified in a way that increased their subjectivity or complexity, the changes made to 
develop POPI UK do not seem adequate to explain the difference in inter-rater reliability 
between the original POPI tool and the POPI UK tool.  
 
An alternative explanation for the difference in agreement between this study and that of 
the original POPI tool is the different settings of patients. All cases used in the original 
POPI study were drawn from an emergency department population, whereas in this 
study, half were from the emergency department and half from an inpatient group. It is 
not possible to calculate whether agreement differed for the emergency department 
compared with inpatient group in this study due to the anonymisation and randomisation 
process.  
 
There are a number of ways in which these populations differ. In particular, the average 
number of prescriptions was much higher for inpatient cases (4.3 per patient) than 
emergency department cases (1.1 per patient) in the POPI UK clinical validation study 
(see Chapter 4), introducing a higher number of medications that need to be reviewed by 
the rater. By comparison the figures in the original POPI tool study were 1.1 
prescriptions per patient in the emergency department setting and 2.1 in the community 
pharmacy setting. Their data excluded patients who had no prescriptions, as per their 
exclusion criteria. 
 
The higher number of prescriptions per patient in the inpatient setting of the POPI UK 
tool validation study as compared to any of the other settings tested may suggest a higher 
degree of complexity, which could contribute to less reliability between raters.  
 
In addition, in the report of the original POPI tool validation study, the detection of 
potentially irrational prescribing was measured as a binary outcome as compared with 
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three options in this study (Y/N/U). This would increase inter-rater agreement as 
meas red in he original s d . Indeed, omi ing he U  responses in his s d  res l s in 
complete agreement (Kappa=1) on cases where neither rater scored their response as 
U . Of co rse, his does no  indica e ha  he res l s of his s d  o ld have been 
Kappa of 1 for inter-rater reliability of the POPI UK criteria if raters were asked to rate 
all responses Y/N, as the cases of uncertainty may have resulted in guessing and 
therefore introduced disagreement. However, even assuming entirely divergent guesses 
between raters or between sessions, this would have resulted in an increased Kappa value. 
 
Lastly, the methodology used in the study of the original POPI tool was to compare each 
rater back to a fixed gold standard result. It did not, therefore, directly compare raters 
who were unpractised with the tool against each other. It is possible that there was less 
disagreement between each rater and the gold standard results than there might have 
been between raters. 
 
It is therefore not possible to directly compare the results between the reliability testing of 
the original POPI criteria and the POPI UK criteria.  
 
5.6.3 Limitations of the study 
 
Like several of the studies reviewed by Hanlon et al (171), this study evaluated inter-rater 
reliability between two similar raters (in this case, both junior doctors). Given the highly 
technical clinical information included in the POPI criteria, it may be that raters with 
different clinical backgrounds would show more disagreement while more experienced 
clinicians or pharmacists might show more agreement.  
 
The incl sion of he coding of ncer ain  added bo h comple i  o he anal sis of his 
s d  and grea er informa ion regarding he sers  e perience of he POPI UK tool. A 
more in-depth interview of users of the tool would provide more detail on which areas of 
the tool are challenging to use, whether due to subjectivity, technical knowledge 
requirements, or need for detailed information that may not be readily available in patient 
notes or retrospective datasets. 
 




This study demonstrated fair to good inter-rater and intra-rater reliability for the POPI 
UK tool, suggesting that it has comparable precision to other widely accepted rational 
prescribing tools such as the MAI for older adults.  
 
The relative complexity of the POPI UK criteria likely contributes to a lower precision 
than they might otherwise have, as well as meaning they are time-consuming to apply 
(15). Many of the criteria require technical knowledge such as good working knowledge 
of drug groups and symptomatology, and there are subjective areas in some criteria such 
as evaluating the severity of a sore throat. In addition, several criteria require detailed 
information to be available about the patient, such as co-morbidities or discussions that 
were had ( fail re o propose hooping co gh  does no  req ire a prescrip ion, per se, 
only a discussion). This level of detail is comparable between the original and POPI UK 
criteria. While these detailed criteria have some advantages in increasing the clinical 
validity of the tool in terms of aiming for truly rational prescribing, they also increase the 
difficulty of using the tool. For instance, while there are large prescribing datasets 
available such as GP practice prescribing data, these are unlikely to contain sufficient 
detail to evaluate against all of the POPI UK criteria. However, for prospectively 
collected data, the high level of detail in the criteria may increase their sensitivity and 
specificity for identifying genuinely irrational prescribing. 
 
 
Avenues for future research include a direct comparison between the original POPI tool 
and POPI UK using the same data and methodology or evaluation of inter-rater reliability 
of the POPI UK with raters from different clinical backgrounds and levels of experience. 
It would also be interesting and may inform further development of the POPI UK to re-
test the criteria with the removal of all criteria that were rated as uncertain, to test the 
hypothesis that this would increase inter- and intra-rater reliability. If so, this could guide 
the development of a more reliable rational prescribing tool. 






Rational prescribing by definition should achieve an optimum balance between the 
therapeutic benefits of prescribed medicines and minimal harms to individuals, 
communities, and healthcare systems in the form of adverse effects, medication 
resistance, and excess cost (12). Inappropriate prescribing has both economic and human 
costs (183). Prescribing for children is complicated by the need for individualised 
calculated dosing regimens and a dearth of high-quality evidence on which to base 
practice (5). 
 
Rational prescribing tools provide a means of studying quality of prescribing with a 
quantitative approach. These allow assessment by prescribers of their own prescribing, 
service-level evaluations of prescribing for quality improvement purposes, research into 
influences on decision-making in prescribing, and comparison between patterns of 
irrational prescribing across different clinical settings, regions, or times, or between 
groups of prescribers. 
 
Prior to this thesis, there was no rational prescribing tool for evaluating the quality of 
prescribing for children across a range of clinical settings in the UK. The work as 
described in this thesis has identified all available paediatric rational prescribing tools, 
developed a new rational prescribing tool that can be used to evaluate and compare 
quality of prescribing for children in any clinical setting within UK practice, and also 
provided evidence for the accuracy and precision of this tool. 
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6.2 Summary of findings 
6.2.1 Systematic review of paediatric rational prescribing tools 
 
Chapter 2 reports a systematic review of medical, nursing and pharmaceutical literature 
for paediatric rational prescribing tools. The original search resulted in three publications 
all relating to a single rational prescribing tool, the POPI (Pediatrics: Omissions of 
Prescriptions and Inappropriate prescriptions) tool. This tool was developed using 
French, UK and USA guidelines relating to paediatric prescribing, using the Delphi 
consensus method. The tool is designed to address frequent paediatric pathology 
categories according to physiological systems, meaning that it can be applied in a wide 
range of clinical settings. 
 
An update of the systematic review in 2019 demonstrated a further paediatric rational 
prescribing tool that has been published since the systematic review was completed. This 
tool, the PIPc (Potentially Inappropriate Prescribing in children) is designed specifically 
for use in primary care settings in the UK (117). It comprises twelve indicators across 
four physiological categories. These were also designed by Delphi consensus and are 
intended to be used to evaluate prescribing where clinical data were unavailable, such as 
dispensing datasets. The updated search also identified the POPI UK. 
 
Analysis of the systematic review included exploring the characteristics of the rational 
prescribing tools that were found. A number of limitations were identified in both tools, 
including barriers to applying the criteria to the types of clinical data they were designed 
to assess. 
 
6.2.2 Developing POPI UK 
 
The original POPI tool was developed using a combination of national guidelines from 
France, the UK, and the US. A number of criteria could not be readily applied to UK 
practice, due to references to medications outwith the British national formulary or 
criteria that were contradicted by UK clinical guidelines. In order to develop a tool 
applicable to paediatric practice across the UK, a study was undertaken to modify the 
original POPI criteria, with the aim of retaining as much as possible of the criteria 
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developed through the Delphi consensus method while ensuring that the criteria would 
provide a justified evaluation of rational prescribing in the context of UK paediatric 
practice.  
 
Overall, no change was made to 49 criteria. Twenty-nine criteria were modified to 
concord more closely with UK guidelines. Four criteria were condensed into two criteria 
due to being linked within single UK guidelines. Twenty-three were omitted due to the 
absence of relevant UK guidance or conflicting UK guidance. One category title was 
amended to concord with terminology in use in the UK. 
 
The novel POPI UK tool comprises 80 criteria that can be used to evaluate rational 
prescribing for children in UK practice. 
 
 
6.2.3 Clinical evaluation of the POPI UK tool 
 
In order to evaluate the usefulness of the POPI UK tool, two studies were undertaken to 
assess its validity as a measure of rational prescribing. The first of these studies was an 
evaluation of the tool in terms of accuracy, by testing whether it was of appropriate scope 
and sensitivity to detect instances of potentially irrational prescribing in UK paediatric 
practice. Clinical and prescribing data on 598 paediatric cases were collected prospectively 
in o differen  clinical con e s, a children s emergenc  depar men  and a children s 
inpatient ward. 
 
This study demonstrated that 96% of patients in the study population had at least one 
documented clinical symptom, sign, or diagnosis that falls within the scope of the POPI 
UK tool. Even excluding the highly prevalent vitamins criterion, relevant to 242 cases, the 
majority of patients (89%) had at least one relevant clinical indication, suggesting that the 
tool has broad enough scope to be used to evaluate prescriptions in both studied settings. 
Furthermore, 262 instances of potentially irrational prescribing were detected, suggesting 
that the criteria are relevant to UK paediatric practice in at least the two settings studied.     
 
The study also highlighted some drawbacks to the POPI UK criteria. In 38 prescriptions, 
it was not possible to determine whether or not prescribing was rational according to the 
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modified criteria due to subjectivity or a higher level of clinical information being 
required than was accessible even through prospective collection of data. The comparison 
of results of this study to the published use of the original POPI criteria showed that 
exclusion of patients with no medicines prescribed may have caused a falsely low rate of 
omissions detected in the French study, as well as raising concern about how criteria 
requiring highly detailed and sometimes non-clinical information were scored on 
retrospective data. Lack of discussion of these issues in reports about the original POPI 
criteria mean that its limitations may not have been fully illustrated in those studies. 
 
In addition, there were a number of common diagnoses in the POPI UK study 
population that are not included within the criteria, including viral-induced wheeze, 
sepsis, and soft tissue injuries. These may present future targets for subsequent 




6.2.4 Inter- and intra-rater reliability study of the POPI UK tool 
 
The second study to evaluate the POPI UK tool was a repeatability study to test its 
precision. An inter- and intra-rater reliability study measures the closeness of results when 
the test is applied to the same data either by two different raters or by the same rater at 
different times. Higher precision may increase the usefulness of the tool for use in both 
quality improvement and research. 
 
The study methodology was designed to be similar to the studies of precision of other 
rational prescribing tools to facilitate clearer interpretation of the results.  The measured 
inter- and intra-rater repeatability of the POPI UK criteria were 0.44 and 0.57 
respec i el . These correspond o good  reliabili y according to the classifications used 
for other rational prescribing tools (171) but were significantly lower than those reported 
for the original POPI criteria of 0.8 and 0.71 respectively. This is in spite of the fact that 
over half of the modified criteria are identical to the original tool and may relate to the 
differing study populations and study designs. The POPI UK tool was tested against both 
an emergency department population and inpatient population, whereas the original tool 
was only tested in emergency department patients. The clinical evaluation study of the 
Chapter 6: Conclusions 
 152 
POPI UK tool, showed that the inpatient population had a much higher number of 
prescriptions per patient compared with the emergency department group, and may 
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6.3 Practical implications 
The POPI UK tool is a novel paediatric rational prescribing tool that has practical 
applications in a variety of areas. In all of these applications, the limitations of the tool in 
terms of its complexity, time-consuming nature, and the need for detailed patient 
information would be challenges that would need to be overcome to achieve the greatest 




The tool can also be used to facilitate research into paediatric rational prescribing. This 
field has been described as an e idence based deser  (101) and the POPI UK criteria 
provide a means of quantitative and qualitative analysis that can be applied in a variety of 
settings. Rational prescribing tools have been used extensively in research in other fields, 
for ins ance Beers  cri eria ha e been sed o in es iga e ra ional prescribing for older 
adults in a variety of settings (67, 110, 184-186).  
 
The POPI UK tool could be used in a similar way to explore whether there is a difference 
in quality of prescribing for children in non-specialist settings such as undifferentiated 
emergency departments and general practice as compared to paediatric departments. It 
could also be used to investigate whether there are differences in prescribing between 
different groups of prescribers, including non-medical prescribers, and examine factors 
associated with better prescribing. Equally, the tool could be used to investigate the 
relationship between rational prescribing and patient outcomes, to identify the impact of 
higher and lower quality prescribing on patients. However, it is he a hor s view that 
significant changes to the tool would greatly improve its usefulness and effectiveness, as 
discussed in Section 6.5. 
 
6.3.2 Quality improvement 
 
As a measure of rational prescribing, the POPI UK criteria can be used in audit by or on 
behalf of prescribers to evaluate rational prescribing or guide targets for interventions to 
improve quality of prescribing. 
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Medical audits are systematic and quantitative assessments of clinical care that require a 
standard against which to compare contemporary practice (187), (188). Audits have been 
demonstrated to be an effective component of prescribing education for both medical 
and non-medical prescribers (189) and a prescribing audit has recently become a 
mandatory component of general practitioner training in the UK. In a pilot of this 
scheme, positive feedback from trainees on the impact upon their practice included 
q o a ions s ch as, An e cellen  a  of spending more ime on m  prescribing and 
iden if ing errors hich I didn  hink I as making , and I al a s look at prescribing 
hen debriefing b  doing a ba ch enabled hemes o appear  (190). 
 
More broadly within medicine, audits have been found in a Cochrane review of evidence 
to have moderate evidence for improvement in adherence of practitioners with desired 
standards, and are more effective when clear targets are set out for health 
professionals(191).  The evidence for improvement in patient outcomes was weaker but 
remained favourable. 
 
Rational prescribing also accommodates system-level considerations of high-quality 
prescribing such as cost-effectiveness and community impact. One of the tenets of 
ra ional prescribing is ha  Pa ien s recei e medica ions appropria e o heir clinical 
needs, in doses that meet their own individual requirements, for an adequate period of 
ime, and a  he lo es  cos  o hem and heir comm ni  (42). Using prescribing 
indicators and audit to guide interventions has been a successful strategy not only in 
decreasing the rate of antibiotic use, and thus expenditure on antibiotics, but this 
reduction in use has been associated with decreased antibiotic resistance(192), which 
would have substantial beneficial ramifications for the wider community. 
 
POPI UK have the advantage of being designed to be applicable to paediatric practice 
whether in hospital or primary care and could be used in such settings as an audit tool to 
evaluate rational prescribing or to test quality of prescribing before and after 
interventions. 
 
In the case of applying POPI UK for the purposes of an audit, where a target or gold 
standard rate of compliance may be set against which to compare data, users of the tool 
should consider that detection of potentially irrational prescribing by a tool does not 
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necessaril  indica e poor prescribing, nor o ld a perfec  score  indica e ha  here is no 
poor prescribing occurring. All that is being tested is adherence to the specific criteria in 
the tool. 
 
In this context, the tool can be used to identify patterns or types of potentially irrational 
prescribing and provide an opportunity for reflection and consideration of factors 
contributing to what is detected, as well as to measure rates before and after an 
intervention. It is often the case that the standard set in an audit, aiming for 100% 
compliance, may have good clinical reasons for deviation and less than 100% is identified 
both before and after an intervention. This does not necessarily reduce the usefulness of 
the exercise. 
 
The appropriate target compliance level may vary from criterion to criterion. The case of 
contraception for women of child-bearing potential on isotretinoin would seem to be a 
case for 100% compliance, b  he Pregnanc  Pre en ion programme does allo  for 
the exclusion of women who are not sexually active, which could mean incorrect 
assessment of a potentially inappropriate omission were such a case audited. In the case 
of antibiotic prophylaxis for children with sickle cell anaemia, the criteria do 
accommodate penicillin allergy with the alternative of erythromycin, but of course allergy 
to both is possible and would mandate deviation. However, the same provisos are true of 
many targets set in audits (i.e. there may be a reason beneficial to the patient for non-
adherence to other targets). So long as audits are used to study a phenomenon, and not as 
a tool to judge or punish a department or group, 100% compliance could certainly be 
used as a target, accepting that no measure is perfect. The setting of this standard may 
well depend on settings and factors like how much clinical information they will be able 
to gather about the patient and would be for the individual or organisation undertaking 
the audit to consider. 
 
  




Rational prescribing tools can also be used in medical education. Prescription audit has 
been demonstrated to improve prescribing skills in medical students(193). Other rational 
prescribing ools, incl ding Beers  cri eria and STOPP (Screening Tool of Older Persons  
Potentially Inappropriate Prescriptions) criteria, have been used as educational tools (194, 
195). In a single-blind study using rational prescribing tools to teach medical students 
about age-related pharmacokinetics, pharmacodynamics, and how to elicit the goals of 
drug treatment, student feedback was positive and students in the intervention group 
using the tools were able to identify significantly more potentially inappropriate medicines 
than those in the control group(194).  
 
As the POPI UK criteria cover many categories of irrational prescribing, including 
overprescribing, underprescribing and different types of misprescribing, in an educational 
setting the criteria could be used to identify if there were particular types of irrational 
prescribing that were more prevalent. This could guide further education into rational 
decision-making around prescribing. 
 
6.3.4 Reflection on impact upon my own practice 
This section is the personal reflection of the author on the impact of this work on her own clinical practice. 
 
While undertaking the research contained within this thesis, I have continued clinical 
practice as a General Practice Specialist Trainee in settings with paediatric prescribing, 
including emergency departments, inpatient wards, and in general practice.  
 
The primary purpose of this work was not personal clinical development, however the 
value of the work to my own practice has been significant. The principles of rational 
prescribing are essential to the principles of good medical practice and engagement in this 
research strengthened my understanding of the practical applications of rational 
prescribing to practice. The General Medical Council ethical guidance to doctors in 
Good medical prac ice: D ies of a doc or  commends doc ors o prescribe dr gs, 
incl ding repea  prescrip ions, onl  hen o  ha e adeq a e kno ledge of he pa ien s 
heal h and are sa isfied ha  he dr gs or rea men  ser e he pa ien s needs  and o 
pro ide effec i e rea men s based on he bes  a ailable e idence (196).  
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I have learnt a great deal through studying rational prescribing for children in so much 
depth, and have been aware of both in terms of prescribing practices directly applicable 
to my clinical work and more subtle transformation of my attitude and approach to 
prescribing. Examples of specific learning points have been an increased awareness of the 
guidelines reflected in the POPI UK criteria, such as the recommendation for vitamin 
supplementation for children, the need to advocate for whooping cough vaccination to 
pregnant women, the importance of oral rehydration therapy for diarrhoea and vomiting, 
and the reminder to think of analgesia when prescribing antibiotics for ear infections.  
 
The subtler but perhaps more meaningful change I have taken from my work has been in 
e al a ing he al e of ha  I prescribe be ond he simple q es ion, Will his rea  he 
disease I ha e diagnosed?  The necessi  of a rea men  being effec i e for a gi en 
condition is only one part of that treatment being rational. Other aspects, such as wider 
system and societal considerations around cost effectiveness and drug resistance, are 
essential in general practice, where 300 million consultations take place every year, 
compared to 23 million ED attendances (197).  
 
The importance of high-quality prescribing has been recognised by the Royal College of 
General Practitioners, who have introduced a mandatory prescribing assessment to the 
training of GPs. I was in a cohort completing the first mandatory prescribing assessment, 
which highlights many of the principles of rational prescribing by asking trainees to 
reflect on the quality of a randomly collected sample of their prescriptions not only 
according to the right choice of drug, but dosage, duration, instructions, follow-up, 
documentation, and review. In both my personal reflection and detailed discussion with 
my clinical supervisor, my prescribing for paediatric patients was highlighted as very 
good; I believe this is in a large part due to the amount of thought and research I have 
been involved in in this area of practice. 
 
In addition, the academic collaboration with paediatric research nurses, paediatric clinical 
pharmacologists, and paediatric pharmacists has given me access to a wealth of paediatric 
pharmacological expertise, which has fostered my development in this area. By seeking to 
disseminate my research to a broader audience, I have benefited from the process of peer 
review of my publications and have also been fortunate to present the work to two 
Chapter 6: Conclusions 
 158 
different audiences in the Royal College of Paediatrics and Child Health, which has 
helped me to better articulate my research findings and their relevance to clinical practice, 
provided further critical analysis of the results, and led me to ask more questions of my 
work. 
 
6.4 Strengths, challenges and limitations 
 
This thesis has a number of strengths. The systematic literature review demonstrated a 
relative paucity of rational prescribing tools for use in paediatric practice and identified 
two paediatric rational prescribing tools, PIPc, which was developed for application to 
primary care settings and POPI, designed to be used in any paediatric setting but founded 
in French clinical guidelines. 
 
The POPI UK criteria comprise a tool using up-to-date British clinical guidelines, and the 
subsequent validation studies demonstrated relevance to UK paediatric practice, the 
ability to detect potentially irrational prescribing using the tool, and a good degree of 
repeatability. These new findings have direct applicability to both clinical and academic 
medicine as discussed in 6.3. Practical Implications. 
 
The clinical validation study protocol was modelled on WHO recommendations of 
rational prescribing studies (54). Data were gathered from two different areas of 
paediatric practice, taking in a range of prescribers including GP trainees, paediatric 
trainees, nurse practitioners, and consultant paediatricians.  
 
The protocol for the repeatability study was modelled after similar studies that have been 
used to evaluate rational prescribing tools for older adults, facilitating direct comparison 
of results and providing a foundation for future in-depth research.  
 
A limitation of this work was the development of the UK tool through modification of 
the French POPI criteria. As discussed in Sections 1.4 and 3.1, rational prescribing tools 
have often been developed through Delphi consensus method, with other examples of 
tools being updated, as in this work, for application of criteria developed in one country 
to be used in another.  
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As the original POPI criteria were selected through French prevalence data, it is possible 
that the criteria may be of less relevance to UK practice. On the other hand, British 
guidelines were applied to the development of the original tool and 49 of the 80 criteria 
comprising POPI UK are unchanged from the original criteria. This shows a significant 
degree of agreement in practice. Only 22 of the 105 POPI criteria were omitted due to 
absence of evidence in UK guidelines which, as discussed in Section 3.4.2,, does not 
necessarily reflect irrelevance to UK practice. 
 
Ultimately, the clinical study of POPI UK demonstrated a high degree of relevance of the 
criteria to UK clinical practice, but with some areas of potentially valuable study excluded, 
such as viral-induced wheeze and sepsis. Further study of the applicability of POPI UK in 
community settings, including general practice, is needed It is unlikely a single rational 
prescribing tool would have the scope to apply to all areas of interest and is probable that 
there will always be value in having several different tools available to study rational 
prescribing in children in the UK, as is now the case with both PIPc and POPI UK. 
 
A second limitation of the thesis is limited direct comparison to the studies that have 
been undertaken for the original POPI tool, which were published after completion of 
the studies of POPI UK.  
 
Resource and time constraints applied limitations to study design. For instance, screening 
for the systematic review was by a single researcher for title and abstract, with a second 
reviewer only included for full-text screening due to such constraints and the high 
number of articles eligible for screening.  
 
An area where this limitation had particular impact is the fact that all data were gathered 
from a single hospital, and therefore there may be some factors affecting patient 
populations or prescribing practices that are not more broadly generalisable, or missed 
factors which relate to prescribing in other settings such as primary care. Further research 
using the POPI UK POPI criteria would be valuable not only to study differences in 
rational prescribing in different settings across the UK, but also to further validate the use 
of the tool in a wider variety of settings. 
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Similarly, the fact that the large majority of data were collected by a single researcher may 
have affected evaluation of the tool. As a result of this, as both developer of the tool and 
rater of the findings, the author was extremely familiar with the POPI UK criteria 
throughout the process.  This is somewhat mitigated by the inclusion of two different 
raters for the repeatability study, however it would be beneficial to evaluate whether there 
were unidentified obstacles to other prescribers or researchers making use of the tool, 
particularly non-medical prescribers given the high degree of clinical detail contained 
within the tool. 
 
One challenge that was identified early in the research process was designing patient 
information leaflets for the study that were accessible to parents and children. As 
discussed in Chapter 1, the additional complexity of informed family decision-making is 
one of the perceived barriers to research involving children (87). In fact, it is important to 
develop information resources accessible to both children and adults of varying literacy 
levels and cognitive ability (92). However, ethical and legal issues mean that institutions 
may have mandatory language that must be included in participant information materials, 
which sometimes necessitates inclusion of technical language that reduces the readability 
of content. 
 
As discussed in Chapter 2, in the case of designing participant information material for 
his s d  bo h readabili  scoring ools and families  feedback ere sed d ring he 
design process to maximise their accessibility and usefulness. Following review by 
University governance, it was necessary to include certain mandatory text, which provided 
additional and important information to participants but unfortunately increased the 
reading age grade of the documents. This was partly overcome by agreement that 
mandatory text must be available to all participants in the parent/carer information sheets 
and for participants aged over 16 who could give consent, in the 16-18 years information 
sheets, but did not need to be included in age-specific leaflets for younger ages, which 
were aimed at communicating with younger people in the study in order to facilitate 
informed assent. Further small amendments were made following review by the ethics 
committee, some of which included simplification of language. 
 
This demonstrates the challenge in developing research literature that is accessible to a 
large majority of stakeholders while also having sufficient detail and clarity to 
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communicate information about the research and provide the foundation for truly 
informed consent. This is not an issue unique to paediatric research, but developing 
literature that is explicitly aimed at a range of ages brought the issue into greater visibility. 
One essential and effective resolution of this issue is ensuring that researchers provide 
time for full discussion of all information that is provided in writing. Not only does this 
provide participants with an important opportunity to ask questions, this also gives the 
researcher an opportunity to ensure that the information has been understood before 
seeking consent. This was a key part of the protocol for obtaining informed consent for 
the clinical validation study for the POPI UK criteria. 
 
 
6.5 Future research  
 
There are a number of avenues that invite further research building upon the work of this 
thesis.  
 
Despite its limitations, as discussed in section 6.3 there are a number of research 
applications for the POPI UK criteria. The tool could be used to investigate independent 
factors associated with higher quality rational prescribing for children and to test 
interventions designed to improve quality of prescribing. It could further be used in 
research investigating to what extent irrational prescribing is associated with poorer 
patient outcomes, and whether there are particular settings or types of irrational 
prescribing where the impact may be more harmful. 
 
It would be useful to directly compare the existing tools evaluating the same prescribing 
data with unmodified original POPI criteria, the PIPc, and the POPI UK criteria to 
explore whether the tools have different sensitivities for detecting different categories or 
types of irrational prescribing. It would also be useful to compare the inter- and intra-
rater reliability of the tools within a controlled setting where similar patient data and 
raters were used. 
 
However, this work has shown that while there are extant paediatric rational prescribing 
tools, and one product of this work is a tool that can be used in any paediatric practice 
setting in the UK, the limitations and complexities of the existing tools currently reduce 
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their effectiveness. It is recommended that the criterion related to ibuprofen prescribing 
be modified to more accurately reflect UK guidelines, which recommend three to four 
times daily prescribing. To advance the study of paediatric rational prescribing, further 
modification of the POPI UK tool could be undertaken to reduce its complexity. 
Options that might increase its reliability and reduce the time taken to apply the criteria 
would include: significantly reducing the number of criteria; removing all subjective 
criteria, and; targeting areas of prescribing that are highly prevalent and likely to be 
detected in most areas of practice, such as management of fever and pain, nausea and 
vomiting, and respiratory tract infections.  
 
For example, the POPI UK criteria could be modified into a short paediatric prescribing 
tool of a similar size to the WHO prescribing indicators or the MAI, between five to ten 
criteria. Preferably, selected criteria would be explicit, in order to be readily applicable to 
varied sources of data. This would ideally be guided by a Delphi consensus method 
involving experts from a variety of paediatric practice settings including general, 
emergency, and community paediatrics as well as general practice, and involving both 
physicians and pharmacists. Further work would then also be required to validate such a 
tool. 
 
Regardless of which tool is considered, whether the POPI UK in its current form or 
another modified or novel tool, rational prescribing tools require regular updating to 
maintain currency against evidence and prevalent practices. This process can be seen 
through the stepwise updates of the Beers criteria over time (63, 65, 66). This would 
therefore be an important element of future work involving POPI UK. 
 
6.6 Final conclusions 
 
This thesis has identified the absence of a rational prescribing tool for the evaluation of 
paediatric rational prescribing in non-general practice settings in the UK, and the research 
herein: i) reports the development of a novel paediatric rational prescribing tool, POPI 
UK, for use in a range of UK paediatric settings; ii) demonstrates clinical relevance, real-
world detection of irrational prescribing by the POPI UK; iii) demonstrates the POPI 
UK has an acceptable level of reliability, and; iii) presents the POPI UK criteria as a 
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rational prescribing tool for future application to educational, clinical governance, and 
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Abstract: Rational prescribing criteria have been well established in adult medicine for both research
and quality improvement in the appropriate use of medicines. Paediatric rational prescribing has
not been as widely investigated. The aims of this review were to identify and provide an overview
of all paediatric rational prescribing tools that have been developed for use in paediatric settings.
A systematic literature search was made of MEDLINE, Embase, CINAHL and IPA from their earliest
records until July 2019 for all published paediatric rational prescribing tools. The characteristics
of the tools were recorded including method of development, types of criteria, aspects of rational
prescribing assessed, and intended practice setting. The search identified three paediatric rational
prescribing tools: the POPI (Pediatrics: Omissions of Prescriptions and Inappropriate Prescriptions)
tool, the modified POPI (UK) tool, and indicators of potentially inappropriate prescribing in children
(PIPc). PIPc comprises explicit criteria, whereas POPI and the modified POPI (UK) use a mixed
approach. PIPc is designed for use in primary care in the UK and Ireland, POPI is designed for use in
all paediatric practice settings and is based on French practice standards, and the modified POPI
(UK) is based on UK practice standards and is designed for use in all paediatric practice settings.
This review describes three paediatric rational prescribing tools and details their characteristics.
This will provide readers with information for the use of the tools in quality improvement or research
and support further work in the field of paediatric rational prescribing.
Keywords: rational prescribing; paediatrics; rational use of medicines
1. Introduction
Rational prescribing has been defined by the World Health Organisation as “when patients
receive the appropriate medicines, in doses that meet their own individual requirements, for an
adequate period of time, and at the lowest cost both to them and the community” [1]. It has been
poorly studied in paediatric patients; a field that has been described as “an evidence based desert” [2].
Irrational prescribing has wide-ranging impacts, from adverse drug reactions and progression of
inappropriately managed disease to additional system healthcare costs and antimicrobial resistance.
The use of criteria lists as tools to quantify rational prescribing in adult medicine is well established [3].
There are a number of potential benefits to rational prescribing tools; assessment tools enable
quantification of the quality of prescribing, which facilitates research into interventions aiming to
improve prescribing and allows prescribing in di↵erent settings to be compared. This facilitates deeper
research into root causes of problematic prescribing or excellent prescribing and fosters collaboration
between di↵erent groups.
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A 2014 systematic review of rational prescribing tools for adults by Kaufmann et al. identified
46 published tools [4]. Of these, 22% did not have a stated target population, while 78% were
specifically targeted to prescribing for older adults. Older adults have been identified as a group
vulnerable to irrational prescribing due to a variety of factors, including the frequent existence of
co-morbidities, polypharmacy, care taking place in a number of di↵erent settings, and the e↵ect of
ageing on the selection of appropriate medications [5]. Many similar challenges exist in paediatric
medicine, with well-recognised developmental changes in physiology and metabolism having a
significant impact on pharmacokinetics in children of di↵erent ages [6]. In addition, children may
receive medications in a number of di↵erent settings, including general practice, undi↵erentiated
emergency departments, walk-in centres, paediatric wards in district general hospitals, and specialist
paediatric hospital settings. This means that prescribers with varied levels of paediatric experience
and expertise may be responsible for prescribing.
Kaufmann et al. explicitly excluded tools targeted to children in their 2014 review. The aim
of this review was to carry out a systematic review of paediatric rational prescribing tools in order
to produce a comprehensive overview of current tools available to measure rational prescribing in
children. This will hopefully facilitate others studying this area.
2. Methods
The systematic literature search was designed to identify articles describing tools to assess rational
(or inappropriate) prescribing for children.
Inclusion criteria were: articles describing tools targeted at evaluating the rationality or
appropriateness of prescriptions for children (aged less than or equal to 18 years), updated and
revised versions of previously published tools, and including tools limited to specific drugs, drug
groups, diseases or disease groups.
Exclusion criteria were: tools targeting adults, tools without specified target patient groups,
indicators that assess rates or percentages of prescription types in a population, articles describing
a validation study of a previously published tool, educational interventions aimed at improving
prescribing, and guidelines describing recommended prescribing.
Search Strategy
The search was conducted in four databases in order to attempt to capture relevant medical, nursing
and pharmaceutical research. These were: Ovid MEDLINE, Embase, International Pharmaceutical
Abstracts (IPA) and CINAHL. Databases were searched from their earliest records possible until the
start of July 2019.
Search terms to capture studies including children were derived from the recommended search
strategy described by Kastner et al. 2006 [7], as these have demonstrated high sensitivity. The MeSH
term “inappropriate prescribing” was introduced in 2011, and was previously incorporated in the
broad term “Drug therapy”. Search terms for rational prescribing were derived from the systematic
review of adult rational prescribing tools by Kaufmann et al. 2014 [4]. The combined terms were:
(inappropriate prescribing or suboptimal prescribing or inappropriate medication or inappropriate
practices or drug prescriptions or Medication Appropriateness Index) and (child* or children* or
p*ediatric* or infant* or adolescent*).
All potentially relevant publications were screened by title and abstract and articles that met the
exclusion criteria were excluded. The remaining articles were retrieved in full. Full-texts were examined
by FC and a second researcher who performed independent full-text screening, independently assessing
articles according to the inclusion and exclusion criteria. After this process, any articles without
consensus were resolved by discussion and mutual agreement. A manual search of the bibliographies
of included texts was completed.
Included articles were analysed by FC to extract the development process and characteristics of
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3. Results
The search produced 2142 potentially relevant publications. 234 duplicated articles were removed.
1908 articles were screened by title and abstract and 1736 were excluded (Figure 1). One hundred
seventy-two articles were selected for full-text review by two reviewers of which 163 were excluded.
The excluded articles screened at full-text did not meet the inclusion criterion of describing rational
prescribing tools. Four full-texts were unavailable online from University library resources, and from
the British Library. In the case of the four full-texts that were unavailable the abstracts suggested
that these articles would not meet the inclusion criteria, although this could not be determined with
certainty. Five articles met the inclusion criteria. Bibliography mining of the included articles did not
identify any further relevant articles.
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3.1. Rational Prescribing Tools Identified
In total, five relevant articles were identified, relating to three paediatric rational prescribing tools.
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Table 1. Results of systematic literature search.
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2011 France POPI 9 (partial list)
Prot-Labarthe et al. [9]
POPI (Pediatrics: Omission of
Prescriptions and
Inappropriate prescriptions):
development of a tool to
identify inappropriate
prescribing.
2014 France POPI 105
Prot-Labarthe et al. [10]




2016 France POPI 101
Corrick et al. [11] Developing paediatric rationalprescribing criteria. 2017 UK Modified (UK) POPI 80
Barry et al. [12]
PIPc study: development of
indicators of potentially
inappropriate prescribing in
children (PIPc) in primary care
using a modified Delphi
technique.
2016 Ireland and UK PIPc 12
Three relevant articles were identified relating to a single tool: POPI (Pediatrics: Omissions of
Prescriptions and Inappropriate Prescriptions) tool [9–11]. All three included articles are very similar,
two in French and one in English, and describe the process of developing the POPI tool. The earliest,
from 2011, is a letter describing the tool, giving nine examples of the gastro-intestinal criteria. The 2014
and 2016 articles are English and French language, respectively. They report the consensus validation of
the tool and give full details of the criteria. The number of criteria listed di↵ers due to the combination
of several criteria together in the latter publication. Note that the 2014 article states there are 104 criteria
but lists 105. For the purposes of clarity, from this point reference to the POPI criteria is specifically to
the wording and numbering in the English 2014 publication unless otherwise stated.
The other two relevant articles relate to two additional rational prescribing tools. One of these
describes the modified (UK) POPI tool [12], a modification of the above POPI tool for application to
use in the UK published by the authors of this review in 2017. The other relates to the development of
a rational prescribing tool for the evaluation of paediatric prescribing in primary care, indicators of
potentially inappropriate prescribing in children (PIPc) [13]. This was developed in Ireland and the
UK and published in September 2016.
3.2. Characteristics of the Identified Paediatric Rational Prescribing Tools
All three tools are examples of explicit or mixed rational prescribing tools and are comprised of
a number of explicit criteria defining potentially inappropriate prescriptions (PIPs) and potentially
inappropriate omissions (PIOs). Both POPI and the modified POPI (UK) also contain some criteria
with implicit features.
The POPI tool comprises 105 criteria (80 PIPs and 25 PIOs) categorised by the authors according to
broadly grouped clinical conditions: diverse illnesses, digestive problems, ENT-pulmonary problems,
dermatological problems, and neuropsychiatric disorders. The groups are further subdivided
into particular symptoms or conditions. The criteria cover a range of aspects of inappropriate
prescribing, including overprescribing, underprescribing, and almost all areas of misprescribing except
drug-food interactions.
The modified (UK) POPI tool comprises 80 criteria under the same categories as the original POPI
tool, except for the removal of one subcategory (Mosquitos [sic]). The criteria include 60 PIPs and
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PIPc comprises twelve criteria of potentially inappropriate prescribing or omissions, categorised
according to four physiological systems: respiratory, gastrointestinal, dermatological, and neurological.
Seven criteria describe PIPs with potential overprescribing or misprescribing practices, five relate
to PIOs.
The characteristics of the identified tools are summarised in Table 2, where bullet points identify
aspects of irrational prescribing that are covered by each tool.
3.3. Development of the Popi Tool
The methodology used to develop the POPI tool was designed to closely match the development
of the STOPP/START criteria, according to the authors [10]. The STOPP/START criteria are criteria
for rational prescribing in older people developed in 2008 [14] comprising two lists; the “STOPP”
list of PIPs, and the “START” list of PIOs. In the STOPP/START tool, the authors structured their
criteria according to physiological systems to mirror the usual organisation of drug formularies.
The propositions were validated using an 18-member panel Delphi consensus where agreement was
determined by the kappa-statistic for agreement and participants were able to suggest additional
criteria if desired [15].
The POPI tool was developed in part by the Delphi consensus method. Prior to the Delphi
consensus process, the authors compiled a list of possible propositions.
The authors structured POPI around 100 propositions classified according to biological systems
and divided into omissions and inappropriate prescriptions. The number of propositions was chosen
as “a good compromise between the number of major biological system to explore, the number of items
in the geriatric lists and the maximum number of items compatible with a tool easy use” [8] (p. 2).
The authors then compiled a list of health problems frequently encountered in paediatric practice,
according to frequency in the general population (source not specified), prevalence (derived from data
from the French National Insurance Fund for Employers for long term conditions), and frequency as
cause for hospitalisation (per French hospital medico-administrative records). The authors identified
health problems from this list, referred to as “themes”, that would either require drug intervention or
where pharmacological intervention would be considered inappropriate.
For each selected theme, the authors conducted a literature search to identify recommendations
on management. There was a requirement for recommendations to be evidence-based but the authors
did not specify the level of evidence. Only recommendations published after 2000 were accepted and
these were then weighted by date of publication. Accepted sources of recommendations were the
French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Produits de Santé),
the French National Authority for Health (Haute Autorité de Santé Française), the French Society
for Paediatricians (Sociétè Française de Pédiatrie), the American Academy of Pediatrics (National
Guideline Clearing House), and the National Institute for Health and Clinical Evidence (NICE)
Cochrane Library [sic]. They also used the MEDLINE database to search for examples of medication
error and inappropriate prescription (search strategy unpublished).
The propositions were then validated by a two-round Delphi consensus. Sixteen experts, including
pharmacists and paediatricians, were included, of whom ten responded to both rounds. The process of
recruitment of experts is not described, only that most pharmacists were members of the French Society
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Initially, 108 propositions were presented to the experts. There is inconsistency between the
2014 (English) compared with the 2016 (French) publication in that the 2014 paper states 104 criteria
were validated, whereas the 2016 paper states 101 criteria were validated. Furthermore, while it is
stated in the 2014 paper that 104 propositions were validated, in fact 105 propositions are included
in their final list. The di↵erence between the two papers is due to three instances of combining two
statements into a single criterion, and the omission of one proposition in the 2016 (French) publication.
Specifically, two propositions about desmopressin for nocturnal enuresis are combined into one and
six propositions about atopic eczema are combined into four. A proposition about benzyl benzoate for
scabies is omitted. Other than this, the described process and criteria are the same.
Two propositions were removed following the consensus study due to new contraindications
having been published for the use of these drugs in children, therefore 102 propositions were ultimately
validated. In the 2016 French language publication describing the consensus validation of the POPI
tool [11], the authors state that 101 of 108 criteria were validated. For the purposes of evaluation and
discussion below, the English language published list of 105 validated propositions in the 2011 report
is used.
3.4. Development of the Modified Popi UK) Tool
The modified POPI (UK) tool was developed in order to apply the POPI tool, which was based on
a mixture of French, UK, and US guidelines, to UK practice [12]. A number of medications identified
in the original POPI criteria are either not in usual use or unavailable in the UK, while some criteria
directly conflicted with national UK clinical guidelines.
Each of the 105 criteria in the English language publication of the POPI tool were compared to
relevant UK clinical guidelines from NICE, the Scottish Intercollegiate Guideline Network (SIGN), and
the British National Formulary for Children (BNFc). In cases where there were no relevant guidelines or
directly contradictory guidelines, criteria were removed. If guidelines di↵ered, criteria were modified
to reflect UK guidelines.
In comparison to the original criteria, 49 criteria were not changed. 29 were modified to meet UK
guidelines, four criteria were combined into two, and 23 were omitted altogether. Omitted criteria
included the removal of the clinical category of “Mosquitos”, which comprised seven criteria.
3.5. Development of the PIPc
Like the POPI tool, the PIPc was developed by a two-round Delphi consensus method.
Initial propositions were selected via a systematic literature search for previously developed indicators
for paediatric prescribing.
Inclusion criteria were:
• Describe prescribing that is hazardous or known to be ine↵ective
• Describe prescribing in keeping with best practice/current guidelines
• Apply to the population of children < 16 years
Exclusion criteria were:
• Medications unavailable in the study setting
• Criteria that could not be applied in the absence of clinical information
• Criteria containing medications with a low prevalence of use
A steering group of academic and clinical general practitioners (GPs), academic and clinical
pharmacists, a pharmacoepidemiologist/statistician, and a postdoctoral researcher, assessed each
criterion. Those that were not felt to meet the above conditions were excluded. In some cases, criteria
were modified to meet the need to be applicable without access to clinical information, for example
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The panel for the Delphi consensus comprised eighteen specialists, nine from the Republic of
Ireland (three GPs, three paediatricians, and three pharmacists) and nine from the UK (three GPs, three
paediatricians, and three pharmacists).
The two-round Delphi consensus resulted in twelve criteria being accepted into the final PIPc.
3.6. Characteristics of the Tools
The use of the POPI tool is not specifically limited to any particular clinical setting. The propositions
were selected from paediatric health problems in the general population and as causes for hospitalisation,
suggesting the tool would be relevant to both primary and secondary care. However, no primary
care specialists or general practitioners were involved in the development of the tool. The paediatric
population is not explicitly defined by the authors but some propositions are age-specific, for instance
pharmacological treatment for attention deficit disorder is described as inappropriate “before age six
(before school)” [8] (p. 7) and topical 0.1% tacrolimus is considered inappropriate for atopic eczema
“before 16 years of age” [8] (p. 6).
The criteria of the POPI tool cover a wide range of the aspects of rational prescribing, including
all three categories of underprescribing, overprescribing, and misprescribing. Underprescribing errors
are specifically identified in the tool as omissions. The inappropriate prescription propositions include
some examples of overprescribing and misprescribing.
The modified POPI (UK) tool shares the characteristics of the original POPI tool.
The PIPc is a tool that has been designed specifically for application in primary care settings.
Unlike the POPI tool, it has been developed to be applicable without access to clinical information,
meaning that it can be used to evaluate data from large previously collected prescribing databases
where clinical information is often either omitted or concealed.
The authors of the PIPc define their paediatric population as children under 16 years of age.
The age at which young people transition from paediatric to adult healthcare services can vary
depending on health needs, social circumstances such as attendance in full-time education, and
availability of specialist services [16]. In addition to the population specified for the tool, some criteria
further specify particular age ranges, for example, “Loperamide should not be prescribed to children
under 4 years” [11] (p. 8).
The PIPc criteria describe almost as broad a range of types of potentially irrational prescribing as
POPI despite having far fewer criteria. The only aspects of irrational prescribing not contained within
the PIPc that are covered by POPI are misprescribing of dosage, duration, and duplication.
3.7. Validation studies
The POPI tool has been evaluated in both a clinical validation [17] and repeatability study [18]
(Table 3). The very high rate of PIPs in the community pharmacy is not further analysed in the
published report.
Table 3. Validation or repeatability studies.
Tool Setting Number ofChildren Prevalence of PIPS Prevalence of PIOs Reference
POPI
Emergency
department 15973 3.3% 2.6% 17
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The published repeatability study of the POPI tool [18] found good repeatability despite the high
complexity and mixed implicit and explicit approach of the tool.
The POPI tool was developed using French, American and UK guidelines and has been validated
in clinical practice, with the above study showing that it is able to detect some potentially irrational
prescribing in French settings. It is not yet known whether it detects irrational prescribing that
correlates to adverse events or patient outcomes, or whether it could be used to evaluate prescribing
outside French practice.
Although not published as a clinical validation study, there is a published study using the PIPc
criteria to detect potentially irrational prescribing [19] (Table 3). In this study, the criteria were applied
to a national pharmacy claims database in Ireland, the Primary Care Reimbursement Service (PCRS)
with a cross-sectional methodology. The database records pharmacy claims for medicines for eligible
patients prescribed by general practitioners or transcribed from hospital prescriptions by general
practitioners, with limited patient demographic data (age, gender and region). No clinical details
of the patients are recorded. The rate of PIO rose to 11.5% when including the criterion relating to
co-prescription of a space device. Similarly, a single criterion had a large impact on PIPs and when this
criterion, relating to carbocisteine, was removed the PIP rate fell to 0.29%.
One significant limitation in this study was that it highlighted the di culty in applying even
the intentionally simple and explicit criteria of PIPc to retrospective anonymised data. The age of
patients in the PCRS database was recording in age bands of 0–4 years, 5–11 years, and 12–15 years.
In several cases, these bands overlapped age limits described in PIPc criteria. In order to analyse the
data, the authors made calculations to estimate the number of children of a certain age. For example,
to calculate the number of children under 2 years in the 0–4 years band, the total number of children in
the band was divided by 5 and multiplied by 2. This assumes a normal distribution of ages, which
may not be the case.
There is no published repeatability study of PIPc.
A clinical validation study of the modified POPI (UK) tool has only been published in abstract
form [12] (Table 3). There is currently no published repeatability study for the modified POPI (UK) tool.
3.8. Comparison with Existing Adult Rational Prescribing Tools
All of the paediatric tools identified cover a range of types of rational prescribing, with the POPI
and modified POPI (UK) tools covering a particularly broad range. By comparison, the majority of
adult tools identified by Kaufmann et al. [4] had a narrower focus.
Of the 46 adult tools identified by Kaufmann et al., the median number of aspects of rational
prescribing covered by each tool was 4.5, similar to the PIPc, which covers five aspects. However, four
tools did cover eight or nine categories of prescribing, which is comparable to the POPI and modified
POPI (UK), which cover eight.
The PIPc is designed for use in primary care settings, while the POPI tool and modified POPI
(UK) are developed for application in a range of settings. The breadth of applications of both the POPI
tool and modified POPI (UK) tool is similar to a number of rational prescribing tools for older adults,
which have been used in settings including nursing homes, emergency departments, and primary care.
Of the adult tools evaluated by Kaufmann et al., the majority of tools (28) were explicit, a minority
(8) were implicit, and the remaining 10 used a mixed approach like POPI. Implicit criteria may be more
accurate, as they can take into account individual patient requirements, but this may come at the cost
of reliability as they are more dependent on the rater’s knowledge and judgement [5]. The reverse
is true of explicit tools, which are less reliant on rater judgement and therefore might be expected
to have greater repeatability and reliability and be less time-consuming to apply, with concomitant
lower accuracy. Therefore, mixed tools may stand to inherit both the advantages and disadvantages of
each approach.
The authors of the original POPI state that the tool comprises explicit criteria; however, in both the
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considerations. Other propositions require taking into account the patient’s co-morbidities and entire
medication regimen, characteristics that are usually considered components of implicit (patient-specific)
criteria. For example, several propositions require the rater to make subjective judgements, such as in
the theme of Attention Deficit Disorder, which includes “Pharmacological treatment before age six . . .
except in severe cases” [7] (p. 7).
In some cases, the modified POPI (UK) amended criteria replace subjective judgements with explicit
quantified cut-o↵s to reflect similarly precise recommendations in the UK guidelines. For instance
where the original POPI tool lists a PIO of “Asthma inhaler appropriate for the child’s age”, the
modified POPI (UK) criterion reads, “Asthma inhaler appropriate for the child’s age (aged < 5 years,
either Metered Dose Inhaler with spacer system or nebuliser; age 3–5 years Dry Powder Inhaler may
be appropriate)” [12].
The PIPc criteria are entirely explicit and do not require evaluation of a patient’s condition or
subjective judgements. One criterion that may require non-anonymised data for full evaluation,
however, is the recommendation in the Respiratory System theme, that “Children under 12 years who
are prescribed a pressurised metered-dose inhaler should also be prescribed a spacer device at least
every 12 months” [11] (p. 8). In order to assess this with certainty, the rater would need to be able
to see all prescriptions for the child within the prior twelve months. Nonetheless, these criteria are
all explicit.
4. Discussion
This systematic literature review identified three rational prescribing tools for use in paediatric
practice, the PIPc, the POPI tool, and the modified POPI (UK) tool.
There are a number of research and clinical applications for rational prescribing tools.
The varying characteristics of the three paediatric rational prescribing tools identified have
implications for their use and impact in future work. PIPc is intended only for primary care settings,
while the POPI and modified (UK) POPI tools can be applied in any paediatric setting.
All three tools could be used for both clinical governance and research purposes to identify areas of
problematic prescribing, compare rates of irrational prescribing between settings, grades or specialties
of prescribers, or regions. Because the tools provide a means to quantify rational prescribing, they may
also facilitate the evaluation of educational or quality improvement interventions. The tools could also
be used to assess factors associated with problematic prescribing.
In terms of structure and complexity, the POPI tool comprises a relatively high number of criteria
compared with many other tools, although there is one published tool targeted at older adults with 392
quality indicators (not all of which relate to rational prescribing), ACOVE-3 [20]. The PIPc has closer to
the lowest number of criteria of the adult tools. Some of the tools detailed in the Kaufmann systematic
review have as few as ten criteria, for instance the Medication Appropriateness Index (MAI) [21],
which is also targeted at older adults. A simple count of criteria is not necessarily a useful measure
of complexity however. For example, in the case of the MAI, it is intended that all ten criteria are
applied to each drug a patient is prescribed, where some systems simply list medications that are
contraindicated or essential.
The high number of propositions and mixed implicit and explicit approach of the POPI tool makes
it quite high in complexity, thus it requires a high level of clinical knowledge to apply. Some patients
may fall within multiple themes, for instance Pain and fever might be expected alongside a number
of other themes with an infectious focus, such as Urinary Infections and ENT Infections, and other
themes describe long-term conditions that any child might have as co-morbidity. The theme of Vitamin
Supplements and Antibiotic Prophylaxis includes a proposition describing minimum vitamin D intake,
which would need to be assessed for every child. This would therefore require a high level of familiarity
with the tool for accurate use and necessitates access to a high level of information about each patient.
By contrast, the PIPc is by design a tool that is simpler to apply and that requires minimal clinical
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of asthma in two criteria, which it appears that a rater is intended to presume on the basis of the
prescriptions described, e.g., “An inhaled short-acting beta-2 agonist should be prescribed to children
under 5 years who are also taking a leukotriene receptor antagonist for presumed asthma” [11] (p. 8).
The PIPc is likely to be quicker to apply and does not require the high level of clinical information
required by the POPI tool. However, it is also less broad and therefore it will not identify some aspects
of irrational prescribing such as duplication, inappropriate drug duration, or incorrect drug dosage.
There are also fewer clinical conditions included within the PIPc as compared with POPI, which may
not reduce its e cacy as a screening tool in general settings but might reduce its usefulness in more
specialist settings.
Further work comparing the sensitivity of the tools to detect rational prescribing and their utility
in di↵erent clinical settings would be informative. In addition, it would be valuable to assess whether
higher rates of irrational prescribing as detected by the tools is associated with poorer clinical outcomes
or increased rates of adverse drug events.
As electronic prescribing becomes increasingly widespread, algorithmic clinical decision support
systems have been developed to help alert clinicians to potentially inappropriate prescribing. In the
older adult population where the Beers criteria and STOPP/START criteria are well-established, a
computerised clinical decision support system integrating these rational prescribing tools has been
developed [22]. This may be another avenue for further development towards greater rational
prescribing for children by integrating one or more of the identified rational prescribing tools in a
similar model.
The study of rational prescribing in children is a neglected area of research [23,24]. Studies of
the value of these tools in di↵erent clinical settings by di↵erent investigators is needed to evaluate
how useful the tools are. Such studies are essential to improve rational prescribing in di↵erent
paediatric populations.
5. Conclusions
This systematic literature search identified three rational prescribing tools for use in assessing
potentially inappropriate prescribing in paediatric settings, the PIPc, the POPI tool, and the modified
POPI (UK) tool. We have outlined the characteristics of the tools, including their modes of design,
aspects of rational prescribing assessed, and intended practice settings, which may assist readers in
making use of the tools in their own clinical practice or for further research. The paucity of paediatric
rational prescribing tools compared to adult tools shows that this remains a relatively underdeveloped
field of study with great potential for future research.
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Assessment Tools of Rational Prescribing in Children
Corrick FJ, Sammons HM.
Division of Medical Sciences & Graduate Entry Medicine , University of Nottingham, 
Derbyshire Children’s Hospital, Derby, UK.
Results
Conclusions
Antibiotic prescriptions were the most common topic of
studies of rational prescribing for children. In particular,
studies looking at rational use of antibiotics have
demonstrated inappropriately high rates of antibiotic
prescribing for conditions with low probability of clinical
benefit:
• Risk et al2 evaluated prescribing for children <5 years in
20 centres in The Gambia and found that
approximately half of children presenting with
diarrhoea or uncomplicated upper respiratory tract
infection were prescribed antibiotics
• One review found that children in Italy are almost
fourfold more likely to be prescribed antibiotics than in
the UK
Only 1 screening tool was identified with the systematic
search: the POPI (Pediatrics: Omissions of Prescriptions
and Inappropriate Prescriptions) criteria3, developed in
France in 2015 (see Table 1). This contains region-specific
guidance based on French, British and American clinical
guidelines and has yet to be validated clinically.
Table 1- An excerpt of the POPI criteria
Rational prescribing seeks to ensure that patients receive optimal medicines appropriate to their clinical need and at 
the lowest cost, both to them and their community. Irrational prescribing can lead to suboptimal treatment for 
patients, increased rates of adverse events or drug interactions, and waste of organisational resources that could be spent 
on health needs. The situation in paediatric prescribing has been described as an “evidence-based desert”1 with high 
rates of use of off-label and unlicensed drugs. The aim of this study was to review the current research literature on 
rational prescribing in paediatrics and to conduct a systematic literature search for screening tools designed for use in this 
field.
References:
1) Sutcliffe, A.G. & Wong, I.C.K., 2006. Rational prescribing for children. BMJ (Clinical research ed.), 332(7556), pp.1464–5. 
2) Risk, R. et al., 2013. Rational prescribing in paediatrics in a resource-limited setting. Archives of disease in childhood, 98(7), pp.503–9.
3) Prot-Labarthe, S. et al., 2014. POPI (Pediatrics: Omission of Prescriptions and Inappropriate Prescriptions): Development of a tool to identify inappropriate prescribing. PLoS ONE, 9(6).
We conducted a review of the research into rational prescribing in paediatrics and performed a 
systematic literature search in Embase and Medline for screening tools for the assessment of 
rational prescribing in paediatrics (patients<18 years). 
Inappropriate prescriptions
Loperamide before 3 years of age
Loperamide in the case of invasive diarrhea
The use of Diosmectite (Smecta) in combination with another medication
The use of Saccharomyces boulardii (Ultralevure) in powder form, or in a capsule that has to be opened prior to ingestion, to treat patients









Mucolytic drugs, mucokinetic drugs, or helicidine before two years of age
Alimemazine (Theralene), oxomemazine (Toplexil), promethazine (Phenergan, and other types)
Terpene-based suppositories
Omissions
Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming months or years (only
applicable if the previous vaccination was more than 10 years ago). This booster vaccination should also be proposed to the family and
entourage of expectant parents (parents, grand-parents, nannies/child minders)
BRONCHIOLITIS IN INFANTS
Inappropriate prescriptions
Beta2 agonists, corticosteroids to treat an infant’s first case of bronchiolitis
H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis
Antibiotics in the absence of signs indicating a bacterial infection (acute otitis media, fever, etc.)
Omissions
0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl delivered by a nebulizer)
Palivizumab in the following cases: (1) babies born both at less than 35 weeks of gestation and less than six months prior to the onset of a
seasonal RSV epidemic; (2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six
months; (3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities
ENT INFECTIONS
Inappropriate prescriptions
An antibiotic other than amoxicillin as a first-line treatment for acute otitis media, strep throat, or sinusitis (provided that the patient is not
allergic to amoxicillin). An effective dose of amoxicillin for an pneumoncoccal infection is 80–90 mg/kg/day and an effective dose for a
streptococcal infection is 50 mg/kg/day
Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children less than three years old
Antibiotics for nasopharyngitis, congestive otitis, sore throat before three years of age, or laryngitis; antibiotics as a first-line treatment for
acute otitis media showing few symptoms, before two years of age
Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more than three months
Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat
Nasal or oral decongestant (oxymetazoline (Aturgyl), pseudoephedrine (Sudafed), naphazoline (Derinox), ephedrine (Rhinamide),
tuaminoheptane (Rhinofluimicil), phenylephrine (Humoxal))
H1-antagonists with sedative or atropine-like effects (pheniramine, chlorpheniramine), or camphor; inhalers, nasal sprays, or suppositories
containing menthol (or any terpene derivatives) before 30 months of age
Ethanolamine tenoate (Rhinotrophyl) and other nasal antiseptics
Ear drops in the case of acute otitis media
Omissions
Doses in mg for drinkable (solutions of) amoxicillin or josamycin
Paracetamol combined with antibiotic treatment for ear infections to relieve pain
ASTHMA
Inappropriate prescriptions




POPI: A Tool to Identify Inappropriate Prescribing
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e101171
Although rational prescribing for children appears to be an area of increasing research activity, only 1 screening tool was
identified by a systematic search of the literature: the POPI criteria. There is evidence that prescribing practices vary greatly
between regions but a paucity of validated assessment tools to compare prescribing practice at different times or in different
areas.
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  negative experiences were neonatal placements in level 1 training,
with issues around training, rotas and support and the second
area was membership examinations and the ST3 year. The great-
est proportion of positive experiences were related to the training
programme being run-through and the associated ‘sense of
security’.
Conclusion The emotional mapping exercise was a novel
approach to exploring trainee experience and was successful in
engaging trainees at all levels. Trainees reported value in seeing
shared experiences with immediate visual representation of their
views. The exercise highlighted two main ‘hotspots’ resulting in
low morale during training. The latter part of the session was
spent creating a list of recommendation to address both ‘hotspot’
areas, that trainees felt would improve the quality of their train-
ing and experiences.
G211 IMPACT OF A LEADERSHIP PROGRAMME ON FRONT
LINE QUALITY IMPROVEMENT
1S Madaiah, 2M Purva. 1Service improvement/Quality Improvement, Hull and East Yorkshire
NHS Trust, Hull, UK; 2Hull and East Yorkshire NHS Trust, Hull, UK
10.1136/archdischild-2017-313087.208
Background Doctors in postgraduate training rarely have the
opportunity to develop skills to implement changes where they
work1. By empowering them to make improvements to the sys-
tems that they see, there is the potential to make significant
improvement in the quality of patient care that they deliver2. We
describe a leadership programme designed to provide experiential
learning on safety and quality projects to develop not only
knowledge of quality improvement but improve leadership and
management skills through engagement of frontline staff.
Aim To engage and empower a trainee doctor in Quality
improvement projects and provide supervised opportunity to
develop skills as a Healthcare leader in Quality improvement to
improve quality of patient care.
Method The programme consists of a structured introduction to
quality improvement theory and practice supported by an experi-
enced quality Director. Phased exposure to quality improvement
projects commencing form data collection to analysis to presenta-
tion is provided. Oppurtunties to participate in trust wide steer-
ing groups, shape strategy, influence front line care delivery and
attend board level meetings to work with senior healthcare lead-
ers is provided.
Results Major involvment in a major trust wide quality improve-
ment programme to improve response to deterioating patients
which has resulted in early but significant statistical improvement
in performance of nursing staff. Key project to overhaul the tissue
viablity pathway has been undertaken with plans to roll out
changes trust wide. Project to address key mortality indicators
around chest infection launched. Undertaking structured case
note review to understand key mortality reasons for the trust.
Conclusion The programme has provided continuous learning on
patient safety and quality improvement projects. It has provided
also an understanding of the importance of engaging key stake-
holders, overcoming resistance and undertaking successful change
management. Such programmes are key to developing future
healthcare leaders and should be supported going forward.
REFERENCES
1. Developing future clinical leaders for quality improvement: experience from a Lon-
don children’s hospital. Jane Runnacles,Beki Moult,Peter Lachman
2. ‘Wading through treacle’: quality improvement lessons from the frontline Alice
Roueche1,2, Jocelyn Hewitt3
G212 DEVELOPING PAEDIATRIC RATIONAL PRESCRIBING
CRITERIA
1,2FJ Corrick, 1,2S Conroy, 1,2I Choonara, 1,2H Sammons. 1Faculty of Medicine and Health
Sciences, University of Nottingham, Nottingham, UK; 2Academic Division of Child Health,
Royal Derby Hospital, Derby, UK
10.1136/archdischild-2017-313087.209
Aims Rational prescribing is the therapeutically sound and cost-
effective use of drugs (World Health Organisation, 2008). Criteria
lists are well-established as research tools in rational prescribing
for adults but only one tool has been developed for paediatric
practice. The French ‘POPI’ criteria comprise 105 inappropriate
prescriptions or omissions. Having revised these to align with UK
clinical guidelines, our aim was to assess the usefulness of the
modified POPI criteria by evaluating their relevance to UK paedi-
atric patients.
Methods This study was a single centre prospective observational
study of 400 paediatric patients (0–18 years) in a children’s emer-
gency department and two paediatric wards. The only exclusion
criterion was lack of parent/carer consent. Diagnoses, symptoms
and prescriptions were recorded and checked against the modi-
fied POPI tool.
Results Patient age ranged from 3 days to 17 years. The median
number of prescriptions per patient was 2.5 (range 0–26). 343
patients attended with at least one clinical indication in the tool.
255 were in the category of Pain or Fever; the next most fre-
quent were Nausea, Vomiting or Gastro-oesophageal Reflux
(n=123), Cough (n=77) and Diarrhoea (n=36). 29 cases had
one or more inappropriate prescriptions or omissions; these
related to Pain or Fever (n=25), Bronchiolitis (n=3), Nausea,
Vomiting or Gastro-oesophageal Reflux (n=1), and Asthma
(n=1) and comprised 20 omissions and 12 inappropriate
prescriptions.
Conclusions The modified POPI criteria detected 32 inappropri-
ate prescriptions or omissions. However, 7/21 clinical categories
were not relevant to any patients in the study. Furthermore, a
number of frequent presentations are absent from the criteria,
including sepsis (n=36), viral-induced wheeze (n=35) and lower
respiratory tract infections (n=26). In 27 cases, it was not possi-
ble to determine objectively whether or not an inappropriate pre-
scription had occurred, highlighting complexity and subjectivity
within the criteria. This study demonstrates the potential for a
criteria list to act as a useful tool in studying rational prescribing
for children. However, it also highlighted a number of limitations
that must be resolved in order to develop an effective paediatric
rational prescribing tool.
G213 ABSTRACT: UNDIAGNOSED DISEASES IN A SPECIALIST
CHILDREN’S HOSPITAL
H Vincent, S Da Roza, L Kerecuk. Rare Diseases, NHS, Birmingham, UK
10.1136/archdischild-2017-313087.210
Aims There is limited information on how many patients are
undiagnosed. The aim was to evaluate the proportion of paediat-
ric inpatients without a diagnosis on Undiagnosed Day in a spe-
cialist hospital serving both the general local population, and
tertiary referrals in 34 specialties.
Abstracts
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Appendix 7:  
The original POPI criteria 
 
DIVERSE ILLNESSES 
PAIN AND FEVER 
Inappropriate prescriptions 
Prescription of two alternating antipyretics as a first-line treatment  
Prescription of a medication other than paracetamol as a first line treatment (except in the case of migraine) 
Rectal administration of paracetamol as a first-line treatment  
The combined use of two NSAIDs  
Oral solutions of ibuprofen administered in more than three doses per day using a graduated pipette of 10mg/kg (other 
than Advil)  
Opiates to treat migraine attacks 
Omissions 
Failure to give sugar solution to new-born babies and infants under four months old two minutes prior to venepuncture 
Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 hours 
URINARY INFECTIONS  
Inappropriate prescriptions  
Nitrofurantoin used as a prophylactic  
Nitrofurantoin used as a curative agent in children under six years of age, or indeed any other antibiotic if avoidable  
Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy)  
Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy) 
VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS  
Inappropriate prescriptions  
Fluoride supplements prior to six months of age  
Omissions  
Insufficient intake of vitamin D. Minimum vitamin D intake: Breastfed baby = 1 000 to 1 200 IU/day; Infant ,18 
months of age (milk enriched in vitamin D) = 600 to 800 IU/day; Child aged between 18 months and five years, and 
adolescents aged between 10 and 18 years: two quarterly loading doses of 80 000 to 100 000 IU/day in winter 
(adolescents can take this dose in one go)  
Antibiotic prophylaxis with phenoxymethylpenicillin (Oracilline) starting from two months of age and lasting until 
five years of age for children with sickle-cell anemia: 100 000 IU/kg /day (in two doses) for children weighing 10kg 
or less and 50 000 IU/kg/day for children weighing over 10kg (also in two doses) 
MOSQUITOS  
Inappropriate prescriptions  
The use of skin repellents in infants less than six months old and picardin in children less than 24 months old  
Citronella (lemon grass) oil (essential oil)  
Anti-insect bracelets to protect against mosquitos and ticks  
Ultrasonic pest control devices, vitamin B1, homeopathy, electric bug zappers, sticky tapes without insecticide  
Omissions  
DEET: ‘‘30%’’ (max) before 12 years old; ‘‘50%’’ (max) after 12 years old  
IR3535: ‘‘20%’’ (max) before 24 months old; ‘‘35%’’ (max) after 24 months old  
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Mosquito nets and clothes treated with pyrethroids 
DIGESTIVE PROBLEMS 




Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube)  
Gastric antisecretory drugs to treat gastroesophageal reflux, dyspepsia, the crying of new-born babies (in the absence 
of any other signs or symptoms), as well as faintness in infants  
The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk factors  
The use of type H2 antihistamines for long periods of treatment  
Erythromycin as a prokinetic agent  
The use of setrons (5-HT3 antagonists) for chemotherapy-associated nausea and vomiting 
Omissions  
Oral rehydration solution 
DIARRHOEA 
Inappropriate prescriptions  
Loperamide before 3 years of age  
Loperamide in the case of invasive diarrhea  
The use of Diosmectite (Smecta) in combination with another medication  
The use of Saccharomyces boulardii (Ultralevure) in powder form, or in a capsule that has to be opened prior to 
ingestion, to treat patients with a central venous catheter or an immunodeficiency  
Intestinal antiseptics 
Omissions 
Oral rehydration solution 
ENT-PULMONARY PROBLEMS 
COUGH 
Inappropriate prescriptions  
Pholcodine  
Mucolytic drugs, mucokinetic drugs, or helicidine before two years of age  
Alimemazine (Theralene), oxomemazine (Toplexil), promethazine (Phenergan, and other types)  
Terpene-based suppositories 
Omissions  
Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming 
months or years (only applicable if the previous vaccination was more than 10 years ago). This booster vaccination 
should also be proposed to the family and entourage of expectant parents (parents, grand-parents, nannies/child 
minders) 
BRONCHIOLITIS IN INFANTS 
Inappropriate prescriptions  
Beta2 agonists, corticosteroids to treat an infant’s first case of bronchiolitis 
H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis  
Antibiotics in the absence of signs indicating a bacterial infection (acute otitis media, fever, etc.) 
Omissions  
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0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl 
delivered by a nebulizer)  
Palivizumab in the following cases: (1) babies born both at less than 35 weeks of gestation and less than six months 
prior to the onset of a seasonal RSV epidemic;  
(2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six 
months;  
(3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities 
ENT infections 
Inappropriate prescriptions  
An antibiotic other than amoxicillin as a first-line treatment for acute otitis media, strep throat, or sinusitis (provided 
that the patient is not allergic to amoxicillin). An effective dose of amoxicillin for an pneumoncoccal infection is 
80–90 mg/kg/day and an effective dose for a streptococcal infection is 50 mg/kg/day  
Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children less than three years 
old  
Antibiotics for nasopharyngitis, congestive otitis, sore throat before three years of age, or laryngitis; antibiotics as a 
first-line treatment for acute otitis media showing few symptoms, before two years of age 
Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more 
than three months  
Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat 
Nasal or oral decongestant (oxymetazoline (Aturgyl), pseudoephedrine (Sudafed), naphazoline (Derinox), ephedrine 
(Rhinamide), tuaminoheptane (Rhinofluimicil), phenylephrine (Humoxal))  
H1-antagonists with sedative or atropine-like effects (pheniramine, chlorpheniramine), or camphor; inhalers, nasal 
sprays, or suppositories containing menthol (or any terpene derivatives) before 30 months of age  
Ethanolamine tenoate (Rhinotrophyl) and other nasal antiseptics  
Ear drops in the case of acute otitis media 
Omissions  
Doses in mg for drinkable (solutions of) amoxicillin or josamycin 
Paracetamol combined with antibiotic treatment for ear infections to relieve pain 
ASTHMA 
Inappropriate prescriptions  
Ketotifen and other H1-antagonists, sodium cromoglycate 
Cough suppressants 
Omissions  
Asthma inhaler appropriate for the child’s age 
Preventative treatment (inhaled corticosteroids) in the case of persistent asthma 
DERMATOLOGICAL PROBLEMS 
ACNE VULGARIS 
Inappropriate prescriptions  
Minocycline  
Isotretinoin in combination with a member of the tetracycline family of antibiotics  
The combined use of an oral and a local antibiotic  
Oral or local antibiotics as a monotherapy (not in combination with another drug)  
Cyproterone+ethinylestradiol (Diane 35) as a contraceptive to allow isotretinoin per os  
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Androgenic progestins (levonorgestrel, norgestrel, norethisterone, lynestrenol, dienogest, contraceptive implants or 
vaginal rings) 
Omissions  
Contraception (provided with a logbook/diary) for menstruating girls taking isotretinoin  
Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic therapy 
SCABIES 
Inappropriate prescriptions  
The application of benzyl benzoate (Ascabiol) for periods longer than eight hours for infants and 12 hours for 
children or for pregnant girls 
Omissions  
A second dose of ivermectin two weeks after the first  
Decontamination of household linen and clothes and treatment for other family members 
LICE 
Inappropriate prescriptions  
The use of aerosols for infants, children with asthma, or children showing asthma-like symptoms such as dyspnoea 
RINGWORM 
Inappropriate prescriptions  
Treatment other than griseofulvin for Microsporum 
Omissions  
Topical treatment combined with an orally-administered treatment  
Griseofulvin taken during a meal containing a moderate amount of fat 
IMPETIGO 
Inappropriate prescriptions  
The combination of locally applied and orally administered antibiotic  
Fewer than two applications per day for topical antibiotics  
Any antibiotic other than mupirocin as a first-line treatment (except in cases of hypersensitivity to mupirocin) 
HERPES SIMPLEX 
Inappropriate prescriptions  
Topical agents containing corticosteroids  
Topical agents containing acyclovir before six years of age 
Omissions  
Paracetamol during an outbreak of herpes  
Orally administered acyclovir to treat primary herpetic gingivostomatitis 
ATOPIC ECZEMA 
Inappropriate prescriptions  
A strong dermocorticoid (clobetasol propionate 0.05% Dermoval, betamethasone dipropionate Diprosone) applied to 
the face, the armpits or groin, and the backside of babies or young children  
More than one application per day of a dermocorticoid, except in cases of severe lichenification  
Local or systemic antihistamine during the treatment of outbreaks  
Topically applied 0.03% tacrolimus before two years of age  
Topically applied 0.1% tacrolimus before 16 years of age  




Inappropriate prescriptions  
Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of myoclonic 
epilepsy  
Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabaline, tiagabine, or vigabatrin in the case of epilepsy 
with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy)  
Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL 
DEPRESSION 
Inappropriate prescriptions  
An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy)  
Tricyclic antidepressants to treat depression 
NOCTURNAL ENURESIS 
Inappropriate prescriptions  
Desmopressin administered by a nasal spray  
Desmopressin in the case of daytime symptoms  
An anticholinergic agent used as a monotherapy in the absence of daytime symptoms  
Tricyclic agents in combination with anticholinergic agents  
Tricyclic agents as a first-line treatment 
ANOREXIA 
Inappropriate prescriptions  
Cyproheptadine (Perlactin), clonidine 
ATTENTION DEFICIT DISORDER WITH OR WITHOUT HYPERACTIVITY 
Inappropriate prescriptions  
Pharmacological treatment before age six (before school), except in severe cases  
Antipsychotic drugs to treat attention deficit disorder without hyperactivity  
Slow release methylphenidate as two doses per day, rather than only one dose 
Omissions  
Recording a growth chart (height and weight) if the patient is taking methylphenidate 
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Appendix 8:  
The POPI UK criteria 
 
Code DIVERSE ILLNESSES 
A PAIN AND FEVER 
 Inappropriate prescriptions 
1 Prescription of two alternating antipyretics as a first-line treatment 
2 Prescription of a medication other than paracetamol or ibuprofen as a first-line treatment for 
pain (except in the case of migraine) 
3 The combined use of two NSAIDs 
4 Doses of ibuprofen administered in more than three doses per day or exceeding maximum 
dose of 30mg/kg over three doses per day 
5 Opiates to treat migraine attacks 
 Omissions 
6 Failure to give an osmotic laxative to patients being treated with morphine for a period of 
more than 48 hours 
B URINARY INFECTIONS 
 Inappropriate prescriptions 
1 Antibiotic prophylaxis following an initial infection without complications (except in the case 
of uropathy) 
2 Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of 
uropathy) 
C VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS 
 Omissions 
1 Healthy Start vitamins for infants and children 6 months- 5 years or having less than 500mL 
infant formula per day 
2 Antibiotic prophylaxis with phenoxyethylpenicillin (penicillin V) from age 1 month until 5 
years for children with sickle-cell anaemia at a dose of: 
• 125 mg twice a day for infants and children up to 5 years of age. 
• 250 mg twice a day for children from 6 to 12 years of age. 
• 500 mg twice a day for adults and children older than 12 years of age. 
OR Erythromycin for children who are allergic to penicillin, at a dose of: 
• 125 mg twice a day for infants and children up to 2 years of age. 
• 250 mg twice a day for children older than 2 years of age. 
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 DIGESTIVE PROBLEMS 
D NAUSEA, VOMITING, OR GASTROESOPHAGEAL REFLUX 
 Inappropriate prescriptions 
1 Metoclopramide 
2 Domperidone 
3 Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube) 
4 Acid-suppressing drugs to treat overt regurgitation in the absence of feeding difficulties, 
distress, or faltering growth 
5 The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in 
patients without risk factors 
6 The use of H2 receptor antagonists for more than 4 weeks 
7 Erythromycin 
 Omissions 
8 Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated 
(shock, red flag symptoms despite ORS, persist vomiting of ORS) 
E DIARRHOEA 
 Inappropriate prescriptions 
1 Loperamide before 4 years of age 
2 Loperamide in the case of invasive diarrhoea 
 Omissions 
3 Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated 
(shock, red flag symptoms despite ORS, persist vomiting of ORS) 
 ENT-PULMONARY PROBLEMS 
F COUGH 
 Inappropriate prescriptions 
1 Pholcodine 
2 Mucolytic drugs, mucokinetic drugs, or helicidine before two years of age 
3 Alimemazine (Theralene), oxomemazine (Toplexil), promethazine (Phenergan, and other 
types) 
 Omissions 
4 Failure to propose a whooping cough vaccine for pregnant women. 
G BRONCHIOLITIS IN INFANTS 
 Inappropriate prescriptions 
1 Antibiotics, ß2 agonists or corticosteroids to treat bronchiolitis 
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2 H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis 
 Omissions 
3 Palivizumab in high-risk cases, defined as: 
1) children < 2 years with chronic lung disease on home oxygen or who have prolonged 
use of oxygen 
2) infants < 6 months with left-to-right shunt haemodynamically significant congenital 
heart disease and/or pulmonary hypertension 
3) children < 2 years with severe congenital immunodeficiency 
H ENT INFECTIONS 
 Inappropriate prescriptions 
1 An antibiotic for < 4 days symptoms of acute upper respiratory tract infection (except : 
• bilateral acute otitis media in children younger than 2 years 
• acute otitis media in children with otorrhoea 
• acute sore throat/acute pharyngitis/acute tonsillitis when three or more Centor 
criteria are present. 
2 Antibiotic treatment for a sore throat except in severe cases (anticipated to be no more than 
20% of cases) 
3 Antibiotics to treat otitis media with effusion in the first 6-12 weeks 
4 Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat 
5 Nasal or oral decongestant (oxymetazoline (Aturgyl), pseudoephedrine (Sudafed), naphazoline 
(Derinox), ephedrine (Rhinamide), tuaminoheptane (Rhinofluimicil), phenylephrine 
(Humoxal)) 
6 Sedating antihistamines (pheniramine, chlorpheniramine) before 2 years (except for 
anaphylaxis) 
7 Ear drops in the case of acute otitis media 
 Omissions 
8 Doses in mg for drinkable (solutions of) amoxicillin or josamycin 
9 Paracetamol combined with antibiotic treatment for ear infections to relieve pain 
I ASTHMA 
 Inappropriate prescriptions 
1 Ketotifen and other antihistamines 
2 Cough suppressants 
 Omissions 
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3 Asthma inhaler appropriate for the child’s age (aged < 5 years, either Metered Dose Inhaler 
with spacer system or nebuliser; age 3-5 years Dry Powder Inhaler may be appropriate) 
4 Preventative treatment (inhaled corticosteroids) in the case of persistent asthma 
 DERMATOLOGICAL PROBLEMS 
J ACNE VULGARIS 
 Inappropriate prescriptions 
1 Minocycline 
2 The combined use of an oral and a local antibiotic 
3 Oral or local antibiotics as a monotherapy (not in combination with another drug) 
4 Cyproterone+ethinylestradiol (Diane 35) as a contraceptive to allow isotretinoin per os 
 Omissions 
5 Contraception for menstruating girls taking isotretinoin 
6 Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic 
therapy 
K SCABIES 
 Inappropriate prescriptions 
1 Benzyl benzoate 
 Omissions 
2 A second application of permethrin or malathion one week after the first 
3 Decontamination of household linen and clothes and same day treatment of all members of 
the household 
L LICE 
 Inappropriate prescriptions 
1 The use of aerosols for infants, children with asthma, or children showing asthma-like 
symptoms such as dyspnoea 
M RINGWORM 
 Inappropriate prescriptions 
1 Oral treatment other than griseofulvin 
 Omissions 
2 Topical treatment combined with an orally-administered treatment 
3 Griseofulvin taken during a meal containing a moderate amount of fat 
N IMPETIGO 
 Inappropriate prescriptions 
1 The combination of locally applied and orally administered antibiotic 
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2 Fewer than two applications per day for topical antibiotics 
3 Any antibiotic other than fusidic acid as a first-line treatment (except in cases of 
hypersensitivity to fusidic acid) 
O HERPES SIMPLEX 
 Inappropriate prescriptions 
1 Topical agents containing corticosteroids 
2 Topical agents containing aciclovir before six years of age 
 Omissions 
3 Paracetamol during an outbreak of herpes 
4 Orally administered aciclovir to treat severe herpetic gingivostomatitis 
P ATOPIC ECZEMA 
 Inappropriate prescriptions 
1 A potent topical corticosteroid applied to the face, or for > 14 days applied to the axilla or 
groin 
2 More than one application per day of a dermocorticoid, except in cases of severe 
lichenification 
3 Prescription of antihistamines except as a trial for severe itching or where sleep disturbance 
has a significant impact on the child or carers 
4 Topically applied 0.03% tacrolimus before 2 years of age 
5 Topically applied 0.1% tacrolimus before 16 years of age 
6 Oral corticosteroids to treat outbreaks 
 NEUROPSYCHIATRIC DISORDERS 
Q EPILEPSY 
 Inappropriate prescriptions 
1 Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in 
the case of myoclonic epilepsy 
2 Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabaline, tiagabine, or vigabatrin in 
the case of epilepsy with absence seizures (especially for childhood absence epilepsy or 
juvenile absence epilepsy) 
3 Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y 
mL 
R DEPRESSION 
 Inappropriate prescriptions 
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1 An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of 
pharmacotherapy) 
2 Tricyclic antidepressants to treat depression 
S NOCTURNAL ENURESIS 
 Inappropriate prescriptions 
1 Desmopressin administered by a nasal spray 
2 Desmopressin in the case of daytime symptoms 
3 An anticholinergic agent used as a monotherapy in the absence of daytime symptoms 
4 Tricyclic agents in combination with anticholinergic agents 
5 Tricyclic agents as a first-line treatment 
T ANOREXIA 
 Inappropriate prescriptions 
1 Prescription of medications as a sole or primary treatment for anorexia nervosa 
U ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY 
 Inappropriate prescriptions 
1 Pharmacological treatment before age 6 (before school), except in severe cases 
2 Antipsychotic drugs to treat attention deficit hyperactivity disorder 
3 Modified release methylphenidate as two doses per day, rather than only one dose 
 Omissions 
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Appendix 13:  
Updated parental and participant information sheets using mandatory language with a 
Kincaid reading grade of 9.5 
 
Title of Study: Rational Prescribing for Children 
 
Name of Researcher(s):  Dr Ella Corrick, Dr Helen Sammons  
 
We would like to invite you to take part in our research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you. One of our 
team will go through the information sheet with you and answer any questions you have. Talk to 
others about the study if you wish. Ask us if there is anything that is not clear. 
 
What is the purpose of the study? 
 
The study is testing a new checklist, called “POPI” (Paediatric Omissions of Prescriptions and 
Inappropriate Prescriptions), which will be used to check that medicines are being prescribed for 
children in line with the most up-to-date guidelines and scientific evidence. 
This is the first time POPI has been used in the UK so our main question will be: 
1) Is POPI useful in the UK? 
We will also use POPI to see if there are any ways in which our prescribing could be improved, 
so we are also testing: 
2) Does POPI identify any missed or inappropriate prescriptions according to the checklist? 
It only involves looking at prescriptions that have already been written and includes looking at 
children who did not have any medicines prescribed.  
 
Why have we been invited? 
 
You are being invited to take part because your child is attending Royal Derby Hospital. We are 
inviting 600 participants like you to take part 
 
Do we have to take part? 
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It is up to you to decide whether or not to take part.  If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If your child is aged 6-
15 years we would like them to also be involved in the decision-making process and will ask them 
to sign their agreement (“assent”) if they would like to take part. If you decide to take part you are 
still free to withdraw at any time and without giving a reason. This would not affect your legal 
rights. 
 
What will happen to my child if we take part? 
 
One of our team will talk to you and ask if you want to join in. 
If you are happy to take part, we will record your prescriptions (list of medicines) and reason for 
being in hospital from your medical notes. You won’t need to do anything else. 
It will only take 10 minutes but you can stop at any time. If you decide to stop, this will not 
affect the care you receive, simply let one of your child’s medical team or one of the researchers 
know.  
It will not be possible for any information that has already been collected to be deleted or 
removed from the study. 
 
Expenses and payments 
 
Participants will not be paid to participate in the study. 
 
What are the possible disadvantages and risks of taking part?  
 
There are no risks or disadvantages that have been identified. 
 
What are the possible benefits of taking part? 
 
We cannot promise the study will help you but the information we get from this study may help 
us study the use of medicines in children in the future. 
 
What happens when the research study stops? 
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After the project finishes next summer, if you want to find out what happened you will be able 
to read about it on our website: 
https://nottingham.ac.uk/research/groups/paediatricmedicines/index.aspx 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions.  The researchers contact 
details are given at the end of this information sheet. If you remain unhappy and wish to 
complain formally, you can do this by contacting the Patient Advice & Liaison Service 
(PALS)   
• Freephone: 0800 783 7691 
• Office: 01332 785156 
• Email: dhft.contactpals@nhs.net 
• Text: 07799 337500  
 
Will our taking part in the study be kept confidential? 
 
We will follow ethical and legal practice and all information about you will be handled in 
confidence. 
 
If you join the study, some parts of your child’s medical records and the data collected for the 
study will be looked at by authorised persons from the University of Nottingham who are 
organising the research. They may also be looked at by authorised people to check that the study 
is being carried out correctly. All will have a duty of confidentiality to your child as a research 
participant and we will do our best to meet this duty.  
 
All information which is collected about your child during the course of the research will be kept 
strictly confidential, stored in a secure and locked office, and on a password protected database.  
Any information about your child which leaves the hospital will have his/her name and address 
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removed (anonymised) and a unique code will be used so that he/she cannot be recognised from 
it.   
 
Your child’s personal data (address, telephone number) will be kept for up to 3 months after the 
end of the study so that we are able to contact you about the findings of the study and possible 
follow-up studies (unless you advise us that you do not wish to be contacted).  All other data 
(research data) will be kept securely for 7 years.  After this time your child’s data will be disposed 
of securely.  During this time all precautions will be taken by all those involved to maintain your 
child’s confidentiality, only members of the research team will have access to your child’s personal 
data. 
 
If a missed prescription or possible inappropriate prescription were to be identified according to 
the checklist, the consultant doctor looking after your child would be informed at the time. 
 
What will happen if we don’t want to carry on with the study?  
 
Your participation is voluntary and you are free to withdraw at any time, without giving any reason, 
and without your legal rights being affected. If you withdraw then the information collected so far 
cannot be erased and this information may still be used in the project analysis. 
 
Involvement of the General Practitioner/Family doctor (GP)  
 
Your GP will not be involved in this study. 
 
What will happen to the results of the research study? 
 
The results may be published in academic journals or presented at conferences. They will also be 
included in an academic dissertation about the project. All data will be anonymised. These 
publications will be publicised on our website: 
https://nottingham.ac.uk/research/groups/paediatricmedicines/index.aspx 
 
Who is organising and funding the research? 
This research is being organised by the University of Nottingham and has no external funding. 
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Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by [complete when allocated] Research Ethics Committee. 
 
Further information and contact details 
 
Chief investigator:   Dr Helen Sammons 
                                           Associate Professor in Child Health 
                                           Division of Medical Sciences & Graduate 
Entry Medicine 
School of Medicine 
Faculty of Medicine & Health Sciences 
University of Nottingham 
Royal Derby Hospital Centre  
Uttoxeter Road, Derby, DE22 3DT 





Researcher:  Dr Fenella Corrick 
Postgraduate student (MRes) 
Division of Medical Sciences & Graduate Entry Medicine 
                                           School of Medicine 
                                             Faculty of Medicine & Health Sciences 
                                             University of Nottingham 
                                             Royal Derby Hospital Centre  
Uttoxeter Road, Derby, DE22 3DT  
stxfc2@nottingham.ac.uk                                                     
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Appendix 14:  
Ethics approval from the Brighton & Sussex Research Ethics Committee (REC reference 



















Appendix 15:  
University of Nottingham Research & Development department sponsorship letter 
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Appendix 16:  
Derby Hospitals NHS Foundation Trust approval letter 
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